
<html lang="en"     class="pb-page"  data-request-id="6c55b117-c9b4-4a89-a653-933d45452674"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-18;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c00489"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression" /></meta><meta name="dc.Creator" content="Ozgun  Kilic" /></meta><meta name="dc.Creator" content="Marcos R.  Matos de Souza" /></meta><meta name="dc.Creator" content="Abdulaziz A.  Almotlak" /></meta><meta name="dc.Creator" content="Yiao  Wang" /></meta><meta name="dc.Creator" content="Jill M.  Siegfried" /></meta><meta name="dc.Creator" content="Mark D.  Distefano" /></meta><meta name="dc.Creator" content="Carston R.  Wagner" /></meta><meta name="dc.Description" content="Overexpression of the epidermal growth factor receptor (EGFR) on various cancers makes it an important target for cancer immunotherapy. We recently demonstrated that single-chain variable fragment-..." /></meta><meta name="Description" content="Overexpression of the epidermal growth factor receptor (EGFR) on various cancers makes it an important target for cancer immunotherapy. We recently demonstrated that single-chain variable fragment-..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 27, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00489" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00489" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00489" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00489" /></link>
        
    
    

<title>Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00489" /></meta><meta property="og:title" content="Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0008.jpeg" /></meta><meta property="og:description" content="Overexpression of the epidermal growth factor receptor (EGFR) on various cancers makes it an important target for cancer immunotherapy. We recently demonstrated that single-chain variable fragment-based bispecific chemically self-assembled nanorings (CSANs) can successfully modify T cell surfaces and function as prosthetic antigen receptors (PARs) allowing selective targeting of tumor antigens while incorporating a dissociation mechanism of the rings. Here, we report the generation of anti-EGFR fibronectin (FN3)-based PARs with high yield, rapid protein production, predicted low immunogenicity, and increased protein stability. We demonstrated the cytotoxicity of FN3-PARs successfully while evaluating FN3 affinities, CSAN valencies, and antigen expression levels. Using an orthotopic breast cancer model, we showed that FN3-PARs can suppress tumor growth with no adverse effects and FN3-PARs reduced immunosuppressive programmed cell death ligand-1 (PD-L1) expression by downregulating EGFR signaling. These results demonstrate the potential of FN3-PARs to direct selective T cell-targeted tumor killing and to enhance antitumor T cell efficacy by modulating the tumor microenvironment." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00489"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00489">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00489&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00489&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00489&amp;href=/doi/10.1021/acs.jmedchem.0c00489" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 10235-10245</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00898" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00567" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ozgun Kilic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ozgun Kilic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ozgun++Kilic">Ozgun Kilic</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6735-8830" title="Orcid link">http://orcid.org/0000-0001-6735-8830</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Marcos R. Matos de Souza</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marcos R. Matos de Souza</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Virology, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marcos+R.++Matos+de+Souza">Marcos R. Matos de Souza</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9365-3224" title="Orcid link">http://orcid.org/0000-0002-9365-3224</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Abdulaziz A. Almotlak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Abdulaziz A. Almotlak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Abdulaziz+A.++Almotlak">Abdulaziz A. Almotlak</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yiao Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yiao Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yiao++Wang">Yiao Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jill M. Siegfried</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jill M. Siegfried</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jill+M.++Siegfried">Jill M. Siegfried</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Mark D. Distefano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark D. Distefano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+D.++Distefano">Mark D. Distefano</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2872-0259" title="Orcid link">http://orcid.org/0000-0002-2872-0259</a></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Carston R. Wagner</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carston R. Wagner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#5f283e38313a6f6f6c1f2a3231713a3b2a"><span class="__cf_email__" data-cfemail="4c3b2d2b22297c7c7f0c39212262292839">[emailÂ protected]</span></a>. 2231 6th Street S.E., Cancer & Cardiovascular Research Building.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carston+R.++Wagner">Carston R. Wagner</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7927-719X" title="Orcid link">http://orcid.org/0000-0001-7927-719X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00489&amp;href=/doi/10.1021%2Facs.jmedchem.0c00489" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 10235â10245</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 27, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 March 2020</li><li><span class="item_label"><b>Published</b> online</span>27 August 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00489" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00489</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10235%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DOzgun%2BKilic%252C%2BMarcos%2BR.%2BMatos%2Bde%2BSouza%252C%2BAbdulaziz%2BA.%2BAlmotlak%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D18%26contentID%3Dacs.jmedchem.0c00489%26title%3DAnti-EGFR%2BFibronectin%2BBispecific%2BChemically%2BSelf-Assembling%2BNanorings%2B%2528CSANs%2529%2BInduce%2BPotent%2BT%2BCell-Mediated%2BAntitumor%2BResponses%2Band%2BDownregulation%2Bof%2BEGFR%2BSignaling%2Band%2BPD-1%252FPD-L1%2BExpression%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10245%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00489"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">818</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00489" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ozgun&quot;,&quot;last_name&quot;:&quot;Kilic&quot;},{&quot;first_name&quot;:&quot;Marcos&quot;,&quot;last_name&quot;:&quot;R. Matos de Souza&quot;},{&quot;first_name&quot;:&quot;Abdulaziz&quot;,&quot;last_name&quot;:&quot;A. Almotlak&quot;},{&quot;first_name&quot;:&quot;Yiao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jill&quot;,&quot;last_name&quot;:&quot;M. Siegfried&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;D. Distefano&quot;},{&quot;first_name&quot;:&quot;Carston&quot;,&quot;last_name&quot;:&quot;R. Wagner&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;10235-10245&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00489&quot;},&quot;abstract&quot;:&quot;Overexpression of the epidermal growth factor receptor (EGFR) on various cancers makes it an important target for cancer immunotherapy. We recently demonstrated that single-chain variable fragment-based bispecific chemically self-assembled nanorings (CSANs) can successfully modify T cell surfaces and function as prosthetic antigen receptors (PARs) allowing selective targeting of tumor antigens while incorporating a dissociation mechanism of the rings. Here, we report the generation of anti-EGFR fibronectin (FN3)-based PARs with high yield, rapid protein production, predicted low immunogenicity, and increased protein stability. We demonstrated the cytotoxicity of FN3-PARs successfully while evaluating FN3 affinities, CSAN valencies, and antigen expression levels. Using an orthotopic breast cancer model, we showed that FN3-PARs can suppress tumor growth with no adverse effects and FN3-PARs reduced immunosuppressive programmed cell death ligand-1 (PD-L1) expression by downregulating EGFR signaling. These results&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00489&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00489" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00489&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00489" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00489&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00489" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00489&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00489&amp;href=/doi/10.1021/acs.jmedchem.0c00489" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00489" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00489" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00489%26sid%3Dliteratum%253Aachs%26pmid%3D32852209%26genre%3Darticle%26aulast%3DKilic%26date%3D2020%26atitle%3DAnti-EGFR%2BFibronectin%2BBispecific%2BChemically%2BSelf-Assembling%2BNanorings%2B%2528CSANs%2529%2BInduce%2BPotent%2BT%2BCell-Mediated%2BAntitumor%2BResponses%2Band%2BDownregulation%2Bof%2BEGFR%2BSignaling%2Band%2BPD-1%252FPD-L1%2BExpression%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D18%26spage%3D10235%26epage%3D10245%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/jmcmar.2020.63.issue-18/20200924/jmcmar.2020.63.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Overexpression of the epidermal growth factor receptor (EGFR) on various cancers makes it an important target for cancer immunotherapy. We recently demonstrated that single-chain variable fragment-based bispecific chemically self-assembled nanorings (CSANs) can successfully modify T cell surfaces and function as prosthetic antigen receptors (PARs) allowing selective targeting of tumor antigens while incorporating a dissociation mechanism of the rings. Here, we report the generation of anti-EGFR fibronectin (FN3)-based PARs with high yield, rapid protein production, predicted low immunogenicity, and increased protein stability. We demonstrated the cytotoxicity of FN3-PARs successfully while evaluating FN3 affinities, CSAN valencies, and antigen expression levels. Using an orthotopic breast cancer model, we showed that FN3-PARs can suppress tumor growth with no adverse effects and FN3-PARs reduced immunosuppressive programmed cell death ligand-1 (PD-L1) expression by downregulating EGFR signaling. These results demonstrate the potential of FN3-PARs to direct selective T cell-targeted tumor killing and to enhance antitumor T cell efficacy by modulating the tumor microenvironment.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer immunotherapy has generated widespread interest over the last decade due to the promise of potent, selective, and long-lasting eradication of tumors. The common formats that have been developed for T cell-redirecting immunotherapies are chimeric antigen receptors (CARs) and bispecific antibodies. CAR-T cells are generated by genetically modifying a patientâs T cells to express a protein targeting a tumor-specific antigen.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In contrast, bispecific antibodies generally incorporate at least two domains, one targeting the T cell and the other targeting the tumor antigen of interest, resulting in T cell redirection to the tumor antigen-expressing cells.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a></div><div class="NLM_p">Recently, two CAR-T cell therapies have been clinically approved for B-cell lymphomas.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7 ref8">(4â8)</a> However, for solid tumors, only modest clinical success has been observed for CARs due to a number of reasons, including CAR-T cell exhaustion, antigen loss, insufficient tumor penetration, and toxicity toward normal tissues.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Traditionally, single-chain variable fragments (scFvs) have been used as the tumor-targeting ligand for CARs. However, recently engineered protein scaffolds have been utilized to design CARs with improved properties and comparable efficacy to scFv-based CARs.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10â13)</a></div><div class="NLM_p">Engineered protein scaffolds have several advantages over traditional scFvs.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Generally, they are smaller in size, have high stability, and are easier to recombinantly produce and isolate.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Protein scaffolds such as fibronectins, affibodies, and DARPins are amenable to modifications and have been used in various therapeutic applications such as kinase modulation, drug delivery, and immunotherapy.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20 ref21">(16â21)</a> Fibronectins derived from the 10th type III domain of human fibronectin (FN3) exhibit low immunogenicity and thus have been investigated for their immune cell targeting and tumor imaging.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Analogous to the complementarity-determining regions of antibodies, the flexible loops connecting the seven Î²-strands of fibronectins can be engineered to provide target-specific binders with high affinity and specificity.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> One such target, epidermal growth factor receptor (EGFR), is a well-studied cancer biomarker and an established target for cancer therapeutics.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> A series of EGFR-targeting fibronectins differing in affinity and stability have been discovered by mRNA display previously.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> CAR-T cells expressing one of these EGFR-targeting fibronectins have shown <i>in vitro</i> and <i>in vivo</i> efficacies.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> When compared to cetuximab scFv CARs, FN3 and affibody CARs were able to similarly reduce the growth of xenograft tumors.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Additionally, the FN3 and affibody CARs demonstrated enhanced efficacy <i>in vitro</i> and <i>in vivo</i> when the CARs were engineered with dual-targeting ligands.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In another study, HER2-targeting DARPin CARs displayed improved cytotoxicity compared to scFv-based CARs.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Similarly, vascular endothelial growth factor receptor-2 (VEGFR-2) targeting FN3 CARs demonstrated cytotoxicity to VEGFR-2-positive cells when they were expressed in Jurkat and primary T cells.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Collectively, these studies suggest that alternative protein scaffolds can be deployed in CAR-T cells with at least similar efficacy to that observed for traditional scFv-based CARs.</div><div class="NLM_p last">Our group has investigated the use of prosthetic antigen receptor (PAR)-T cells. PAR-T cells are prepared by incubation of T cells with bispecific chemically self-assembling nanorings (CSANs) that afford multimeric bispecific constructs incorporating an anti-CD3 scFv and a tumor-targeting scFv.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The multivalency of the CSANs enables functionalization of T cells <i>via</i> multiple binding interactions to CD3 on the cell surface with high stability both <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The enhanced avidity of the rings provides enhanced binding and selectivity to T cells and the targeted antigen of interest.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> We have successfully demonstrated the <i>in vitro</i> and <i>in vivo</i> efficacy of scFv-based prosthetic antigen receptors (PARs).<a onclick="showRef(event, 'ref26 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref29">(26,29)</a> However, generating scFv-based monomers to form the rings is dependent on refolding steps that increase the time required for purification, with significantly reduced protein yields.<a onclick="showRef(event, 'ref26 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref26 ref29 ref30">(26,29,30)</a> In contrast, the FN3-based monomers used for the preparation of bispecific CSANs lack cysteines and thus can be expressed as soluble proteins by <i>Escherichia coli</i>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> We demonstrate that CSANs prepared from Î±CD3-scFv-DHFR<sup>2</sup> and Î±EGFR-FN3-DHFR<sup>2</sup> monomers are highly stable and enable the exploration of targeted affinity tuning of the associated PAR-T cells to EGFR.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In addition, we investigated the antitumor potency of Î±EGFR/Î±CD3 PAR-T cells both <i>in vitro</i> and <i>in vivo</i>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35103" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35103" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Preparation of FN3-1DD Fusion Proteins</h3><div class="NLM_p">Four EGFR-binding fibronectins were generated with mRNA display and their sequences have been previously reported.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Of the four EGFR-binding fibronectins, clones E1 (<i>K</i><sub>d</sub> = 0.7 nM) and E4 (<i>K</i><sub>d</sub> = 0.13 nM) were selected due to their lack of cysteines. Cysteine-free proteins generally result in faster purification, higher protein yields, and the potential to incorporate site-specific cysteines for further conjugation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> E1 and E4 were fused to the N terminus of the DHFR<sup>2</sup> (1DD) construct, yielding E1-1DD and E4-1DD. Both fusion proteins were expressed in <i>E. coli</i> as soluble proteins, allowing much faster protein purification protocols. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed that pure E1-1DD (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S1A</a>) and E4-1DD (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S1B</a>) were obtained after column purifications, and size exclusion chromatography (SEC) data confirmed the monomeric nature of E1-1DD (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S1C</a>) and E4-1DD (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S1D</a>). Similar to previous studies, upon incubation with methotrexate (MTX), ring formation was readily observed (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S1C,D</a>) and the ring structure was further confirmed by cryogenic transmission electron microscopy (cryo-TEM) (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S1E,F</a>).<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a></div><div class="NLM_p last">For T cell targeting, we have previously designed and utilized an Î±CD3-scFv-DHFR<sup>2</sup> fusion protein (1DD-CD3). 1DD-CD3 contains a one-amino acid glycine linker between the two DHFRs and a 15-amino acid glycineâserine linker between the C-terminal DHFR and the Î±CD3-scFv, derived from the Î±CD3 monoclonal antibody, UCHT1.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Additionally, a low-affinity EGFR peptide (<i>K</i><sub>d</sub> > 1 Î¼M)<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> fused to the 1DD construct, 1DD-EGF, was also expressed as a soluble protein in <i>E. coli</i> for comparison with E1-1DD and E4-1DD.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Fibronectin CSANs Showed Binding to EGFR-Positive Cancer Cells and Internalization</h3><div class="NLM_p last">E1-1DD and E4-1DD showed selective binding to EGFR-positive cancer cells, in correlation with the receptor densities of the cells (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S1GâI</a>). The affinity titration experiments demonstrated high affinity toward EGFR for both E1-1DD (<i>K</i><sub>d</sub> = 67.3 nM) and E4-1DD (<i>K</i><sub>d</sub> = 26.3 nM) (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S1J,K</a>). We also observed binding of E1-1DD and E4-1DD to the mouse mammary cell line HC-11 (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S2A,B</a>). Consistent with the rapid internalization of EGFR, fluorescence microscopy studies demonstrated that E1-1DD monomers and the resulting E1-CSANs undergo endocytosis by the EGFR-overexpressing epidermoid carcinoma cell line. At 37 Â°C, both the monomers and CSANs were found to be internalized, while binding to the cell membrane was observed at 4 Â°C (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S3AâF</a>).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> EGFR Downregulation of E1-1DD</h3><div class="NLM_p last">EGFR signaling is detrimental to cancer cell survival<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and, therefore, the anticancer activity of tyrosine kinase inhibitors (TKI) and mAb therapies typically rely on preventing this signaling pathway.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Previously, E1 has been shown to inhibit EGFR phosphorylation with IC<sub>50</sub> = 38 nM against A431 cells.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> We investigated whether this effect was retained in the E1-1DD fusion construct. Compared to the control phosphate-buffered saline (PBS) group, a significant decrease in phospho-EGFR along with a decrease in the phosphorylation of downstream targets, AKT and ERK 1/2, was observed for E1-1DD-treated MDA-MB-231 cells (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S4A</a>). Nevertheless, the downregulation of receptor signaling was not accompanied by an increase in cytotoxicity. Even at high concentrations (8Î¼M), E1-1DD treatment had no effect on MDA-MB-231 cell proliferation (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S4B</a>).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Bispecific CSANs Bound Both to Cancer Cells and T Cells</h3><div class="NLM_p">Previously, we have demonstrated that bispecific CSANs can be prepared by mixing a 1:1:1 ratio of the chemical dimerizer, bis-MTX, and two different antigen-targeting DHFR<sup>2</sup> monomers.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Similarly, bispecific Î±EGFR/Î±CD3 CSANs were generated by mixing Bis-MTX with equal molar amounts of 1DD-CD3 and either E1-1DD or E4-1DD. The bispecific nature of the Î±EGFR/Î±CD3 CSANs was confirmed by checking binding of the rings to two cell lines where each cell type is positive for either CD3 or EGFR (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). The bound rings were detected using an Alexa Fluor 647-labeled anti-His antibody, which will only detect the EGFR-targeting FN3 CSANs since, among the protein constructs, only E1-1DD and E4-1DD contained a His-Tag and 1DD-CD3 was tag free. Since peripheral blood mononuclear cells (PBMCs) were EGFR negative, and CD3 positive, E1-1DD-only and E4-1DD-only CSANs did not show binding to PBMCs alone (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S5</a>). However, when E1-1DD or E4-1DD was mixed with bis-MTX and 1DD-CD3, due to the bispecific nature of the construct, the CSANs were able to bind to cells <i>via</i> 1DD-CD3 and show a fluorescence signal through E1-1DD or E4-1DD present on the ring, supporting the argument that the mixture yields two bispecific CSANs rather than two homogeneous rings. Furthermore, binding of the rings to both the T cells and MDA-MB-231 cells indicates that the rings contain both Î±CD3- and Î±EGFR-targeting ligands. In addition, as determined by size exclusion chromatography (SEC) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B) and dynamic light scattering (DLS) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C), the hydrodynamic radius and size distribution of the bispecific rings were found to be similar to the values previously observed for CSANs.<a onclick="showRef(event, 'ref26 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref28 ref29">(26,28,29)</a> Furthermore, cryo-TEM images of E1-CD3 and E4-CD3 bispecific CSANs both confirmed the ring structure and hydrodynamic radius determined by DLS (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>D).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Bispecific CSAN formation and characterization. (A) The bispecific nature of CSANs was confirmed by binding to two cell types. Effector T cells (left) are only CD3 positive and cancer cells (right) are only EGFR positive. (B) The monomeric nature of E1-1DD and CD3-1DD and size distribution of E1-CD3 bispecific rings upon dimerizer addition were confirmed by size exclusion chromatography (SEC). (C) The mean diameter and polydispersity of the bispecific rings were determined by dynamic light scattering (DLS). (D) Ring formation was also confirmed by cryo-TEM imaging of the E1-CD3 and E4-CD3 bispecific nanorings (scale bar, 10 nm).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Controlled Disassembly of the Bispecific CSANs Was Obtained with Trimethoprim</h3><div class="NLM_p last">A common concern with current immunotherapy approaches is the potential for overactivation of the T cells, leading to potentially life-threatening cytokine release syndrome.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> CSANs have a major advantage over these treatments because CSANs can be disassembled by the addition of an FDA-approved drug, trimethoprim, thus preventing overstimulation of the T cells. Previously, we have demonstrated that trimethoprim treatment leads to disassembly of the CSANs, disruption of bispecific CSANs-induced cellâcell interactions, and reduction in the levels of IL-2, IL-6, IFN-Î³, and TNF-Î± <i>in vivo</i>.<a onclick="showRef(event, 'ref26 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref29">(26,29)</a> Similarly, both E1 and E4 Î±CD3 bispecific CSANs could be dissociated with the addition of trimethoprim in a concentration-dependent manner (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S6A,B</a>).</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Î±EGFR-FN3-PARs Were Selectively Cytotoxic to EGFR-High Cell Lines</h3><div class="NLM_p">Besides being highly expressed on cancer cells, EGFR is also present on normal tissues, particularly the epidermis.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Therefore, selectivity toward higher EGFR-expressing cancer cells is crucial to avoid toxicity.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> We investigated the cytotoxicity of the Î±EGFR/Î±CD3 CSANs to cell lines with variable EGFR expression levels. We determined the cytotoxicity of the E1-1DD- and E4-1DD-based Î±EGFR/Î±CD3 CSANs toward the cell lines A431 (epidermal, 13 Ã 10<sup>6</sup> EGFR per cell, 100%), MDA-MB-231 triple-negative breast cancer (TNBC, 0.7 Ã 10<sup>6</sup> EGFR per cell, 5.38% relative to A431), and MCF-7 (breast, 0.2 Ã 10<sup>5</sup> EGFR per cell, 0.15% relative to A431). These results were compared to those for low-affinity EGFR-binding peptide (pEGF-1DD, <i>K</i><sub>d</sub> > 1 Î¼M)-based Î±EGFR/Î±CD3 CSANs developed previously by our laboratory.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> No significant toxicity was observed for each of the Î±EGFR/Î±CD3 CSANs toward the lowest EGFR-expressing cell line, MCF-7 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). In contrast, significant and comparable cytotoxicity was observed for each of the E1-1DD- and E4-1DD-based Î±EGFR/Î±CD3 CSANs toward higher EGFR-expressing MDA-MB-231 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B) and A431 cells (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). In both cases, maximum cytotoxicity was observed after treatment with 12.5 nM of the CSANs. Similarly, the cytokine profiles observed for the treatment groups correlated with the levels of cytotoxicity, with significant production of IL-2 and IFN-Î³ observed for the treatment of MDA-MB-231 cells with E1-1DD- and E4-1DD-based Î±EGFR/Î±CD3 CSANs, compared to MCF-7 cells (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>AâD). As observed for induced cytotoxicity, the maximum cytokine production occurred after treatment with 12.5 nM of the CSANs. These results suggest that Î±EGFR/Î±CD3 CSAN-induced cytotoxicity is dependent on the affinity of the Î±EGFR ligand and the cell surface expression levels of EGFR.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cytotoxicity of EGFR-targeting PAR-T cells. In a 96-well plate, 0.5 Ã 10<sup>4</sup> cells were seeded and incubated with the protein treatments for 24 h. The supernatants were analyzed for cytotoxicity using the lactate dehydrogenase (LDH) assay. (A) Cytotoxicity toward MCF-7 cells. (B) Cytotoxicity toward MDA-MB-231 cells. (C) Cytotoxicity toward A431 cells. *<i>P</i> < 0.05 with respect to nontreated controls, by one-way analysis of variance (ANOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cytokine release profile of EGFR-targeting PAR-T cells. In a 96-well plate, 0.5 Ã 10<sup>4</sup> cells were seeded and incubated with the protein treatments for 24 h. The supernatants were analyzed for cytotoxicity using the ELISA kit. (A) IL-2 released from MCF-7 cells after cytotoxicity study. (B) IL-2 released from MDA-MB-231 cells after cytotoxicity study. (C) IFN-Î³ released from MCF-7 cells after cytotoxicity study. (D) IFN-Î³ released from MDA-MB-231 cells after cytotoxicity study. *<i>P</i> < 0.05 with respect to nontreated controls, by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Valency Modulation of the Bispecific CSANs Did Not Enhance Cytotoxicity <i>In Vitro</i></h3><div class="NLM_p">Previously, we reported that the distribution of each monomer in a bispecific ring could be modified by mixing different equivalences of each monomer during ring formation.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Based on this quantitative understanding of the effects of valency, affinity, and antigen expression on CSAN cell surface binding, we prepared CSANs with different monomer distributions ranging from predominantly displaying the Î±CD3 scFv to predominantly displaying the Î±EGFR FN3 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). We hypothesized that a higher Î±CD3 valency of the rings would enhance cytotoxicity by enabling initial and preferred binding to the T cells over the tumor cells. Consequently, we prepared variable-valency CSANs, by mixing variable ratios of the Î±CD3-1DD monomer with E1-1DD (1:7â7:1), and compared their cytotoxicity to other CSANs prepared with the Î±CD3-1DD monomer and the non-ligand-binding monomer, 1DD. As can be seen in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B, varying the Î±CD3 to Î±EGFR valency with the Î±CD3-1DD- and E1-1DD-based bispecific CSANs did not affect the cytotoxicity of the bispecific CSANs. As observed before (<i>vide supra</i>), T cell-directed cytotoxicity was observed toward the high EGFR-expressing MDA-MB-231 cell line, but not the lower EGFR-expressing MCF-7 cell line. (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B,C) Thus, regardless of whether the CSANs were predominantly directed toward the T cells or the tumor cells, no significant selectivity for T cell-induced cytotoxicity was observed under 2D culture conditions.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Valency modulation of bispecific CSANs. Cells (0.5 Ã 10<sup>4</sup>) were seeded in 96-well plates and incubated with 25nM of protein treatments for 24 h. The cell lysis was quantified by the lactate dehydrogenase (LDH) assay. (A) Schematic demonstrating that by varying the valency of the rings, we can shift binding of rings predominantly to either cancer cells or T cells. (B) LDH-based cytotoxicity results for MDA-MB-231 cells when valency was modulated from CD3-targeting high (left) to EGFR-targeting high (right). Other than the PBS control and 2:6 valency groups, at every valency examined, E1-CD3 rings were significantly more cytotoxic compared to 1DD-CD3 rings. (C) LDH-based cytotoxicity results for MCF-7 cells when the valency was modulated from CD3-targeting high (left) to EGFR-targeting high (right). There was no significant difference between E1-CD3 and 1DD-CD3 rings at any valency ratio. *<i>P</i> < 0.05 with respect to E1-CD3 rings and 1DD-CD3 ring controls, by a two-tailed Studentâs t test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Bispecific CSANs Showed <i>In Vivo</i> Tumor Reduction and Increased Survival</h3><div class="NLM_p">To evaluate the <i>in vivo</i> efficacy of targeting EGFR-expressing tumors with Î±EGFR/Î±CD3 CSANs, we elected to carry out antitumor studies with E1-1DD-based bispecific CSANs with an Î±CD3-1DD and E1-1DD monomer ratio of 4:4 and a triple-negative breast cancer (TNBC) orthotopic xenograft model. MDA-MB-231 cells were injected into the fourth mammary fat pad of young adult female immunodeficient Non-Obese Diabetic (NOD) scid Î³(NSG) mice. Five days after the tumor induction, PBMCs were administered to the mice <i>via</i> an intravenous (IV) injection. Once the tumor sizes reached 100 mm<sup>3</sup>, the mice were randomly distributed into three groups (<i>n</i> = 5), and treated with the Î±EGFR/Î±CD3 CSANs. The control groups were treated with either Î±CD3 CSANs or PBS. Each mouse received six consecutive doses (IV) every 2 days, and the tumor size and weight of each mouse were determined throughout the study (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Significant antitumor activity was observed after the second dose of the Î±EGFR/ Î±CD3 CSANs and continued throughout the course of the study compared to the control groups (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Although the E1 FN3 cross-reacts with both murine and human EGFR, no significant weight loss was observed for the Î±EGFR/Î±CD3 CSANs treatment group (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). One major side effect of EGFR-based treatments is the potential for the development of skin rash due to the expression of EGFR on epidermal cells.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Nevertheless, no significant development of skin rash was observed for the Î±EGFR/Î±CD3 CSAN-treated mice. Interestingly, the mice in the control groups showed symptoms of graft-versus-host disease (GvHD), such as weight loss and loss of fur, while the Î±EGFR/Î±CD3 CSAN-treated group exhibited no such symptoms.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Taken together, these results indicate that Î±EGFR PAR-T cells have the potential to exhibit potent and nontoxic antitumor activity toward high EGFR-expressing tumors.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vivo</i> efficacy study of FN3-PARs using an orthotopic NSG mouse model. NSG mice (6â8 weeks old) were implanted with 1.0 Ã 10<sup>6</sup> MDA-MB-231 and 20 Ã 10<sup>6</sup> PBMCs. Mice in each group (<i>n</i> = 5) received a total of six treatments of 1 mg/kg intravenously, given every other day. Tumor volume and body weight were monitored to track disease progression. (A) Schematic demonstrating the time of tumor and PBMC implantation and the treatment schedule. (B) Mean tumor volumes were measured every other day and recorded. Tumor volume measurements were done with a caliper. Arrows indicate the days of treatment. *<i>P</i> < 0.05 with respect to nontreated controls, by two-way ANOVA, followed by Dunnettâs test for multiple comparisons. (C) The average body weight within each group is recorded. Arrows indicate the days of treatment. There was no significant difference between the average weights within each group throughout the study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Analysis of Tumors by Immunohistochemistry (IHC)</h3><div class="NLM_p">To evaluate the long-term effects of bispecific CSANs therapy, all tumors were collected and processed for immunohistochemistry (IHC) 10 days after the last treatment. Hematoxylin and eosin (H&E) staining demonstrated the differential tumor cellular morphology between the two control groups (PBS, CD3) and the Î±EGFR/Î±CD3 CSAN treatment groups (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S7AâC</a>). While the tumors were densely packed in the control groups, the treatment group exhibited higher levels of stroma. In addition, we observed the presence of cells positive for the proliferative marker Ki67 in the treatment group, consistent with the presence of proliferating T cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representative immunohistochemistry (IHC) images and quantification. (A) ki67, (B), CD3, (C) total EGFR, (D) phospho-EGFR, (E) programmed cell death ligand-1(PD-L1), and (F) programmed cell death-1 (PD-1). Brown staining indicates that the cell is positive for the markers listed. For each staining representative image for PBS, CD3 and E1-CD3 groups are shown. On the right side of the image panels, the expression of each marker is quantified, where blue indicates low expression, red indicates medium expression, and green indicates high expression for the marker within regions of each image.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A major concern in cancer immunotherapy for solid tumors is the inability of T cells to infiltrate into the tumor.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> T cell infiltration was observed for both the Î±EGFR/Î±CD3 CSAN-treated groups as well as the control groups, shown by staining with an Î±CD3 antibody (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Consequently, the injected T cells successfully proliferated in mice and survived even 10 days after the last treatment. A major hurdle in cancer immunotherapy is the loss of the targeted antigen, reducing the effectiveness of immune cell-targeted therapies.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> IHC analysis revealed no significant difference in the levels of EGFR expression between the Î±EGFR/Î±CD3 CSAN and Î±CD3 CSAN treatment groups and only a minor difference between the treatment groups and the PBS control group (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C).</div><div class="NLM_p last">Since MDA-MB-231 cells express high levels of PD-L1, an immunosuppressive marker, and EGFR signaling enhances PD-L1 expression, we investigated the effect of treatment Î±EGFR/Î±CD3 CSANs on PD-L1.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39â41)</a> When the MDA-MB-231 tumors were examined by IHC, those that had been treated with Î±EGFR/Î±CD3 CSANs exhibited decreased levels of phosphorylated EGFR (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D) as well as decreased levels of PD-L1 and PD-1 expression compared to the control groups (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>E,F). The effect on this pathway was further confirmed in a parallel study in which the tumors were harvested nearly a month after the last treatment and subjected to western blot analysis (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">Figure S8A,B</a>). While the phosphorylated and total EGFR levels were similar between PBS- and E1-CD3-treated groups, the PD-L1 downregulation was significant, even 27 days after the last treatment, indicating that the bispecific CSANs had a long-term effect on immune modulation. Thus, the Î±EGFR/Î±CD3 CSANs contributed to enhanced T cell-targeted cytotoxicity as well as a reduction in the immunosuppressive capabilities of the tumor microenvironment.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have previously demonstrated that bispecific CSANs can function as tumor-targeting T cell engagers. Î±CD3/Î± epithelial cell adhesion molecule (EpCAM) CSANs were shown to efficiently eradicate tumors from NSG mice orthotopically implanted with the EpCAM-overexpressing breast cancer cell line, MCF-7, with no observable cytokine-based toxicities.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In addition, while immunotoxins targeting EpCAM have been shown to undergo rapid internalization, no significant internalization of Î±EpCAM CSANs has been observed.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In contrast, we have demonstrated that Î±EGFR CSANs can undergo rapid internalization. Consequently, we decided to characterize the efficacy of T cell-targeted tumor cell killing with Î±CD3/Î±EGFR CSANs, to assess the potential effect of potential rapid CSAN internalization on antitumor activity. Additionally, since Î±EGFR CSANs are cross-reactive with mouse EGFR, animal studies with this scaffold provide insights on the potential for human toxicities. Although our previous results with Î±CD3/Î±EpCAM CSANs proved efficacious, since the Î±EpCAM scFv binds to human EpCAM, but not the murine EpCAM, the potential for off-target toxicities could not be assessed.</div><div class="NLM_p">TNBC is an aggressive form of breast cancer with limited treatment options.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Unlike other forms of breast cancer, which take advantage of EGFR, HER2, and HER3 signaling, TNBC cells are HER2 and HER3 negative and thus exclusively dependent on EGFR overexpression.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Nevertheless, while tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) targeting EGFR are clinically used for lung cancer and colorectal cancer, respectively, they have not shown significant clinical success as breast cancer monotherapies.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Recently, Î±EGFR CAR-T cells have shown promise against solid tumors (30). CAR-T cells incorporating an Î±EGFR scFv have shown efficacy against gliomas, while Î±EGFR FN3 has demonstrated potency against lung cancer.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Consequently, we sought to characterize the antitumor ability of Î±EGFR/Î±CD3 CSANs to induce T cell-directed cell killing against EGFR-expressing cancer cells, including TNBC.</div><div class="NLM_p">To avoid the need for refolding and to enhance stability, we chose to prepare Î±EGFR/Î±CD3 CSANs that incorporated human FN3s, E1 (<i>K</i><sub>d</sub> = 0.7 nM, <i>T</i><sub>m</sub> = 72 Â°C) and E4 (<i>K</i><sub>d</sub> = 0.13 nM, <i>T</i><sub>m</sub> = 69.2 Â°C), which were shown to selectively bind EGFR.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In addition, E1 and E4 were shown to competitively inhibit EGF binding, inhibit EGFR and ERK phosphorylation, and cross-react with both human and murine EGFR.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Similar to the FN3s, the His-tagged FN3 DHFR fusion proteins, E1-1DD and E4-1DD, were solubly expressed by <i>E.coli</i>, yielding 25â35 mg/L after purification by nickel affinity chromatography. In contrast, scFv-based DHFR fusion monomers require an extensive refolding step, due to the inherent presence of disulfide bonds, with protein yields on the order of 1â4 mg/L.</div><div class="NLM_p">Both the E1 and E4 monomers and the corresponding CSANs were shown to bind to cellular EGFR. Similar to past binding studies with E1 and E4, E4-1DD and E4-CSANs exhibited a 2-fold greater affinity for EGFR than E1-1DD and E1-CSANs. Nevertheless, for both E1 and E4, the fusion to DHFR<sup>2</sup> resulted in nearly 85- and 200-fold reductions in binding affinity compared to FN3 E1 and E4.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> When compared to FN3 E1 and E4, the E1 and E4 DHFR<sup>2</sup> monomers and the corresponding CSANs similarly underwent internalization by endocytosis.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The binding of the Î±EGFR CSANs to EGFR on MDA-MB-231 cells was also found to inhibit EGFR phosphorylation. Collectively, these results demonstrated that the fusion of E1 and E4 to the DHFR<sup>2</sup> monomers did not weaken their EGFR binding or impact on EGFR-associated induced signaling.</div><div class="NLM_p">For any CAR or bispecific construct, efficient immune synapse formation is critical for T cell activation, which is affected by several factors.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> T cell activation has been shown to be dependent on antigen density, with cell lines expressing high levels of EGFR, such as MDA-MB-231 (0.7 Ã 10<sup>6</sup> antigens/cell) and A431 (13 Ã 10<sup>6</sup> antigens/cell), able to initiate T cell activation and cell killing when treated with E1-CSANs and E4-CSANs, while MCF-7 cells (2.0 Ã 10<sup>4</sup> antigens/cell) were unable to initiate T cell activation or cytotoxicity with either of the respective CSANs. CAR-T cells have been shown to exhibit cytotoxicity at antigen levels as low as 200 antigens/cell, while bispecific Î±EGFR/Î±CD3-CSANs require higher antigen density to initiate cell killing.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The higher minimum antigen density required for T cell activation with either E1-CSANs or E4-CSANs suggests that T cell activation and cell killing may have greater selectivity for EGFR-overexpressing cells, such as cancer cells, over expression on normal tissues. Indeed, the MCF-7 cells (2.0 Ã 10<sup>4</sup> antigens/cell), which express similar levels of EGFR as those found on normal tissues (3.0 Ã 10<sup>4</sup> antigens/cell), did not undergo Î±EGFR/Î±CD3-CSANs T cell-induced cell killing.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><div class="NLM_p">Recently, we have demonstrated both <i>in vitro</i> and <i>in vivo</i> that the binding specificity of EpCAM-targeted CSANs is dependent on ligand-binding affinity, valency, and the antigen expression levels on the target cells.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Consequently, we analyzed the effect of these factors on the T cell-induced cytotoxicity by FN3-based EGFR-targeting bispecific CSANs. We compared the efficacy of four protein scaffolds with varying Î±CD3 scFv and Î±EGFR FN3 for EGFR. Since there was no difference in the ability of E1 and E4 to induce T cell activation and targeted cell killing, we chose to evaluate E1, since the <i>K</i><sub>d</sub> for E1-1DD (<i>K</i><sub>d</sub> = 67.3 nM) and <i>K</i><sub>d</sub> for Î±CD3-1DD (<i>K</i><sub>d</sub> = 51 nM) were the most similar and therefore would not inherently have a preference for binding to T cells or the target tumor cells.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Despite valency variations from (Î±CD3)1:7(E1) to (Î±CD3)7:1(E1), no significant difference was observed in the efficiency of T cell-induced cell killing. Thus, neither the preference of the Î±CD3/Î±EGFR CSANs for binding to the T cells or tumor cells or the potential for internalization by the tumor cells significantly altered the degree of induced cytotoxicity <i>in vitro</i>. Consequently, we chose to carry out <i>in vivo</i> studies with Î±CD3/Î±EGFR CSANs composed of an equal ratio of Î±EGFR FN3- and Î±CD3 scFv-binding ligands.</div><div class="NLM_p">Based on these results, we investigated the <i>in vivo</i> efficacy of Î±CD3/Î±EGFR CSANs on T cell-induced tumor eradication with an orthotopic triple-negative breast cancer xenograft mouse model implanted with MDA-MB-231 cells and human PBMCs. The bispecific rings effectively prevented tumor progression, with no detectable toxicity associated with targeting EGFR, such as skin rashes and loss of body weight.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Previously, CAR-T cells have been prepared with Î±EGFR FN3.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> In one case, Î±EGFR CAR-T cells prepared with the low-affinity FN3, E3 (<i>K</i><sub>d</sub> = 9.9 nM), exhibited only modest suppression of the growth of NSCLC tumors with a mouse xenograft model.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Attempts to prepare Î±EGFR CAR-T cells from E1 to E4 were not successful. In another study, Î±EGFR CAR-T cells were prepared with E1 and exhibited significant anticancer activity in a mouse pancreatic cancer xenograft model.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Therefore, the observed antitumor activity of Î±CD3/Î±EGFR CSANs appears to be at least as potent as similar FN3-based CAR-T cells.</div><div class="NLM_p">Examination of tumors for untreated and Î±CD3/Î±EGFR CSAN-treated tumors revealed significant infiltration and proliferation of T cells for treated tumors, as well as tumor cell apoptosis and necrosis, compared to control tumors. Surprisingly, while the levels of EGFR expression remained unchanged, substantial suppression of EGFR phosphorylation and PD-L1 and PD-1 expression was observed several days after the last dose of the Î±CD3/Î±EGFR CSANs, compared to control tumors. While current EGFR therapies have shown efficacy against certain TNBC cells, they are ineffective against the MDA-MB-231 cells used in this study, due to the presence of the G13D KRAS mutation.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Consistent with these observations, suppression of EGFR signaling by TKIs and targeted monoclonal antibodies has been shown to suppress tumor expression of PD-L1.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> These observations were not described for alternative protein scaffolds, Î±EGFR CAR-T cells, or Î±EGFR bispecific T cell engagers.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Thus, treatment with Î±EGFR/Î±CD3-CSANs resulted in not only T cell proliferation and directed cell killing but a reduction in the immunosuppressive tumor microenvironment.</div><div class="NLM_p last">Taken together, these results demonstrate the potential for employing FN3-targeted T cell engagers for cancer immunotherapy and Î±CD3/Î±EGFR CSANs in particular. Î±CD3/Î±EGFR CSANs prepared with the FN3, E1, were shown to be nontoxic and to elicit a strong EGFR-targeted T cell-based antitumor response, in addition to decreasing the immunosuppressive nature of the tumor microenvironment. The low toxicity of the Î±CD3/Î±EGFR CSANs is likely due to not just the nature of the Î±EGFR ligand but also the selectivity of the bispecific nanorings for tumor cells expressing relatively high levels of EGFR. As has been demonstrated before, the ability to disassemble the CSANs by dosing with the FDA-approved drug, trimethoprim, offers yet one more temporally implementable safety feature unique to CSANs.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The generality of these findings for other EGFR-expressing tumors is currently under investigation.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05312" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05312" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Cell Lines, Culture Conditions, and T Cell Isolation</h3><div class="NLM_p last">MCF-7, MDA-MB-231, and A431 cancer cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD). Cells were cultured in Dulbeccoâs modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 Î¼g/mL streptomycin at 37 Â°C in 5% CO<sub>2</sub>. Human PBMCs from healthy donor blood samples were isolated from buffy coats (obtained from Memorial Blood Centers, St. Paul, MN) by Ficoll density gradient centrifugation.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> EGFR Antigen Expression Quantification</h3><div class="NLM_p last">EGFR levels of the cancer cells used in this study were quantified using Quantum Simply Cellular Anti-Mouse IgG Fluorescence Calibration Beads from Bangâs Laboratories, Inc. (Fishers, IN) following the manufacturerâs protocol. Briefly, cells and beads were incubated with Alexa Fluor 647-labeled anti-EGFR antibody (Thermo Fisher) for 1 h and, after wash steps, cells and beads were analyzed using the BD LSR II flow cytometer and FACS Diva software.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> DHFR<sup>2</sup> Protein Expression and Purification</h3><div class="NLM_p last">The fusion DHFR<sup>2</sup> constructs were transformed into Rosetta cells from EMD Millipore (Billerica, MA). Colonies picked were cultured in 4 L of lysogeny broth (LB) media, shaken at 250 rpm at 37 Â°C until the OD<sub>600</sub> value reached in the range of 0.5â0.8, and subsequently induced with isopropyl Î²-D-1-thiogalactopyranoside (IPTG; Sigma-Aldrich, St. Louis, MO) at a final concentration of 1 mM. After IPTG induction, cultures were incubated at 37 Â°C for an additional 3 h and centrifuged at 7500 rpm to obtain the cell pellet. 1DD-CD3 was purified from inclusion bodies as described before.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> E1-1DD and E4-1DD were purified by lysing the cell pellet in lysis buffer containing protease inhibitor and further purifying the cell lysate using a Nickel column, yielding 32 and 27 mg/L, respectively.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> CSAN Oligomerization and Characterization</h3><div class="NLM_p last">CSANs were formed by mixing the 1DD monomer with 2 equiv of the C9 dimerizer molecule and incubated at 37 Â°C for 30 min. The CSANs were further characterized by high-pressure liquid chromatography (HPLC) analysis using a Sephadex column for size exclusion chromatography (SEC). The hydrodynamic radius and polydispersity of the rings were determined by dynamic light scattering (DLS) using pUNk by Unchained Labs (Pleasanton, CA). The CSAN samples for cryo-TEM were prepared at 2 Î¼M concentrations in PBS buffer. The CSAN solutions (2.5 Î¼L) were applied to a lacey Formvar/carbon grid (Ted Pella, Inc.; Cat: 01883) in the humidified chamber of a Vitrobot Mark IV (FEI), blotted for 14 s, and plunged into liquid ethane for vitrification. Grids were imaged on a Tecnai Spirit G2 BioTWIN (FEI) equipped with an Eagle 2 k CCD camera (FEI) under a high voltage of 120 kV.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Binding Studies</h3><div class="NLM_p last">Cancer cells were trypsinized and 1.0 Ã 10<sup>5</sup> cells were incubated with 100â500 nM CSANs for 1 h on ice. The cells were washed after incubation with FACS buffer and incubated with anti-His Alexa Fluor 647 antibody (Thermo Fisher Scientific) for 30 min on ice. Cells were again washed with FACS buffer and further analyzed with an LSR II Flow Cytometer. Epitope confirmation was done by a competitive binding assay where the saturating concentration of the ICR-10 PE antibody (Thermo Fisher Scientific) was coincubated with a concentration gradient of unlabeled E1-1DD or E4-1DD. The decrease of the fluorescence signal with increasing unlabeled protein competition was detected with an LSR II Flow Cytometer.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Internalization Studies</h3><div class="NLM_p last">A431 cells were counted and plated on 8-well Î¼-slides from ibidi at a density of 0.2 Ã 10<sup>6</sup> cells per well and cultured overnight at 37 Â°C in 5% CO<sub>2</sub>. Cells were washed and kept on ice for 2 h, followed by 1 h incubation with the Alexa Fluor 647-stained E1-1DD monomers or CSANs. Following the treatment, cells were fixed with 4% paraformaldehyde and stained with Prolong Gold Antifade mounting media. The images were deconvolved with Elements software and further analyzed with FIJI software.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Western Blot Analysis</h3><div class="NLM_p last">MDA-MB-231 cells were plated at 0.4 Ã 10<sup>6</sup> in 6-well plates containing DMEM medium with 10% FBS, 1% GlutaMax, and 1% penicillin/streptomycin. After 24 h, the cells were washed with PBS and incubated with PBS or E1 (0.5 Î¼M) for 24, 48, and 72 hr in serum-free media. Whole-cell lysates were collected using a radioimmunoprecipitation assay (RIPA) buffer with a protease inhibitor (1Ã PBS, 1% nonyl phenoxypolyethoxylethanol (NP-40), 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate containing 1 tablet protease inhibitor cocktail/10 mL buffer [Roche Diagnostics, Indianapolis, Indiana]). Protein concentration was determined using DC assay reagent (Bio-Rad Laboratories). Cell lysates (20 Î¼g) from each sample were electrophoresed on 7.5% sodium dodecyl sulfate-polyacrylamide gels for 80 min and transferred onto a polyvinylidene difluoride membrane for 60 min at 100 V. Membranes were then blocked with 5% milk in 0.1% Tris-buffered saline with Tween (TBST) buffer or 60 min. The membranes were then incubated with the primary antibodies (all from Cell Signaling Technology) at a 1:1000 dilution. The secondary antibody was added after washing three times with TBST for 60 min. Blots were then developed using super signal West Pico according to the manufacturerâs protocol. ImageJ software was used to quantify the results.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Cell Proliferation Assay</h3><div class="NLM_p last">MDA-MB-231 cells were plated in a 96-well plate at 6000 cells/well and cultured overnight. On the second day, media were removed and E1-1DD or 1DD was added to the wells using 1% FBS basal DMEM media, and PBS was used as a control. After 72 h, cell viability was assessed using the MTS reagent CellTiter96 one solution (Promega, Madison, WI). MTS reagent (20 Î¼L) was added to each well and incubated for 30 min. The microplate reader Synergy HT (BioTek) was used to read out the plate at 490 nm and Gene5 software was used to analyze the data.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Cytotoxicity Assay</h3><div class="NLM_p last">For the cytotoxicity assay, 1.0 Ã 10<sup>5</sup> cells were plated per well in a 96-well plate and cultured overnight. The next day, unactivated PBMCs were functionalized with bispecific CSANs for 30 min and then added to the wells containing target cells and incubated for 24 h. The cell lysis in each well was quantified by measuring the lactate dehydrogenase (LDH) released into the media using a nonradioactive cytotoxicity assay (CytoTox 96 Non-Radioactive Cytotoxicity Assay, Promega) following the manufacturerâs manual.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Cytokine Analysis</h3><div class="NLM_p last">The supernatants were collected after the cytotoxicity assay for cytokine analysis using IFN- Î³ and IL-2 ELISA kits (Invitrogen). Cytokine levels were analyzed by comparing the values obtained from samples to a standard curve generated from known concentrations of the cytokines.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>In Vivo</i> Efficacy Study</h3><div class="NLM_p last">All animal protocols were approved by the University of Minnesota Institutional Animal Care and Use Committee (IACUC), complying with both federal and institutional regulations for the humane treatment of animals. On day 0, 6â8 week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice from Jackson Laboratory were injected in the fourth mammary fat pad with 1.0 Ã 10<sup>6</sup> MDA-MB-231 cells in a 1:1 Matrigel/PBS mixture. On day 5, 20 Ã 10<sup>6</sup> PBMCs were injected intravenously. Mice were monitored until the tumors reached 100 mm<sup>3</sup> in size and they were randomized into three treatment groups (<i>n</i> = 5) of PBS, CD3, and E1-CD3. After randomization, mice in each group received a total of six treatments of 1 mg/kg intravenously, given every other day. Additionally, the tumor size and body weight were monitored every other day or daily if necessary. The tumor size was measured by a caliper and the tumor volume was calculated based on (length Ã width<sup>2</sup>)/2. The mice were monitored daily and the endpoint was determined as significant weight loss (%15) or severe dehydration.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Western Blot Analysis of Tumor Lysates</h3><div class="NLM_p last">In a parallel study done for western blot analysis, 10 month old male NSG mice were injected in the flank with 1.0 Ã 10<sup>6</sup> MDA-MB-231 cells in a 1:1 Matrigel/PBS mixture, followed by the same treatment protocol above. Tumors were harvested 27 days after the last treatment. Tumors were homogenized and lysed using RIPA buffer and the total protein concentrations were determined using DC assay reagent (Bio-Rad Laboratories). Cell lysates (50 Î¼g) from each sample were electrophoresed and blotted following the western blot protocol described above.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Immunohistochemistry Analysis</h3><div class="NLM_p last">Resected tumors were prepared in formalin-fixed paraffin-embedded blocks and cut into 5 Î¼m sections. Briefly, after xylene incubation, ethanol dehydration, and antigen retrieval, slides were incubated for 15 min in 3% hydrogen peroxide to block endogenous peroxidase activity. Slides were then stained with hematoxylin and eosin (H&E), Ki76, EGFR, p-EGFR, PD-1, PD-L1, and CD3. Normal goat serum (three drops) in 10 ml of PBS was used as a blocking buffer for 1 hr at room temperature before incubation of the primary antibodies (Vectastatin ABC Kit; Vector Laboratories). Slides were then incubated with the following primary antibodies overnight at 4 Â°C: Ki67 (Abcam; ab833), EGFR (Cell signaling; 4267), p-EGFR (Cell signaling; 3777), PD-1 (Cell signaling; 86163), PD-L1 (Cell signaling; 13684), and CD3 (Abcam; ab16669). The sections were developed using diaminobenzidine (DAB) solution (DAB substrate kit; Vector Laboratories) and counterstained with hematoxylin. A Leica DM 4000B LED microscope was used to visualize the staining and generate images at 10X magnification using LAS4.7 software. The staining was graded as low (<30% positive cells/field), moderate (30â60% positive cells/field), or high (>60% positive cells/field). The proportion of each grade for each antigen was analyzed by the chi-square test and Fisher exact test to determine the significance between control and treatment groups using GraphPad Prism software. Significance was considered if <i>P</i> value <0.05.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Statistical Analysis</h3><div class="NLM_p last">Analysis of <i>in vivo</i> experiments was performed using GraphPad Prism software, version 6.0 (San Diego California). For âtumor sizeâ and âbody weight,â we applied regular two-way ANOVA, followed by Dunnettâs test for multiple comparisons. The survival curves were compared by the log-rank (MantelâCox) test. All results are expressed as mean Â± S.E.M, with significance level set at <i>P</i> â¤ 0.05.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00489" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60628" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60628" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00489?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00489</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Characterization and binding of E1-1DD and E4-1DD; cross-reactivity with mouse EGFR; control groups from the bispecific CSANs PBMC-binding study; internalization of the E1-1DD monomer and rings; control groups from the bispecific CSANs PBMC-binding study; and western blot analysis and quantification of the tumor lysates (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf">jm0c00489_si_001.pdf (1.56 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00489" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76305" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76305" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carston R. Wagner</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , and , University of Minnesota, Minneapolis, Minnesota 55455, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7927-719X" title="Orcid link">http://orcid.org/0000-0001-7927-719X</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#750214121b104545463500181b5b101100"><span class="__cf_email__" data-cfemail="26514741484316161566534b4808434253">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ozgun Kilic</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , and , University of Minnesota, Minneapolis, Minnesota 55455, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6735-8830" title="Orcid link">http://orcid.org/0000-0001-6735-8830</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcos R. Matos de Souza</span> - <span class="hlFld-Affiliation affiliation">Department
of Virology, Universidade Federal do Rio
de Janeiro, Rio de
Janeiro 21941-902, Brazil</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9365-3224" title="Orcid link">http://orcid.org/0000-0002-9365-3224</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abdulaziz A. Almotlak</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology, , and , University of Minnesota, Minneapolis, Minnesota 55455, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yiao Wang</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, , and , University of Minnesota, Minneapolis, Minnesota 55455, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jill M. Siegfried</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology, , and , University of Minnesota, Minneapolis, Minnesota 55455, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark D. Distefano</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, , and , University of Minnesota, Minneapolis, Minnesota 55455, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2872-0259" title="Orcid link">http://orcid.org/0000-0002-2872-0259</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): I am CSO for Tychon Bioscience, LLC and a co-founder.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e1134-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by Tychon Bioscience, LLC, the National Cancer Institute CA185627 (CRW), CA247681 (CRW), GM084152 (MDD) and NSF Grant ECCS-2025124 to the Minnesota Nano Center. We thank Mark Sanders and the University of Minnesota University Imaging Centers for experimental and technical support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">CARs</td><td class="NLM_def"><p class="first last">chimeric antigen receptors</p></td></tr><tr><td class="NLM_term">CSAN</td><td class="NLM_def"><p class="first last">chemically self-assembled nanoring</p></td></tr><tr><td class="NLM_term">DD, DHFR<sup>2</sup> EGFR</td><td class="NLM_def"><p class="first last">epithelial growth factor receptor</p></td></tr><tr><td class="NLM_term">p-EGFR</td><td class="NLM_def"><p class="first last">phosphorylated epithelial growth factor receptor</p></td></tr><tr><td class="NLM_term">EpCAM</td><td class="NLM_def"><p class="first last">epithelial cell adhesion molecule</p></td></tr><tr><td class="NLM_term">FN3</td><td class="NLM_def"><p class="first last">fibronectin</p></td></tr><tr><td class="NLM_term">i.v</td><td class="NLM_def"><p class="first last">intravenous injection</p></td></tr><tr><td class="NLM_term">MTX</td><td class="NLM_def"><p class="first last">methotrexate</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed cell death-1</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed cell death ligand-1</p></td></tr><tr><td class="NLM_term">PARS</td><td class="NLM_def"><p class="first last">prosthetic antigen receptors</p></td></tr><tr><td class="NLM_term">scFvs</td><td class="NLM_def"><p class="first last">single-chain variable fragments</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leyfman, Y.</span></span> <span> </span><span class="NLM_article-title">Chimeric Antigen Receptors: Unleashing a New Age of Anti-Cancer Therapy</span>. <i>Cancer Cell Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>, <span class="NLM_elocation-id">182</span> <span class="refDoi">Â DOI: 10.1186/s12935-018-0685-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1186%2Fs12935-018-0685-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=30459530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2ksrbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&author=Y.+Leyfman&title=Chimeric+Antigen+Receptors%3A+Unleashing+a+New+Age+of+Anti-Cancer+Therapy&doi=10.1186%2Fs12935-018-0685-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptors: unleashing a new age of anti-cancer therapy</span></div><div class="casAuthors">Leyfman, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell International</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">182</span>CODEN:
                <span class="NLM_cas:coden">CCIACC</span>;
        ISSN:<span class="NLM_cas:issn">1475-2867</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Chimeric antigen receptors (CARs) represent a novel facet of modern day synthetic biol. that exemplifies personalized medicine at work through their ability to harness and redirect a patient's immune system to fight cancer.  By combining the target-specificity of antibodies to the effector capabilities of T cells, CARs have yielded high remission rates for many late staged and relapsed/refractory (r/r) hematol. malignancies, including acute lymphoblastic leukemias (ALL) and Non-Hodgkin's lymphomas.  Despite toxicities of cytokine release syndrome and neurotoxicity, recent studies have uncovered their underlying mechanisms and devised effective therapies to manage and possibly prevent them.  In 2017, CAR T cell therapy became a reality for the general public despite the high costs, when Novartis's Kymriah, became the first product to receive FDA approval for pediatric r/r B cell ALL with Gilead's Yescarta following several months later.  Although effective in hematol. malignancies, CAR response has been limited in solid tumors largely attributed to the heterogeneous and immunosuppressive tumor microenvironment along tumor defense mechanisms, such as antigenic escape.  Despite the current challenges of CAR T therapy, this technol. is still in its infancy and its promise will continue to grow as scientists continue to develop novel approaches to enhance its efficacy.  As its prevalence continues to increase, institutions and pharmaceuticals worldwide are investing in this technol. in hopes of driving therapeutic innovation, while providing greater access to their resp. populations through clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Y3AeKgo28LVg90H21EOLACvtfcHk0lhudqNDhVrSIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2ksrbP&md5=f3345b091d5a10940913bf6e13668f7e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1186%2Fs12935-018-0685-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12935-018-0685-x%26sid%3Dliteratum%253Aachs%26aulast%3DLeyfman%26aufirst%3DY.%26atitle%3DChimeric%2520Antigen%2520Receptors%253A%2520Unleashing%2520a%2520New%2520Age%2520of%2520Anti-Cancer%2520Therapy%26jtitle%3DCancer%2520Cell%2520Int.%26date%3D2018%26volume%3D18%26doi%3D10.1186%2Fs12935-018-0685-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dreier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenczewski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syring, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanakam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riethmuller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeuerle, P. A.</span></span> <span> </span><span class="NLM_article-title">Extremely Potent, Rapid and Costimulation-Independent Cytotoxic T-Cell Response against Lymphoma Cells Catalyzed by a Single-Chain Bispecific Antibody</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">690</span>â <span class="NLM_lpage">697</span>, <span class="refDoi">Â DOI: 10.1002/ijc.10557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1002%2Fijc.10557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=12209608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFKgsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=690-697&author=T.+Dreierauthor=G.+Lorenczewskiauthor=C.+Brandlauthor=P.+Hoffmannauthor=U.+Syringauthor=F.+Hanakamauthor=P.+Kuferauthor=G.+Riethmullerauthor=R.+Bargouauthor=P.+A.+Baeuerle&title=Extremely+Potent%2C+Rapid+and+Costimulation-Independent+Cytotoxic+T-Cell+Response+against+Lymphoma+Cells+Catalyzed+by+a+Single-Chain+Bispecific+Antibody&doi=10.1002%2Fijc.10557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody</span></div><div class="casAuthors">Dreier, Torsten; Lorenczewski, Grit; Brandl, Christian; Hoffmann, Patrick; Syring, Uwe; Hanakam, Frank; Kufer, Peter; Riethmuller, Gert; Bargou, Ralf; Baeuerle, Patrick A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">690-697</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A recent study reported on an anti-CD19/anti-CD3 single-chain bispecific antibody (bscCD19ÃCD3) exhibiting high activity against human B lymphoma cell lines.  In the present study, we have explored in detail the in vitro efficacy, T-cell donor variability, binding characteristics, specificity, kinetics and interleukin-2 (IL-2) dependence of bscCD19ÃCD3.  We found that a majority of human donor T cells tested (n = 86) gave half-maximal B-lymphoma cell lysis (ED50) within a range of 10-50 pg/mL bscCD19ÃCD3, corresponding to sub-picomolar concns. of the bispecific antibody.  Under identical exptl. conditions, the anti-CD20 monoclonal antibody rituximab had an at least 100,000-fold lower in vitro efficacy.  The extreme potency of bscCD19ÃCD3 was in sharp contrast to the relatively low affinity of the anti-CD3 and anti-CD19 single-chain Fv portions in KD ranges of 10-7 and 10-9 M, resp.  Cell lysis by bscCD19ÃCD3 was predominantly mediated by the population of CD8/CD45RO-pos. T cells.  Both immortalized CD4- and CD8-pos. human T-cell clones were highly active effector cells as well.  Cell lysis by bscCD19ÃCD3 was rapid and specific.  The resp. parental monoclonal antibodies inhibited cell lysis and CD19-neg. cells were not harmed by T cells in the presence of high amts. of bscCD19ÃCD3.  The potent T-cell stimulus IL-2 could not markedly augment the activity of bscCD19ÃCD3-stimulated T cells.  In conclusion, bscCD19ÃCD3 could redirect unstimulated cytotoxic T cells against CD19-pos. cells in an unexpectedly potent, rapid and specific fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSKchUnK877Vg90H21EOLACvtfcHk0lhudqNDhVrSIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFKgsr0%253D&md5=24a4615794140f62610725a9641ed69b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fijc.10557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10557%26sid%3Dliteratum%253Aachs%26aulast%3DDreier%26aufirst%3DT.%26aulast%3DLorenczewski%26aufirst%3DG.%26aulast%3DBrandl%26aufirst%3DC.%26aulast%3DHoffmann%26aufirst%3DP.%26aulast%3DSyring%26aufirst%3DU.%26aulast%3DHanakam%26aufirst%3DF.%26aulast%3DKufer%26aufirst%3DP.%26aulast%3DRiethmuller%26aufirst%3DG.%26aulast%3DBargou%26aufirst%3DR.%26aulast%3DBaeuerle%26aufirst%3DP.%2BA.%26atitle%3DExtremely%2520Potent%252C%2520Rapid%2520and%2520Costimulation-Independent%2520Cytotoxic%2520T-Cell%2520Response%2520against%2520Lymphoma%2520Cells%2520Catalyzed%2520by%2520a%2520Single-Chain%2520Bispecific%2520Antibody%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D100%26spage%3D690%26epage%3D697%26doi%3D10.1002%2Fijc.10557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, D.</span></span> <span> </span><span class="NLM_article-title">The Development of Bispecific Antibodies and Their Applications in Tumor Immune Escape</span>. <i>Exp. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">12</span> <span class="refDoi">Â DOI: 10.1186/s40164-017-0072-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1186%2Fs40164-017-0072-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=28469973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVGntrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&author=X.+Zhangauthor=Y.+Yangauthor=D.+Fanauthor=D.+Xiong&title=The+Development+of+Bispecific+Antibodies+and+Their+Applications+in+Tumor+Immune+Escape&doi=10.1186%2Fs40164-017-0072-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The development of bispecific antibodies and their applications in tumor immune escape</span></div><div class="casAuthors">Zhang, Xiaolong; Yang, Yuanyuan; Fan, Dongmei; Xiong, Dongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology & Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12/1-12/6</span>CODEN:
                <span class="NLM_cas:coden">EHOXAU</span>;
        ISSN:<span class="NLM_cas:issn">2162-3619</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">During the past two decades, a great evolution of bispecific antibodies (BsAbs) for therapeutic applications has been made.  BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wide range of applications including redirecting T cells or NK cells to tumor cells, blocking two different signaling pathways, dual targeting of different disease mediators, and delivering payloads to targeted sites.  Aside from approved catumaxomab (anti-CD3 and anti-EpCAM) and blinatumomab (anti-CD3 and anti-CD19), many more BsAbs are now in various phases of clin. development.  Here, this review focus on the development of bispecific antibodies and their applications in tumor immune escape.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgF1LZW9dH3LVg90H21EOLACvtfcHk0lhudqNDhVrSIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVGntrc%253D&md5=c5da87ad9e5f525866d314ae1cfef279</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fs40164-017-0072-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40164-017-0072-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DD.%26aulast%3DXiong%26aufirst%3DD.%26atitle%3DThe%2520Development%2520of%2520Bispecific%2520Antibodies%2520and%2520Their%2520Applications%2520in%2520Tumor%2520Immune%2520Escape%26jtitle%3DExp.%2520Hematol.%2520Oncol.%26date%3D2017%26volume%3D6%26doi%3D10.1186%2Fs40164-017-0072-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span> <span> </span><span class="NLM_article-title">Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">767</span> <span class="refDoi">Â DOI: 10.3389/fonc.2019.00767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.3389%2Ffonc.2019.00767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=31482064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BB3MrkvVyguw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=Y.+Caoauthor=W.+Luauthor=R.+Sunauthor=X.+Jinauthor=L.+Chengauthor=X.+Heauthor=L.+Wangauthor=T.+Yuanauthor=C.+Lyuauthor=M.+Zhao&title=Anti-CD19+Chimeric+Antigen+Receptor+T+Cells+in+Combination+With+Nivolumab+Are+Safe+and+Effective+Against+Relapsed%2FRefractory+B-Cell+Non-Hodgkin+Lymphoma&doi=10.3389%2Ffonc.2019.00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma</span></div><div class="casAuthors">Cao Yaqing; Sun Rui; Cheng Lin; Wang Luqiao; Lu Wenyi; Yuan Ting; Lyu Cuicui; Zhao Mingfeng; Jin Xin; He Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">767</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment for patients with refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL), and combination with PD1 inhibitors may further improve the efficacy of anti-CD19 CAR (CD19 CAR)-T cells in the treatment of lymphomas.  In a single-center study, we evaluated the safety and efficacy of a combination therapy with CD19 CAR-T cells and an anti-PD-1 antibody (nivolumab) in patients with relapsed/refractory B-NHL.  A total of 11 patients with refractory/relapsed B-NHL were recruited and subsequently received CD19 CAR-T cells and nivolumab.  The primary end points were safety and feasibility.  The infusions were safe, and no dose-limiting toxicities occurred.  Grade 1 or 2 cytokine release syndrome (CRS) was observed in 25% (3/11) and 50% (6/11) of the patients, respectively, and only one patient (1/11) experienced neurotoxicity.  The objective response rate (ORR) and complete response (CR) rate were 81.81% (9/11) and 45.45% (5/11), respectively.  The median follow-up time was 6 (1~15) months.  The median progression-free survival (PFS) time was 6 months (1~14 months), and 3 patients continued to have a response at the time of this writing.  Our study demonstrated that the combination of CD19 CAR-T cells and nivolumab was feasible and safe and mediated potent anti-lymphoma activity, which should be examined further in prospective clinical trials in refractory/relapsed B-NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbUklrjYont4xhnOQkIHOxfW6udTcc2ea0PDTEL6Frv7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrkvVyguw%253D%253D&md5=6bc45fcdc1fa2f8b5d87f5351a80f2c3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00767%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DT.%26aulast%3DLyu%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DM.%26atitle%3DAnti-CD19%2520Chimeric%2520Antigen%2520Receptor%2520T%2520Cells%2520in%2520Combination%2520With%2520Nivolumab%2520Are%2520Safe%2520and%2520Effective%2520Against%2520Relapsed%252FRefractory%2520B-Cell%2520Non-Hodgkin%2520Lymphoma%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26doi%3D10.3389%2Ffonc.2019.00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brentjens, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davila, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borquez-Ojeda, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasielewska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rijo, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedvat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinherz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maslak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadelain, M.</span></span> <span> </span><span class="NLM_article-title">CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">177ra38</span> <span class="refDoi">Â DOI: 10.1126/scitranslmed.3005930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1126%2Fscitranslmed.3005930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=23515080" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&author=R.+J.+Brentjensauthor=M.+L.+Davilaauthor=I.+Riviereauthor=J.+Parkauthor=X.+Wangauthor=L.+G.+Cowellauthor=S.+Bartidoauthor=J.+Stefanskiauthor=C.+Taylorauthor=M.+Olszewskaauthor=O.+Borquez-Ojedaauthor=J.+Quauthor=T.+Wasielewskaauthor=Q.+Heauthor=Y.+Bernalauthor=I.+V.+Rijoauthor=C.+Hedvatauthor=R.+Kobosauthor=K.+Curranauthor=P.+Steinherzauthor=J.+Jurcicauthor=T.+Rosenblatauthor=P.+Maslakauthor=M.+Frattiniauthor=M.+Sadelain&title=CD19-Targeted+T+Cells+Rapidly+Induce+Molecular+Remissions+in+Adults+with+Chemotherapy-Refractory+Acute+Lymphoblastic+Leukemia&doi=10.1126%2Fscitranslmed.3005930"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005930%26sid%3Dliteratum%253Aachs%26aulast%3DBrentjens%26aufirst%3DR.%2BJ.%26aulast%3DDavila%26aufirst%3DM.%2BL.%26aulast%3DRiviere%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCowell%26aufirst%3DL.%2BG.%26aulast%3DBartido%26aufirst%3DS.%26aulast%3DStefanski%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DOlszewska%26aufirst%3DM.%26aulast%3DBorquez-Ojeda%26aufirst%3DO.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DWasielewska%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DBernal%26aufirst%3DY.%26aulast%3DRijo%26aufirst%3DI.%2BV.%26aulast%3DHedvat%26aufirst%3DC.%26aulast%3DKobos%26aufirst%3DR.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DSteinherz%26aufirst%3DP.%26aulast%3DJurcic%26aufirst%3DJ.%26aulast%3DRosenblat%26aufirst%3DT.%26aulast%3DMaslak%26aufirst%3DP.%26aulast%3DFrattini%26aufirst%3DM.%26aulast%3DSadelain%26aufirst%3DM.%26atitle%3DCD19-Targeted%2520T%2520Cells%2520Rapidly%2520Induce%2520Molecular%2520Remissions%2520in%2520Adults%2520with%2520Chemotherapy-Refractory%2520Acute%2520Lymphoblastic%2520Leukemia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26doi%3D10.1126%2Fscitranslmed.3005930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kochenderfer, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerville, R. P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler-Stevenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranick, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, D.-A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toomey, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span> <span> </span><span class="NLM_article-title">Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">540</span>â <span class="NLM_lpage">549</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2014.56.2025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1200%2FJCO.2014.56.2025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25154820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktlCntr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=540-549&author=J.+N.+Kochenderferauthor=M.+E.+Dudleyauthor=S.+H.+Kassimauthor=R.+P.+T.+Somervilleauthor=R.+O.+Carpenterauthor=M.+Stetler-Stevensonauthor=J.+C.+Yangauthor=G.+Q.+Phanauthor=M.+S.+Hughesauthor=R.+M.+Sherryauthor=M.+Raffeldauthor=S.+Feldmanauthor=L.+Luauthor=Y.+F.+Liauthor=L.+T.+Ngoauthor=A.+Goyauthor=T.+Feldmanauthor=D.+E.+Spanerauthor=M.+L.+Wangauthor=C.+C.+Chenauthor=S.+M.+Kranickauthor=A.+Nathauthor=D.-A.+N.+Nathanauthor=K.+E.+Mortonauthor=M.+A.+Toomeyauthor=S.+A.+Rosenberg&title=Chemotherapy-Refractory+Diffuse+Large+B-Cell+Lymphoma+and+Indolent+B-Cell+Malignancies+Can+Be+Effectively+Treated+with+Autologous+T+Cells+Expressing+an+Anti-CD19+Chimeric+Antigen+Receptor&doi=10.1200%2FJCO.2014.56.2025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD 19 chimeric antigen receptor</span></div><div class="casAuthors">Kochenderfer, James N.; Dudley, Mark E.; Kassim, Sadik H.; Somerville, Robert P. T.; Carpenter, Robert O.; Stetler-Stevenson, Maryalice; Yang, James C.; Phan, Giao Q.; Hughes, Marybeth S.; Sherry, Richard M.; Raffeld, Mark; Feldman, Steven; Lu, Lily; Li, Yong F.; Ngo, Lien T.; Goy, Andre; Feldman, Tatyana; Spaner, David E.; Wang, Michael L.; Chen, Clara C.; Kranick, Sarah M.; Nath, Avindra; Nathan, Debbie-Ann N.; Morton, Kathleen E.; Toomey, Maly Ann; Rosenberg, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">540-549</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR).  We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19+ B-cell malignancies.  Patients and Methods: We treated 15 patients with advanced B-cell malignancies.  Nine patients had diffuse large B-cell lymphoma (DLBCL), two had indolent lymphomas, and four had chronic lymphocytic leukemia.  Patients received a conditioning chemotherapy regimen of cyclophosphamide and fludarabine followed by a single infusion of anti-CD19 CAR T cells.  Results: Of 15 patients, eight achieved complete remissions (CRs), four achieved partial remissions, one had stable lymphoma, and two were not evaluable for response.  CRs were obtained by four of seven evaluable patients with chemotherapy-refractory DLBCL; three of these four CRs are ongoing, with durations ranging from 9 to 22 mo.  Acute toxicities including fever, hypotension, delirium, and other neurol. toxicities occurred in some patients after infusion of anti-CD19 CAR T cells; these toxicities resolved within 3 wk after cell infusion.  One patient died suddenly as a result of an unknown cause 16 days after cell infusion.  CAR T cells were detected in the blood of patients at peak levels, ranging from nine to 777 CAR-pos. T cells/Î¼L.  Conclusion This is the first report to our knowledge of successful treatment of DLBCL with anti-CD19 CAR T cells.  These results demonstrate the feasibility and effectiveness of treating chemotherapy-refractory B-cell malignancies with anti-CD19 CAR T cells.  The numerous remissions obtained provide strong support for further development of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIqip2risUlbVg90H21EOLACvtfcHk0lj2WvNK53hNRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktlCntr4%253D&md5=494054bba74644cd28a1a5977f4d52b0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.56.2025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.56.2025%26sid%3Dliteratum%253Aachs%26aulast%3DKochenderfer%26aufirst%3DJ.%2BN.%26aulast%3DDudley%26aufirst%3DM.%2BE.%26aulast%3DKassim%26aufirst%3DS.%2BH.%26aulast%3DSomerville%26aufirst%3DR.%2BP.%2BT.%26aulast%3DCarpenter%26aufirst%3DR.%2BO.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPhan%26aufirst%3DG.%2BQ.%26aulast%3DHughes%26aufirst%3DM.%2BS.%26aulast%3DSherry%26aufirst%3DR.%2BM.%26aulast%3DRaffeld%26aufirst%3DM.%26aulast%3DFeldman%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%2BF.%26aulast%3DNgo%26aufirst%3DL.%2BT.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DFeldman%26aufirst%3DT.%26aulast%3DSpaner%26aufirst%3DD.%2BE.%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DChen%26aufirst%3DC.%2BC.%26aulast%3DKranick%26aufirst%3DS.%2BM.%26aulast%3DNath%26aufirst%3DA.%26aulast%3DNathan%26aufirst%3DD.-A.%2BN.%26aulast%3DMorton%26aufirst%3DK.%2BE.%26aulast%3DToomey%26aufirst%3DM.%2BA.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DChemotherapy-Refractory%2520Diffuse%2520Large%2520B-Cell%2520Lymphoma%2520and%2520Indolent%2520B-Cell%2520Malignancies%2520Can%2520Be%2520Effectively%2520Treated%2520with%2520Autologous%2520T%2520Cells%2520Expressing%2520an%2520Anti-CD19%2520Chimeric%2520Antigen%2520Receptor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D540%26epage%3D549%26doi%3D10.1200%2FJCO.2014.56.2025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maude, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aplenc, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahnke, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melenhorst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheingold, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teachey, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span> <span> </span><span class="NLM_article-title">Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1507</span>â <span class="NLM_lpage">1517</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1407222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1056%2FNEJMoa1407222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25317870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSls73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1507-1517&author=S.+L.+Maudeauthor=N.+Freyauthor=P.+A.+Shawauthor=R.+Aplencauthor=D.+M.+Barrettauthor=N.+J.+Buninauthor=A.+Chewauthor=V.+E.+Gonzalezauthor=Z.+Zhengauthor=S.+F.+Laceyauthor=Y.+D.+Mahnkeauthor=J.+J.+Melenhorstauthor=S.+R.+Rheingoldauthor=A.+Shenauthor=D.+T.+Teacheyauthor=B.+L.+Levineauthor=C.+H.+Juneauthor=D.+L.+Porterauthor=S.+A.+Grupp&title=Chimeric+Antigen+Receptor+T+Cells+for+Sustained+Remissions+in+Leukemia&doi=10.1056%2FNEJMoa1407222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptor T cells for sustained remissions in leukemia</span></div><div class="casAuthors">Maude, Shannon L.; Frey, Noelle; Shaw, Pamela A.; Aplenc, Richard; Barrett, David M.; Bunin, Nancy J.; Chew, Anne; Gonzalez, Vanessa E.; Zheng, Zhaohui; Lacey, Simon F.; Mahnke, Yolanda D.; Melenhorst, Jan J.; Rheingold, Susan R.; Shen, Angela; Teachey, David T.; Levine, Bruce L.; June, Carl H.; Porter, David L.; Grupp, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1507-1517, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies.  Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.  Methods: We infused autologous T cells transduced with a CD19-directed chimeric antigen receptor (CTL019) lentiviral vector in patients with relapsed or refractory ALL at doses of 0.76 Ã 106 to 20.6 Ã 106 CTL019 cells per kg of body wt.  Patients were monitored for a response, toxic effects, and the expansion and persistence of circulating CTL019 T cells.  Results: A total of 30 children and adults received CTL019.  Complete remission was achieved in 27 patients (90%), including 2 patients with blinatumomab-refractory disease and 15 who had undergone stem-cell transplantation.  CTL019 cells proliferated in vivo and were detectable in the blood, bone marrow, and cerebrospinal fluid of patients who had a response.  Sustained remission was achieved with a 6-mo event-free survival rate of 67% (95% confidence interval [CI], 51 to 88) and an overall survival rate of 78% (95% CI, 65 to 95).  At 6 mo, the probability that a patient would have persistence of CTL019 was 68% (95% CI, 50 to 92) and the probability that a patient would have relapse-free B-cell aplasia was 73% (95% CI, 57 to 94).  All the patients had the cytokine-release syndrome.  Severe cytokine-release syndrome, which developed in 27% of the patients, was assocd. with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.  Conclusions: Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL.  CTL019 was assocd. with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 mo were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMldO024V5VrVg90H21EOLACvtfcHk0lglIDBsa3ujtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSls73K&md5=7f13aaa25ae118901d3bec614b07cc3a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1407222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1407222%26sid%3Dliteratum%253Aachs%26aulast%3DMaude%26aufirst%3DS.%2BL.%26aulast%3DFrey%26aufirst%3DN.%26aulast%3DShaw%26aufirst%3DP.%2BA.%26aulast%3DAplenc%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DD.%2BM.%26aulast%3DBunin%26aufirst%3DN.%2BJ.%26aulast%3DChew%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DV.%2BE.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DLacey%26aufirst%3DS.%2BF.%26aulast%3DMahnke%26aufirst%3DY.%2BD.%26aulast%3DMelenhorst%26aufirst%3DJ.%2BJ.%26aulast%3DRheingold%26aufirst%3DS.%2BR.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DTeachey%26aufirst%3DD.%2BT.%26aulast%3DLevine%26aufirst%3DB.%2BL.%26aulast%3DJune%26aufirst%3DC.%2BH.%26aulast%3DPorter%26aufirst%3DD.%2BL.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26atitle%3DChimeric%2520Antigen%2520Receptor%2520T%2520Cells%2520for%2520Sustained%2520Remissions%2520in%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1507%26epage%3D1517%26doi%3D10.1056%2FNEJMoa1407222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochenderfer, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler-Stevenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbrook, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orentas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroncek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschernia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayne, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackall, C. L.</span></span> <span> </span><span class="NLM_article-title">T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">517</span>â <span class="NLM_lpage">528</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(14)61403-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2FS0140-6736%2814%2961403-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25319501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGjtLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=517-528&author=D.+W.+Leeauthor=J.+N.+Kochenderferauthor=M.+Stetler-Stevensonauthor=Y.+K.+Cuiauthor=C.+Delbrookauthor=S.+A.+Feldmanauthor=T.+J.+Fryauthor=R.+Orentasauthor=M.+Sabatinoauthor=N.+N.+Shahauthor=S.+M.+Steinbergauthor=D.+Stroncekauthor=N.+Tscherniaauthor=C.+Yuanauthor=H.+Zhangauthor=L.+Zhangauthor=S.+A.+Rosenbergauthor=A.+S.+Wayneauthor=C.+L.+Mackall&title=T+Cells+Expressing+CD19+Chimeric+Antigen+Receptors+for+Acute+Lymphoblastic+Leukaemia+in+Children+and+Young+Adults%3A+A+Phase+1+Dose-Escalation+Trial&doi=10.1016%2FS0140-6736%2814%2961403-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial</span></div><div class="casAuthors">Lee, Daniel W.; Kochenderfer, James N.; Stetler-Stevenson, Maryalice; Cui, Yongzhi K.; Delbrook, Cindy; Feldman, Steven A.; Fry, Terry J.; Orentas, Rimas; Sabatino, Marianna; Shah, Nirali N.; Steinberg, Seth M.; Stroncek, Dave; Tschernia, Nick; Yuan, Constance; Zhang, Hua; Zhang, Ling; Rosenberg, Steven A.; Wayne, Alan S.; Mackall, Crystal L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">9967</span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported.  We aimed to define feasibility, toxicity, max. tolerated dose, response rate, and biol. correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells.  This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukemia or non-Hodgkin lymphoma.  Autologous T cells were engineered via an 11-day manufg. process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains.  All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells.  Using a std. 3 + 3 design to establish the max. tolerated dose, patients received either 1 Ã 106 CAR-transduced T cells per kg (dose 1), 3 Ã 106 CAR-transduced T cells per kg (dose 2), or the entire CAR T-cell product if sufficient nos. of cells to meet the assigned dose were not generated.  After the dose-escalation phase, an expansion cohort was treated at the max. tolerated dose.  The trial is registered with ClinicalTrials.gov, no. NCT01593696.  Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concn. could not be generated for two patients (90% feasible).  All patients enrolled were assessed for response.  The max. tolerated dose was defined as 1 Ã 106 CD19-CAR T cells per kg.  All toxicities were fully reversible, with the most severe being grade 4 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 3Â·0-36Â·3).  The most common non-haematol. grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients).  CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukemia.  All toxicities were reversible and prolonged B-cell aplasia did not occur.  National Institutes of Health Intramural funds and St Baldrick's Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoItCLZAV3HoLVg90H21EOLACvtfcHk0lglIDBsa3ujtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGjtLbM&md5=6d2ae3cb6d1672a1f0b3c0fedef2c337</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961403-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961403-3%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DKochenderfer%26aufirst%3DJ.%2BN.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DY.%2BK.%26aulast%3DDelbrook%26aufirst%3DC.%26aulast%3DFeldman%26aufirst%3DS.%2BA.%26aulast%3DFry%26aufirst%3DT.%2BJ.%26aulast%3DOrentas%26aufirst%3DR.%26aulast%3DSabatino%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DN.%2BN.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DStroncek%26aufirst%3DD.%26aulast%3DTschernia%26aufirst%3DN.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26aulast%3DWayne%26aufirst%3DA.%2BS.%26aulast%3DMackall%26aufirst%3DC.%2BL.%26atitle%3DT%2520Cells%2520Expressing%2520CD19%2520Chimeric%2520Antigen%2520Receptors%2520for%2520Acute%2520Lymphoblastic%2520Leukaemia%2520in%2520Children%2520and%2520Young%2520Adults%253A%2520A%2520Phase%25201%2520Dose-Escalation%2520Trial%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D517%26epage%3D528%26doi%3D10.1016%2FS0140-6736%2814%2961403-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albelda, S. M.</span></span> <span> </span><span class="NLM_article-title">CAR T Cell Therapy for Solid Tumors</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">139</span>â <span class="NLM_lpage">152</span>, <span class="refDoi">Â DOI: 10.1146/annurev-med-062315-120245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1146%2Fannurev-med-062315-120245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=27860544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvV2hsrbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2017&pages=139-152&author=K.+Newickauthor=S.+O%E2%80%99Brienauthor=E.+Moonauthor=S.+M.+Albelda&title=CAR+T+Cell+Therapy+for+Solid+Tumors&doi=10.1146%2Fannurev-med-062315-120245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">CAR T Cell Therapy for Solid Tumors</span></div><div class="casAuthors">Newick, Kheng; O'Brien, Shaun; Moon, Edmund; Albelda, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">139-152</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The field of cancer immunotherapy has been re-energized by the application of chimeric antigen receptor (CAR) T cell therapy in cancers.  These CAR T cells are engineered to express synthetic receptors that redirect polyclonal T cells to surface antigens for subsequent tumor elimination.  Many CARs are designed with elements that augment T cell persistence and activity.  To date, CAR T cells have demonstrated tremendous success in eradicating hematol. malignancies (e.g., CD19 CARs in leukemias).  However, this success has yet to be extrapolated to solid tumors, and the reasons for this are being actively investigated.  We characterize some of the challenges that CAR T cells have to surmount in the solid tumor microenvironment and new approaches that are being considered to overcome these hurdles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN74osDaZwLbVg90H21EOLACvtfcHk0lgCshhUc7nqow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvV2hsrbO&md5=9c9442940e68a19f9430e4366c1a3cd0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-062315-120245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-062315-120245%26sid%3Dliteratum%253Aachs%26aulast%3DNewick%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DMoon%26aufirst%3DE.%26aulast%3DAlbelda%26aufirst%3DS.%2BM.%26atitle%3DCAR%2520T%2520Cell%2520Therapy%2520for%2520Solid%2520Tumors%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2017%26volume%3D68%26spage%3D139%26epage%3D152%26doi%3D10.1146%2Fannurev-med-062315-120245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinay, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2466</span>â <span class="NLM_lpage">2476</span>, <span class="refDoi">Â DOI: 10.1016/j.ymthe.2017.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.ymthe.2017.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=28784559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOjurbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2466-2476&author=X.+Hanauthor=G.+E.+Cinayauthor=Y.+Zhaoauthor=Y.+Guoauthor=X.+Zhangauthor=P.+Wang&title=Adnectin-Based+Design+of+Chimeric+Antigen+Receptor+for+T+Cell+Engineering&doi=10.1016%2Fj.ymthe.2017.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering</span></div><div class="casAuthors">Han, Xiaolu; Cinay, Gunce E.; Zhao, Yifan; Guo, Yunfei; Zhang, Xiaoyang; Wang, Pin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2466-2476</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although chimeric antigen receptor (CAR)-engineered T cell therapy has achieved encouraging clin. trial results for treating hematol. cancers, further optimization can likely expand this therapeutic success to more patients and other cancer types.  Most CAR constructs used in clin. trials incorporate single chain variable fragment (scFv) as the extracellular antigen recognition domain.  The immunogenicity of nonhuman scFv could cause host rejection against CAR T cells and compromise their persistence and efficacy.  The limited availability of scFvs and slow discovery of new monoclonal antibodies also limit the development of novel CAR constructs.  Adnectin, a class of affinity mols. derived from the tenth type III domain of human fibronectin, can be an alternative to scFv as an antigen-binding moiety in the design of CAR mols.  We constructed adnectin-based CARs targeting epithelial growth factor receptor (EGFR) and found that compared to scFv-based CAR, T cells engineered with adnectin-based CARs exhibited equiv. cell-killing activity against target H292 lung cancer cells in vitro and had comparable antitumor efficacy in xenograft tumor-bearing mice in vivo.  In addn., with optimal affinity tuning, adnectin-based CAR showed higher selectivity on target cells with high EGFR expression than on those with low expression.  This new design of adnectin CARs can potentially facilitate the development of T cell immunotherapy for cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJmB-M3xf8prVg90H21EOLACvtfcHk0lgCshhUc7nqow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOjurbM&md5=33deaae40e0551a759107d8bd104edb7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2017.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2017.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DCinay%26aufirst%3DG.%2BE.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DAdnectin-Based%2520Design%2520of%2520Chimeric%2520Antigen%2520Receptor%2520for%2520T%2520Cell%2520Engineering%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D2466%26epage%3D2476%26doi%3D10.1016%2Fj.ymthe.2017.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirabayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span> <span> </span><span class="NLM_article-title">Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">773</span>â <span class="NLM_lpage">783</span>, <span class="refDoi">Â DOI: 10.1158/2326-6066.CIR-18-0636</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1158%2F2326-6066.CIR-18-0636" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=30842091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyjur3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=773-783&author=S.+Ahnauthor=J.+Liauthor=C.+Sunauthor=K.+Gaoauthor=K.+Hirabayashiauthor=H.+Liauthor=B.+Savoldoauthor=R.+Liuauthor=G.+Dotti&title=Cancer+Immunotherapy+with+T+Cells+Carrying+Bispecific+Receptors+That+Mimic+Antibodies&doi=10.1158%2F2326-6066.CIR-18-0636"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy with T cells carrying bispecific receptors that mimic antibodies</span></div><div class="casAuthors">Ahn, Sarah; Li, Jingjing; Sun, Chuang; Gao, Keliang; Hirabayashi, Koichi; Li, Hongxia; Savoldo, Barbara; Liu, Rihe; Dotti, Gianpietro</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">773-783</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumors are inherently heterogeneous in antigen expression, and escape from immune surveillance due to antigen loss remains one of the limitations of targeted immunotherapy.  Despite the clin. use of adoptive therapy with chimeric antigen receptor (CAR)-redirected T cells in lymphoblastic leukemia, treatment failure due to epitope loss occurs.  Targeting multiple tumor-assocd. antigens (TAAs) may thus improve the outcome of CAR-T cell therapies.  CARs developed to simultaneously target multiple targets are limited by the large size of each single-chain variable fragment and compromised protein folding when several single chains are linearly assembled.  Here, we describe single-domain antibody mimics that function within CAR parameters but form a very compact structure.  We show that antibody mimics targeting EGFR and HER2 of the ErbB receptor tyrosine kinase family can be assembled into receptor mols., which we call antibody mimic receptors (amR).  These amR can redirect T cells to recognize two different epitopes of the same antigen or two different TAAs in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_2xgL-jMMGbVg90H21EOLACvtfcHk0lgCshhUc7nqow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyjur3P&md5=34466ee0f4919448e1401d1c9561f49c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-18-0636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-18-0636%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DK.%26aulast%3DHirabayashi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DDotti%26aufirst%3DG.%26atitle%3DCancer%2520Immunotherapy%2520with%2520T%2520Cells%2520Carrying%2520Bispecific%2520Receptors%2520That%2520Mimic%2520Antibodies%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2019%26volume%3D7%26spage%3D773%26epage%3D783%26doi%3D10.1158%2F2326-6066.CIR-18-0636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells</span>. <i>Hum. Gene Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">726</span>â <span class="NLM_lpage">736</span>, <span class="refDoi">Â DOI: 10.1089/hum.2017.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1089%2Fhum.2017.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=28796529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVSlsrzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=726-736&author=E.+Sieglerauthor=S.+Liauthor=Y.+J.+Kimauthor=P.+Wang&title=Designed+Ankyrin+Repeat+Proteins+as+Her2+Targeting+Domains+in+Chimeric+Antigen+Receptor-Engineered+T+Cells&doi=10.1089%2Fhum.2017.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells</span></div><div class="casAuthors">Siegler, Elizabeth; Li, Si; Kim, Yu Jeong; Wang, Pin</div><div class="citationInfo"><span class="NLM_cas:title">Human Gene Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">726-736</span>CODEN:
                <span class="NLM_cas:coden">HGTHE3</span>;
        ISSN:<span class="NLM_cas:issn">1043-0342</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR) engineering is a branch of cancer immunotherapy that equips immune cells to target tumor antigens expressed on the cell surface using antibody-derived single-chain variable fragments (scFvs).  However, other antibody mimetics, such as designed ankyrin repeat proteins (DARPins), can also serve as antigen-binding domains in CARs.  This study shows that CAR-engineered T (CAR-T) cells utilizing Her2-targeting DARPins G3 and 929 can target human epidermal growth factor receptor 2 (Her2)-overexpressing cancer cells as effectively as CAR-T cells with the scFv 4D5 in vitro, and G3 CAR-T cells can slow or eliminate tumor growth in vivo as effectively as 4D5 CAR-T cells.  Some DARPins may offer an attractive alternative to scFv usage in CARs, as they are smaller, thermodynamically stable, poorly immunogenic, and can be generated with different binding properties from DARPin libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqledSUXJ6NQrVg90H21EOLACvtfcHk0lh47wqy1ywebA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVSlsrzP&md5=9bbfb1bb6852f16bb3c0732dbc598754</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1089%2Fhum.2017.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fhum.2017.021%26sid%3Dliteratum%253Aachs%26aulast%3DSiegler%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DDesigned%2520Ankyrin%2520Repeat%2520Proteins%2520as%2520Her2%2520Targeting%2520Domains%2520in%2520Chimeric%2520Antigen%2520Receptor-Engineered%2520T%2520Cells%26jtitle%3DHum.%2520Gene%2520Ther.%26date%3D2017%26volume%3D28%26spage%3D726%26epage%3D736%26doi%3D10.1089%2Fhum.2017.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulemzin, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorchakov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikaev, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsova, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkova, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matvienko, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaritskey, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taranin, A. V.</span></span> <span> </span><span class="NLM_article-title">VEGFR2-Specific FnCAR Effectively Redirects the Cytotoxic Activity of T Cells and YT NK Cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">9021</span>â <span class="NLM_lpage">9029</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.24078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.18632%2Foncotarget.24078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=29507671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC1MrnvFyrtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=9021-9029&author=S.+V.+Kulemzinauthor=A.+A.+Gorchakovauthor=A.+N.+Chikaevauthor=V.+V.+Kuznetsovaauthor=O.+Y.+Volkovaauthor=D.+A.+Matvienkoauthor=A.+V.+Petukhovauthor=A.+Y.+Zaritskeyauthor=A.+V.+Taranin&title=VEGFR2-Specific+FnCAR+Effectively+Redirects+the+Cytotoxic+Activity+of+T+Cells+and+YT+NK+Cells&doi=10.18632%2Foncotarget.24078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells</span></div><div class="casAuthors">Kulemzin Sergey V; Gorchakov Andrey A; Chikaev Anton N; Kuznetsova Valeriya V; Volkova Olga Y; Matvienko Daria A; Taranin Alexandr V; Gorchakov Andrey A; Matvienko Daria A; Taranin Alexandr V; Petukhov Alexey V; Zaritskey Andrey Y</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">9021-9029</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">T and NK cells armed with chimeric antigen receptors (CAR) are promising tools for the specific elimination of cancer cells.  In most CAR designs implemented to date, the recognition of target cells is mediated by single-chain variable fragments (scFvs) derived from murine monoclonal antibodies.  This format, however, has a number of limitations, including its relatively large size and potential immunogenicity in humans.  In this study, we explored the feasibility of using human fibronectin type III domains (Fn3) as the antigen recognition domain in CARs.  Human Fn3 domains have lower predicted immunogenicity compared to mouse-derived sequences, and a reduced molecular weight compared to scFvs.  We created a functional CAR using a VEGFR2-specific Fn3 module replacing the conventional scFv.  The resulting FnCAR specifically potentiates the cytotoxic activity of human T cells and YT NK cells in the presence of VEGFR2-positive targets.  These findings demonstrate that Fn3 domains can be used in CARs for antigen recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVdg7un3fKXuLt9HypzAgQfW6udTcc2eZ7RmWwGfuylLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrnvFyrtw%253D%253D&md5=4b2b56bfe75e197ff24f243c8f9dfeb3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.24078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.24078%26sid%3Dliteratum%253Aachs%26aulast%3DKulemzin%26aufirst%3DS.%2BV.%26aulast%3DGorchakov%26aufirst%3DA.%2BA.%26aulast%3DChikaev%26aufirst%3DA.%2BN.%26aulast%3DKuznetsova%26aufirst%3DV.%2BV.%26aulast%3DVolkova%26aufirst%3DO.%2BY.%26aulast%3DMatvienko%26aufirst%3DD.%2BA.%26aulast%3DPetukhov%26aufirst%3DA.%2BV.%26aulast%3DZaritskey%26aufirst%3DA.%2BY.%26aulast%3DTaranin%26aufirst%3DA.%2BV.%26atitle%3DVEGFR2-Specific%2520FnCAR%2520Effectively%2520Redirects%2520the%2520Cytotoxic%2520Activity%2520of%2520T%2520Cells%2520and%2520YT%2520NK%2520Cells%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D9021%26epage%3D9029%26doi%3D10.18632%2Foncotarget.24078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">KÃ¶nning, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolmar, H.</span></span> <span> </span><span class="NLM_article-title">Beyond Antibody Engineering: Directed Evolution of Alternative Binding Scaffolds and Enzymes Using Yeast Surface Display</span>. <i>Microb. Cell Fact.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>, <span class="NLM_elocation-id">32</span> <span class="refDoi">Â DOI: 10.1186/s12934-018-0881-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1186%2Fs12934-018-0881-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=29482656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC1MrlsFeisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&author=D.+K%C3%B6nningauthor=H.+Kolmar&title=Beyond+Antibody+Engineering%3A+Directed+Evolution+of+Alternative+Binding+Scaffolds+and+Enzymes+Using+Yeast+Surface+Display&doi=10.1186%2Fs12934-018-0881-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond antibody engineering: directed evolution of alternative binding scaffolds and enzymes using yeast surface display</span></div><div class="casAuthors">Konning Doreen; Konning Doreen; Kolmar Harald</div><div class="citationInfo"><span class="NLM_cas:title">Microbial cell factories</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pioneered exactly 20 years ago, yeast surface display (YSD) continues to take a major role in protein engineering among the high-throughput display methodologies that have been developed to date.  The classical yeast display technology relies on tethering an engineered protein to the cell wall by genetic fusion to one subunit of a dimeric yeast-mating agglutination receptor complex.  This method enables an efficient genotype-phenotype linkage while exploiting the benefits of a eukaryotic expression machinery.  Over the past two decades, a plethora of protein engineering efforts encompassing conventional antibody Fab and scFv fragments have been reported.  In this review, we will focus on the versatility of YSD beyond conventional antibody engineering and, instead, place the focus on alternative scaffold proteins and enzymes which have successfully been tailored for purpose with regard to improving binding, activity or specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHGxSU2OPDkpggzHGM8X5CfW6udTcc2eZ7RmWwGfuylLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrlsFeisg%253D%253D&md5=9d04ab71c72dfa37f831d4cb098e0f4d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1186%2Fs12934-018-0881-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12934-018-0881-3%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6nning%26aufirst%3DD.%26aulast%3DKolmar%26aufirst%3DH.%26atitle%3DBeyond%2520Antibody%2520Engineering%253A%2520Directed%2520Evolution%2520of%2520Alternative%2520Binding%2520Scaffolds%2520and%2520Enzymes%2520Using%2520Yeast%2520Surface%2520Display%26jtitle%3DMicrob.%2520Cell%2520Fact.%26date%3D2018%26volume%3D17%26doi%3D10.1186%2Fs12934-018-0881-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerra, A.</span></span> <span> </span><span class="NLM_article-title">Engineering of Binding Functions into Proteins</span>. <i>Curr. Opin. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">230</span>â <span class="NLM_lpage">241</span>, <span class="refDoi">Â DOI: 10.1016/j.copbio.2019.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.copbio.2019.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=31207556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2iur7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=230-241&author=M.+Gebauerauthor=A.+Skerra&title=Engineering+of+Binding+Functions+into+Proteins&doi=10.1016%2Fj.copbio.2019.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering of binding functions into proteins</span></div><div class="casAuthors">Gebauer, Michaela; Skerra, Arne</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Biotechnology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">230-241</span>CODEN:
                <span class="NLM_cas:coden">CUOBE3</span>;
        ISSN:<span class="NLM_cas:issn">0958-1669</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Initially emerging as a highly innovative concept in the late 1990s, the concept of creating novel binding reagents based on stable protein scaffolds from outside the Ig (Ig) superfamily has become a well-developed area of research and discovery today.  Numerous scaffolds based on extracellular, membrane-bound or intracellular proteins (or their domains) have been recruited, yielding versatile research reagents and even biol. drug candidates to serve as a viable alternative to antibodies.  This minireview discusses both established and novel concepts in this field and summarizes the current state of clin. development of the more advanced protein scaffolds, in particular Affibody, Adnectin, Anticalin and DARPin drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZlymyT0zZYLVg90H21EOLACvtfcHk0lh47wqy1ywebA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2iur7O&md5=a9a0022281cee8e1336aca51dfc37b28</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.copbio.2019.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.copbio.2019.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DGebauer%26aufirst%3DM.%26aulast%3DSkerra%26aufirst%3DA.%26atitle%3DEngineering%2520of%2520Binding%2520Functions%2520into%2520Proteins%26jtitle%3DCurr.%2520Opin.%2520Biotechnol.%26date%3D2019%26volume%3D60%26spage%3D230%26epage%3D241%26doi%3D10.1016%2Fj.copbio.2019.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edqvist, P.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GrÃ¤slund, T.</span></span> <span> </span><span class="NLM_article-title">Affibody-Derived Drug Conjugates: Potent Cytotoxic Molecules for Treatment of HER2 over-Expressing Tumors</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">84</span>â <span class="NLM_lpage">95</span>, <span class="refDoi">Â DOI: 10.1016/j.jconrel.2018.08.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.jconrel.2018.08.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=30172673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1yltbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2018&pages=84-95&author=M.+Altaiauthor=H.+Liuauthor=H.+Dingauthor=B.+Mitranauthor=P.-H.+Edqvistauthor=V.+Tolmachevauthor=A.+Orlovaauthor=T.+Gr%C3%A4slund&title=Affibody-Derived+Drug+Conjugates%3A+Potent+Cytotoxic+Molecules+for+Treatment+of+HER2+over-Expressing+Tumors&doi=10.1016%2Fj.jconrel.2018.08.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors</span></div><div class="casAuthors">Altai, Mohamed; Liu, Hao; Ding, Haozhong; Mitran, Bogdan; Edqvist, Per-Henrik; Tolmachev, Vladimir; Orlova, Anna; Graeslund, Torbjoern</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-95</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Patients with HER2-pos. tumors often suffer resistance to therapy, warranting development of novel treatment modalities.  Affibody mols. are small affinity proteins which can be engineered to bind to desired targets.  They have in recent years been found to allow precise targeting of cancer specific mol. signatures such as the HER2 receptor.  In this study, we have investigated the potential of an affibody mol. targeting HER2, ZHER2:2891, conjugated with the cytotoxic maytansine derivate MC-DM1, for targeted cancer therapy.  ZHER2:2891 was expressed as a monomer (ZHER2:2891), dimer ((ZHER2:2891)2) and dimer with an albumin binding domain (ABD) for half-life extension ((ZHER2:2891)2-ABD).  All proteins had a unique C-terminal cysteine that could be used for efficient and site-specific conjugation with MC-DM1.  The resulting affibody drug conjugates were potent cytotoxic mols. for human cells over-expressing HER2, with sub-nanomolar IC50-values similar to trastuzumab emtansine, and did not affect cells with low HER2 expression.  A biodistribution study of a radiolabeled version of (ZHER2:2891)2-ABD-MC-DM1, showed that it was taken up by the tumor.  The major site of off-target uptake was the kidneys and to some extent the liver.  (ZHER2:2891)2-ABD-MC-DM1 was found to have a half-life in circulation of 14 h.  The compd. was tolerated well by mice at 8.5 mg/kg and was shown to extend survival of mice bearing HER2 over-expressing tumors.  The findings in this study show that affibody mols. are a promising class of engineered affinity proteins to specifically deliver small mol. drugs to cancer cells and that such conjugates are potential candidates for clin. evaluation on HER2-overexpressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEU1sTv0hKsLVg90H21EOLACvtfcHk0lgR33v8ZGtSng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1yltbjL&md5=bc237905f974dad24fa52a9eed301867</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2018.08.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2018.08.040%26sid%3Dliteratum%253Aachs%26aulast%3DAltai%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DMitran%26aufirst%3DB.%26aulast%3DEdqvist%26aufirst%3DP.-H.%26aulast%3DTolmachev%26aufirst%3DV.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DGr%25C3%25A4slund%26aufirst%3DT.%26atitle%3DAffibody-Derived%2520Drug%2520Conjugates%253A%2520Potent%2520Cytotoxic%2520Molecules%2520for%2520Treatment%2520of%2520HER2%2520over-Expressing%2520Tumors%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2018%26volume%3D288%26spage%3D84%26epage%3D95%26doi%3D10.1016%2Fj.jconrel.2018.08.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zorba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoemberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, D.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of a Human Protein Kinase with Monobodies</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">13937</span>â <span class="NLM_lpage">13942</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1906024116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1073%2Fpnas.1906024116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=31239342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlChu7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=13937-13942&author=A.+Zorbaauthor=V.+Nguyenauthor=A.+Koideauthor=M.+Hoembergerauthor=Y.+Zhengauthor=S.+Kutterauthor=C.+Kimauthor=S.+Koideauthor=D.+Kern&title=Allosteric+Modulation+of+a+Human+Protein+Kinase+with+Monobodies&doi=10.1073%2Fpnas.1906024116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of a human protein kinase with monobodies</span></div><div class="casAuthors">Zorba, Adelajda; Nguyen, Vy; Koide, Akiko; Hoemberger, Marc; Zheng, Yuejiao; Kutter, Steffen; Kim, Chansik; Koide, Shohei; Kern, Dorothee</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">13937-13942</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Despite being the subject of intense effort and scrutiny, kinases have proven to be consistently challenging targets in inhibitor drug design.  A key obstacle has been promiscuity and consequent adverse effects of drugs targeting the ATP binding site.  Here we introduce an approach to controlling kinase activity by using monobodies that bind to the highly specific regulatory allosteric pocket of the oncoprotein Aurora A (AurA) kinase, thereby offering the potential for more specific kinase modulators.  Strikingly, we identify a series of highly specific monobodies acting either as strong kinase inhibitors or activators via differential recognition of structural motifs in the allosteric pocket.  X-ray crystal structures comparing AurA bound to activating vs inhibiting monobodies reveal the atomistic mechanism underlying allosteric modulation.  The results reveal 3 major advantages of targeting allosteric vs. orthosteric sites: extreme selectivity, ability to inhibit as well as activate, and avoidance of competing with ATP that is present at high concns. in the cells.  We envision that exploiting allosteric networks for inhibition or activation will provide a general, powerful pathway toward rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotf-JJNIChYrVg90H21EOLACvtfcHk0lgR33v8ZGtSng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlChu7jF&md5=79aae9cbc4c3785ff611525b45753ad7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1906024116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1906024116%26sid%3Dliteratum%253Aachs%26aulast%3DZorba%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DV.%26aulast%3DKoide%26aufirst%3DA.%26aulast%3DHoemberger%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DKutter%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DKoide%26aufirst%3DS.%26aulast%3DKern%26aufirst%3DD.%26atitle%3DAllosteric%2520Modulation%2520of%2520a%2520Human%2520Protein%2520Kinase%2520with%2520Monobodies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D13937%26epage%3D13942%26doi%3D10.1073%2Fpnas.1906024116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Binz, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶ttler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigrist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekawardhani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolado, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saliba, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpp, M. T.</span></span> <span> </span><span class="NLM_article-title">Design and Characterization of MP0250, a Tri-Specific Anti-HGF/Anti-VEGF DARPin Drug Candidate</span>. <i>MAbs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1262</span>â <span class="NLM_lpage">1269</span>, <span class="refDoi">Â DOI: 10.1080/19420862.2017.1305529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1080%2F19420862.2017.1305529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=29035637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslCmtb7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1262-1269&author=H.+K.+Binzauthor=T.+R.+Bakkerauthor=D.+J.+Phillipsauthor=A.+Corneliusauthor=C.+Zittauthor=T.+G%C3%B6ttlerauthor=G.+Sigristauthor=U.+Fiedlerauthor=S.+Ekawardhaniauthor=I.+Doladoauthor=J.+A.+Salibaauthor=G.+Treschauthor=K.+Probaauthor=M.+T.+Stumpp&title=Design+and+Characterization+of+MP0250%2C+a+Tri-Specific+Anti-HGF%2FAnti-VEGF+DARPin+Drug+Candidate&doi=10.1080%2F19420862.2017.1305529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin drug candidate</span></div><div class="casAuthors">Binz, H. Kaspar; Bakker, Talitha R.; Phillips, Douglas J.; Cornelius, Andreas; Zitt, Christof; Gottler, Thomas; Sigrist, Gabriel; Fiedler, Ulrike; Ekawardhani, Savira; Dolado, Ignacio; Saliba, Johan Abram; Tresch, Gaby; Proba, Karl; Stumpp, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1262-1269</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">MP0250 is a multi-domain drug candidate currently being tested in clin. trials for the treatment of cancer.  It comprises one anti-vascular endothelial growth factor-A (VEGF-A), one anti-hepatocyte growth factor (HGF), and two anti-human serum albumin (HSA) DARPin domains within a single polypeptide chain.  While there is first clin. validation of a single-domain DARPin drug candidate, little is known about DARPin drug candidates comprising multiple domains.  Here, we show that MP0250 can be expressed at 15 g/L in sol. form in E. coli high cell-d. fermn., it is stable in sol./frozen formulation for 2 years as assessed by reverse phase HPLC, it has picomolar potency in inhibiting VEGF-A and HGF in ELISA and cellular assays, and its domains are simultaneously active as shown by surface plasmon resonance.  The inclusion of HSA-binding DARPin domains leads to a favorable pharmacokinetic profile in mouse and cynomolgus monkey, with terminal half-lives of â¼ 30 h in mouse and â¼ 5 days in cynomolgus monkey.  MP0250 is thus a highly potent drug candidate that could be particularly useful in oncol.  Beyond MP0250, the properties of MP0250 indicate that multi-domain DARPin proteins can be valuable next-generation drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6KlL9EtBwKrVg90H21EOLACvtfcHk0lgR33v8ZGtSng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslCmtb7J&md5=62acbc24b39b26234aad5d2fb83c58e9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1080%2F19420862.2017.1305529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2017.1305529%26sid%3Dliteratum%253Aachs%26aulast%3DBinz%26aufirst%3DH.%2BK.%26aulast%3DBakker%26aufirst%3DT.%2BR.%26aulast%3DPhillips%26aufirst%3DD.%2BJ.%26aulast%3DCornelius%26aufirst%3DA.%26aulast%3DZitt%26aufirst%3DC.%26aulast%3DG%25C3%25B6ttler%26aufirst%3DT.%26aulast%3DSigrist%26aufirst%3DG.%26aulast%3DFiedler%26aufirst%3DU.%26aulast%3DEkawardhani%26aufirst%3DS.%26aulast%3DDolado%26aufirst%3DI.%26aulast%3DSaliba%26aufirst%3DJ.%2BA.%26aulast%3DTresch%26aufirst%3DG.%26aulast%3DProba%26aufirst%3DK.%26aulast%3DStumpp%26aufirst%3DM.%2BT.%26atitle%3DDesign%2520and%2520Characterization%2520of%2520MP0250%252C%2520a%2520Tri-Specific%2520Anti-HGF%252FAnti-VEGF%2520DARPin%2520Drug%2520Candidate%26jtitle%3DMAbs%26date%3D2017%26volume%3D9%26spage%3D1262%26epage%3D1269%26doi%3D10.1080%2F19420862.2017.1305529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, R. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinka-Doms, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudkin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, K. T.</span></span> <span> </span><span class="NLM_article-title">Engineering a Targeted Delivery Platform Using Centyrins</span>. <i>Protein Eng., Des. Sel.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">563</span>â <span class="NLM_lpage">572</span>, <span class="refDoi">Â DOI: 10.1093/protein/gzw054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1093%2Fprotein%2Fgzw054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=27737926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlWltro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=563-572&author=S.+D.+Goldbergauthor=R.+M.+F.+Cardosoauthor=T.+Linauthor=T.+Spinka-Domsauthor=D.+Kleinauthor=S.+A.+Jacobsauthor=V.+Dudkinauthor=G.+Gillilandauthor=K.+T.+O%E2%80%99Neil&title=Engineering+a+Targeted+Delivery+Platform+Using+Centyrins&doi=10.1093%2Fprotein%2Fgzw054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering a targeted delivery platform using Centyrins</span></div><div class="casAuthors">Goldberg, Shalom D.; Cardoso, Rosa M. F.; Lin, Tricia; Spinka-Doms, Tracy; Klein, Donna; Jacobs, Steven A.; Dudkin, Vadim; Gilliland, Gary; O'Neil, Karyn T.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Engineering, Design & Selection</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">563-572</span>CODEN:
                <span class="NLM_cas:coden">PEDSBR</span>;
        ISSN:<span class="NLM_cas:issn">1741-0126</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Targeted delivery of therapeutic payloads to specific tissues and cell types is an important component of modern pharmaceutical development.  Antibodies or other scaffold proteins can provide the cellular address for delivering a covalently linked therapeutic via specific binding to cell-surface receptors.  Optimization of the conjugation site on the targeting protein, linker chem. and intracellular trafficking pathways can all influence the efficiency of delivery and potency of the drug candidate.  In this study, we describe a comprehensive engineering expt. for an EGFR binding Centyrin, a highly stable fibronectin type III (FN3) domain, wherein all possible single-cysteine replacements were evaluated for expression, purifn., conjugation efficiency, retention of target binding, biophys. properties and delivery of a cytotoxic small mol. payload.  Overall, 26 of the 94 positions were identified as ideal for cysteine modification, conjugation and drug delivery.  Conjugation-tolerant positions were mapped onto a crystal structure of the Centyrin, providing a structural context for interpretation of the mutagenesis expt. and providing a foundation for a Centyrin-targeted delivery platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_9DH_s_sUabVg90H21EOLACvtfcHk0lj-LZVSvv32_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlWltro%253D&md5=552b7c2e553c457c3a804110d7662e72</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2Fgzw054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252Fgzw054%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DS.%2BD.%26aulast%3DCardoso%26aufirst%3DR.%2BM.%2BF.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DSpinka-Doms%26aufirst%3DT.%26aulast%3DKlein%26aufirst%3DD.%26aulast%3DJacobs%26aufirst%3DS.%2BA.%26aulast%3DDudkin%26aufirst%3DV.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DK.%2BT.%26atitle%3DEngineering%2520a%2520Targeted%2520Delivery%2520Platform%2520Using%2520Centyrins%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D2016%26volume%3D29%26spage%3D563%26epage%3D572%26doi%3D10.1093%2Fprotein%2Fgzw054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sokolova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grishina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospelov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guryev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deyev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balalaeva, I.</span></span> <span> </span><span class="NLM_article-title">Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">219</span> <span class="refDoi">Â DOI: 10.3390/pharmaceutics11050219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.3390%2Fpharmaceutics11050219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslamtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=E.+Sokolovaauthor=O.+Kutovaauthor=A.+Grishinaauthor=A.+Pospelovauthor=E.+Guryevauthor=A.+Schulgaauthor=S.+Deyevauthor=I.+Balalaeva&title=Penetration+Efficiency+of+Antitumor+Agents+in+Ovarian+Cancer+Spheroids%3A+The+Case+of+Recombinant+Targeted+Toxin+DARPin-LoPE+and+the+Chemotherapy+Drug%2C+Doxorubicin&doi=10.3390%2Fpharmaceutics11050219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Penetration efficiency of antitumor agents in ovarian cancer spheroids: the case of recombinant targeted toxin DARPin-LoPE and the chemotherapy drug, doxorubicin</span></div><div class="casAuthors">Sokolova, Evgeniya; Kutova, Olga; Grishina, Alena; Pospelov, Anton; Guryev, Evgeniy; Schulga, Alexey; Deyev, Sergey; Balalaeva, Irina</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">219</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The efficiency of delivering a therapeutic agent into a tumor is among the crucial factors detg. the prospects for its clin. use.  This problem is particularly acute in the case of targeted antitumor agents since many of them are high-mol.-wt. compds.  In this work, the penetration of therapeutic agents of two distinct mol. wts. into the spheroids of ovarian adenocarcinoma overexpressing human epidermal growth factor receptor 2 (HER2) was studied.  It was shown that the low-mol.-wt. chemotherapy drug, doxorubicin (â¼0.5 kDa), effectively penetrates through almost the entire depth of a 300 to 400 Î¼m spheroid, while the penetration depth of the HER2-specific recombinant targeted toxin, DARPin-LoPE (â¼42 kDa), is only a few surface layers of cells and does not exceed 70 Î¼m.  The low penetration of the targeted toxin into spheroid was shown along with a significant decrease in its efficiency against the three-dimensional tumor spheroid as compared with the two-dimensional monolayer culture.  The approaches to increasing the accumulation of agents in the tumor are presented and prospects of their use in order to improve the effectiveness of therapy are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXiF4CaJRhLVg90H21EOLACvtfcHk0lj-LZVSvv32_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslamtb0%253D&md5=34101115c383bc1f47335fc2c9e541b7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics11050219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics11050219%26sid%3Dliteratum%253Aachs%26aulast%3DSokolova%26aufirst%3DE.%26aulast%3DKutova%26aufirst%3DO.%26aulast%3DGrishina%26aufirst%3DA.%26aulast%3DPospelov%26aufirst%3DA.%26aulast%3DGuryev%26aufirst%3DE.%26aulast%3DSchulga%26aufirst%3DA.%26aulast%3DDeyev%26aufirst%3DS.%26aulast%3DBalalaeva%26aufirst%3DI.%26atitle%3DPenetration%2520Efficiency%2520of%2520Antitumor%2520Agents%2520in%2520Ovarian%2520Cancer%2520Spheroids%253A%2520The%2520Case%2520of%2520Recombinant%2520Targeted%2520Toxin%2520DARPin-LoPE%2520and%2520the%2520Chemotherapy%2520Drug%252C%2520Doxorubicin%26jtitle%3DPharmaceutics%26date%3D2019%26volume%3D11%26doi%3D10.3390%2Fpharmaceutics11050219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirie, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittrup, K. D.</span></span> <span> </span><span class="NLM_article-title">Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1774</span>â <span class="NLM_lpage">1782</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-12-1023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1158%2F1535-7163.MCT-12-1023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=23832121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1774-1782&author=C.+M.+Pirieauthor=D.+V.+Liuauthor=K.+D.+Wittrup&title=Targeted+Cytolysins+Synergistically+Potentiate+Cytoplasmic+Delivery+of+Gelonin+Immunotoxin&doi=10.1158%2F1535-7163.MCT-12-1023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin</span></div><div class="casAuthors">Pirie, Christopher M.; Liu, David V.; Wittrup, K. Dane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1774-1782</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted endocytic uptake is a first step toward tissue-specific cytoplasmic macromol. delivery; however, inefficient escape from the endolysosomal compartment makes this generally impractical at present.  We report here a targeted cytolysin approach that dramatically potentiates endosomal release of an independently targeted potent gelonin immunotoxin.  Fibronectin domains engineered for affinity to EGF receptor or carcinoembryonic antigen were fused to the plant toxin gelonin or bacterial pore-forming cytolysins.  These fusion proteins display synergistic activity in both antigen-specific cytotoxicity in vitro, enhancing potency by several orders of magnitude, and in tumor growth inhibition in vivo.  In addn., the no. of internalized gelonin mols. required to induce apoptosis is reduced from approx. 5Ã106 to less than 103.  Targeted potentiation shows promise for enhancing cytoplasmic delivery of other macromol. payloads such as DNA, siRNA, and miRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3N0OkETIhArVg90H21EOLACvtfcHk0lj-LZVSvv32_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7F&md5=be44f50fac1e3baebcdec9ee4196e10a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1023%26sid%3Dliteratum%253Aachs%26aulast%3DPirie%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DD.%2BV.%26aulast%3DWittrup%26aufirst%3DK.%2BD.%26atitle%3DTargeted%2520Cytolysins%2520Synergistically%2520Potentiate%2520Cytoplasmic%2520Delivery%2520of%2520Gelonin%2520Immunotoxin%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1774%26epage%3D1782%26doi%3D10.1158%2F1535-7163.MCT-12-1023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koide, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, S.</span></span> <span> </span><span class="NLM_article-title">The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">1141</span>â <span class="NLM_lpage">1151</span>, <span class="refDoi">Â DOI: 10.1006/jmbi.1998.2238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1006%2Fjmbi.1998.2238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=9837732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADyaK1MXivFCgtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1998&pages=1141-1151&author=A.+Koideauthor=C.+W.+Baileyauthor=X.+Huangauthor=S.+Koide&title=The+Fibronectin+Type+III+Domain+as+a+Scaffold+for+Novel+Binding+Proteins&doi=10.1006%2Fjmbi.1998.2238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The fibronectin type III domain as a scaffold for novel binding proteins</span></div><div class="casAuthors">Koide, Akiko; Bailey, Charles W.; Huang, Xiaolin; Koide, Shohei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1141-1151</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The fibronectin type III domain (FN3) is a small autonomous folding unit which occurs in many animal proteins involving in ligand binding.  The Î²-sandwich structure of FN3 closely resembles that of Ig domains.  We have prepd. a phage display library of FN3 in which residues in two surface loops were randomized.  We have selected mutant FN3s which bind to a test ligand, ubiquitin, with significant affinities, while the wild-type FN3 shows no measurable affinity.  A dominant clone was expressed as a sol. protein and its properties were investigated in detail.  Heteronuclear NMR characterization revealed that the selected mutant protein retains the global fold of FN3.  It also has a modest conformational stability despite mutations at 12 out of 94 residues.  These results clearly show the potential of FN3 as a scaffold for engineering novel binding proteins.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCs6_Saq9nbrVg90H21EOLACvtfcHk0lgFDM718EwvLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFCgtA%253D%253D&md5=f99791d8351f59411b29eec0c675e420</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1998.2238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1998.2238%26sid%3Dliteratum%253Aachs%26aulast%3DKoide%26aufirst%3DA.%26aulast%3DBailey%26aufirst%3DC.%2BW.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DKoide%26aufirst%3DS.%26atitle%3DThe%2520Fibronectin%2520Type%2520III%2520Domain%2520as%2520a%2520Scaffold%2520for%2520Novel%2520Binding%2520Proteins%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1998%26volume%3D284%26spage%3D1141%26epage%3D1151%26doi%3D10.1006%2Fjmbi.1998.2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futter, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eden, E. R.</span></span> <span> </span><span class="NLM_article-title">EGF Receptor Trafficking: Consequences for Signaling and Cancer</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">26</span>â <span class="NLM_lpage">34</span>, <span class="refDoi">Â DOI: 10.1016/j.tcb.2013.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.tcb.2013.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=24295852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2gt7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=26-34&author=A.+Tomasauthor=C.+E.+Futterauthor=E.+R.+Eden&title=EGF+Receptor+Trafficking%3A+Consequences+for+Signaling+and+Cancer&doi=10.1016%2Fj.tcb.2013.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor trafficking: consequences for signaling and cancer</span></div><div class="casAuthors">Tomas, Alejandra; Futter, Clare E.; Eden, Emily R.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-34</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The ligand-stimulated epidermal growth factor receptor (EGFR) has been extensively studied in the anal. of mol. mechanisms regulating endocytic traffic and the role of that traffic in signal transduction.  Although such studies have largely focused on mitogenic signaling and dysregulated traffic in tumorigenesis, there is growing interest in the potential role of EGFR traffic in cell survival and the consequent response to cancer therapy.  Here we review recent advances in our understanding of mol. mechanisms regulating ligand-stimulated EGFR activation, internalization, and post-endocytic sorting.  The role of EGFR overexpression/mutation and new modulators of EGFR traffic in cancer and the response to cancer therapeutics are also discussed.  Finally, we speculate on the relationship between EGFR traffic and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDLWxypVYs-bVg90H21EOLACvtfcHk0lgFDM718EwvLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2gt7zP&md5=850921a0c652f9401704f4152db482a5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2013.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2013.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DTomas%26aufirst%3DA.%26aulast%3DFutter%26aufirst%3DC.%2BE.%26aulast%3DEden%26aufirst%3DE.%2BR.%26atitle%3DEGF%2520Receptor%2520Trafficking%253A%2520Consequences%2520for%2520Signaling%2520and%2520Cancer%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2014%26volume%3D24%26spage%3D26%26epage%3D34%26doi%3D10.1016%2Fj.tcb.2013.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span> <span> </span><span class="NLM_article-title">Epidermal Growth Factor Receptor (EGFR): A Rising Star in the Era of Precision Medicine of Lung Cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">50209</span>â <span class="NLM_lpage">50220</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.16854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.18632%2Foncotarget.16854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=28430586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC1cvpvFaksw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=50209-50220&author=X.+Liuauthor=P.+Wangauthor=C.+Zhangauthor=Z.+Ma&title=Epidermal+Growth+Factor+Receptor+%28EGFR%29%3A+A+Rising+Star+in+the+Era+of+Precision+Medicine+of+Lung+Cancer&doi=10.18632%2Foncotarget.16854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer</span></div><div class="casAuthors">Liu Xiaomin; Wang Ping; Zhang Caiyan; Ma Zhongliang</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">50209-50220</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer is a leading cause of cancer mortality worldwide.  In tumors, the important role of noncoding RNA regulatory networks has been more and more reveal.  EGFR has been identified as an oncogenic driver of NSCLC, especially activating mutations EGFR and its inhibition with specific TKIs can generate dramatic tumor responses.  Studies have shown that EGFR plays significant roles in the progression of NSCLC.  Subset analysis of the small proportion of patients with EGFR-mutant lung cancer showed a disease-free survival benefit, but was underpowered to detect a survival advantage.  Herein, we highlight the progression of EGFR, noncoding RNA, and their roles in carcinogenesis.  We also focus on anti-lung cancer drug development and EGFR-related drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpqnqiBQBfJ6x48Rj5GnGofW6udTcc2eYysasouDh55rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvpvFaksw%253D%253D&md5=f42e000960487683e50bcd3ad83e3fa9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.16854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.16854%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DEpidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%253A%2520A%2520Rising%2520Star%2520in%2520the%2520Era%2520of%2520Precision%2520Medicine%2520of%2520Lung%2520Cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D50209%26epage%3D50220%26doi%3D10.18632%2Foncotarget.16854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emanuel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engle, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamniuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokemeijer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabrizio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das Gupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosselin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cataldo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryseck, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camphausen, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cload, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furfine, E. S.</span></span> <span> </span><span class="NLM_article-title">A Fibronectin Scaffold Approach to Bispecific Inhibitors of Epidermal Growth Factor Receptor and Insulin-like Growth Factor-I Receptor</span>. <i>MAbs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">38</span>â <span class="NLM_lpage">48</span>, <span class="refDoi">Â DOI: 10.4161/mabs.3.1.14168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.4161%2Fmabs.3.1.14168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=21099371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC3M7kt1arug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=38-48&author=S.+L.+Emanuelauthor=L.+J.+Engleauthor=G.+Chaoauthor=R.-R.+Zhuauthor=C.+Caoauthor=Z.+Linauthor=A.+Yamniukauthor=J.+Hosbachauthor=J.+Brownauthor=E.+Fitzpatrickauthor=J.+Gokemeijerauthor=P.+Morinauthor=B.+Morseauthor=I.+M.+Carvajalauthor=D.+Fabrizioauthor=M.+C.+Wrightauthor=R.+Das+Guptaauthor=M.+Gosselinauthor=D.+Cataldoauthor=R.+P.+Ryseckauthor=M.+L.+Doyleauthor=T.+W.+Wongauthor=R.+T.+Camphausenauthor=S.+T.+Cloadauthor=H.+N.+Marshauthor=M.+M.+Gottardisauthor=E.+S.+Furfine&title=A+Fibronectin+Scaffold+Approach+to+Bispecific+Inhibitors+of+Epidermal+Growth+Factor+Receptor+and+Insulin-like+Growth+Factor-I+Receptor&doi=10.4161%2Fmabs.3.1.14168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor</span></div><div class="casAuthors">Emanuel Stuart L; Engle Linda J; Chao Ginger; Zhu Rong-Rong; Cao Carolyn; Lin Zheng; Yamniuk Aaron P; Hosbach Jennifer; Brown Jennifer; Fitzpatrick Elizabeth; Gokemeijer Jochem; Morin Paul; Morse Brent A; Carvajal Irvith M; Fabrizio David; Wright Martin C; Das Gupta Ruchira; Gosselin Michael; Cataldo Daniel; Ryseck Rolf P; Doyle Michael L; Wong Tai W; Camphausen Raymond T; Cload Sharon T; Marsh H Nicholas; Gottardis Marco M; Furfine Eric S</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-48</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Engineered domains of human fibronectin (AdnectinsÂ®) were used to generate a bispecific Adnectin targeting epidermal growth factor receptor (EGFR) and insulin-like growth factor-I receptor (IGF-IR), two transmembrane receptors that mediate proliferative and survival cell signaling in cancer.  Single-domain Adnectins that specifically bind EGFR or IGF-IR were generated using mRNA display with a library containing as many as 10 ( 13) Adnectin variants. mRNA display was also used to optimize lead Adnectin affinities, resulting in clones that inhibited EGFR phosphorylation at 7 to 38 nM compared to 2.6 Î¼M for the parental clone.  Individual, optimized, Adnectins specific for blocking either EGFR or IGF-IR signaling were engineered into a single protein (EI-Tandem Adnectin).  The EI-Tandems inhibited phosphorylation of EGFR and IGF-IR, induced receptor degradation, and inhibited down-stream cell signaling and proliferation of human cancer cell lines (A431, H292, BxPC3 and RH41) with IC 50 values ranging from 0.1 to 113 nM.  Although Adnectins bound to EGFR at a site distinct from those of anti-EGFR antibodies cetuximab, panitumumab and nimotuzumab, like the antibodies, the anti-EGFR Adnectins blocked the binding of EGF to EGFR.  PEGylated EI-Tandem inhibited the growth of both EGFR and IGF-IR driven human tumor xenografts, induced degradation of EGFR, and reduced EGFR phosphorylation in tumors.  These results demonstrate efficient engineering of bispecific Adnectins with high potency and desired specificity.  The bispecificity may improve biological activity compared to monospecific biologics as tumor growth is driven by multiple growth factors.  Our results illustrate a technological advancement for constructing multi-specific biologics in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSFPXML4fLJC6Ufuk_1xoTfW6udTcc2eb8pagJbVogLbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7kt1arug%253D%253D&md5=22b23833330685a20588a745d2d9c706</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.4161%2Fmabs.3.1.14168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fmabs.3.1.14168%26sid%3Dliteratum%253Aachs%26aulast%3DEmanuel%26aufirst%3DS.%2BL.%26aulast%3DEngle%26aufirst%3DL.%2BJ.%26aulast%3DChao%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DR.-R.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DYamniuk%26aufirst%3DA.%26aulast%3DHosbach%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DFitzpatrick%26aufirst%3DE.%26aulast%3DGokemeijer%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DP.%26aulast%3DMorse%26aufirst%3DB.%26aulast%3DCarvajal%26aufirst%3DI.%2BM.%26aulast%3DFabrizio%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DM.%2BC.%26aulast%3DDas%2BGupta%26aufirst%3DR.%26aulast%3DGosselin%26aufirst%3DM.%26aulast%3DCataldo%26aufirst%3DD.%26aulast%3DRyseck%26aufirst%3DR.%2BP.%26aulast%3DDoyle%26aufirst%3DM.%2BL.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DCamphausen%26aufirst%3DR.%2BT.%26aulast%3DCload%26aufirst%3DS.%2BT.%26aulast%3DMarsh%26aufirst%3DH.%2BN.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DFurfine%26aufirst%3DE.%2BS.%26atitle%3DA%2520Fibronectin%2520Scaffold%2520Approach%2520to%2520Bispecific%2520Inhibitors%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520and%2520Insulin-like%2520Growth%2520Factor-I%2520Receptor%26jtitle%3DMAbs%26date%3D2011%26volume%3D3%26spage%3D38%26epage%3D48%26doi%3D10.4161%2Fmabs.3.1.14168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallera, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Prosthetic Antigen Receptors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">10108</span>â <span class="NLM_lpage">10111</span>, <span class="refDoi">Â DOI: 10.1021/jacs.5b06166</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b06166" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KmsrfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=10108-10111&author=J.+Shenauthor=D.+A.+Valleraauthor=C.+R.+Wagner&title=Prosthetic+Antigen+Receptors&doi=10.1021%2Fjacs.5b06166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Prosthetic antigen receptors</span></div><div class="casAuthors">Shen, Jingjing; Vallera, Daniel A.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">10108-10111</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chimeric antigen receptors (CARs) have shown great promise for the immunol. treatment of cancer.  Nevertheless, the need to genetically engineer a patient's T-cells has presented significant prodn. and safety challenges.  To address these issues, we have demonstrated that chem. self-assembled nanorings (CSANs) displaying single chain antibodies can bind to both the CD3 Îµ subunit of the T-cell-receptor/CD3 complex and the CD22 antigen on malignant B cells such as B-leukemias or lymphomas.  We demonstrate that the multivalent and bispecific format allows the antiCD3/antiCD22 CSANs to stably bind to T-cell surfaces for greater than 4 days, while being easily disassembled on the cell membrane by treatment with the nontoxic FDA approved drug, trimethoprim.  In the presence of CD22+ Raji cells, T-cells modified with antiCD3/antiCD22 CSANs were shown to selectively up-regulate the prodn. of interleukin-2 (IL-2) and interferon-Î³ (IFN-Î³) and to initiate cytotoxicity.  Taken together, our results demonstrate that antiCD3/antiCD22 bispecific CSANs offer a potential alternative to CARs, as prosthetic antigen receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLvNnipy3cRrVg90H21EOLACvtfcHk0lhWzpG7OL07Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KmsrfI&md5=8a336e42080592d53b3045acfaeb9fc5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b06166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b06166%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DVallera%26aufirst%3DD.%2BA.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DProsthetic%2520Antigen%2520Receptors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D10108%26epage%3D10111%26doi%3D10.1021%2Fjacs.5b06166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarikaya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallera, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">17247</span>â <span class="NLM_lpage">17257</span>, <span class="refDoi">Â DOI: 10.1021/ja107153a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja107153a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWrtbzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=17247-17257&author=Q.+Liauthor=C.+R.+Soauthor=A.+Feganauthor=V.+Codyauthor=M.+Sarikayaauthor=D.+A.+Valleraauthor=C.+R.+Wagner&title=Chemically+Self-Assembled+Antibody+Nanorings+%28CSANs%29%3A+Design+and+Characterization+of+an+Anti-CD3+IgM+Biomimetic&doi=10.1021%2Fja107153a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic</span></div><div class="casAuthors">Li, Qing; So, Christopher R.; Fegan, Adrian; Cody, Vivian; Sarikaya, Mehmet; Vallera, Daniel A.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">17247-17257</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A no. of clever recombinant methodologies have been developed that recapitulate the valencies of IgG's (bivalent) and IgA's (tetravalent).  Although higher synthetic valencies have been achieved by conjugation of either monoclonal antibodies or single-chain antibodies to nanoparticles and liposomes, a method for the prepn. of recombinant antibodies with valencies similar to IgM's (decavalent) but considerably less than what is generally found after antibody particle conjugation has yet to be devised.  Recently, we have developed a methodol. for the design of bivalent Chem. Self-Assembled Antibody Nanorings (CSANs).  We now report the crystal structure of the nanoring subunit composed of the E. coli DHFR dimer and a methotrexate dimerizer (MTX2-C9) contg. a visible nine methylene linker and a protocol for the prepn. of CSANs from this subunit with valencies similar to IgM's, ranging from 8-10 single chain antibodies (scFvs).  The multivalent CSANs were reversibly assembled from a fusion protein dihydrofolate reductase (DHFR)-DHFR-antiCD3 scFv contg. a single glycine linker between the two DHFR scaffolding proteins.  We also demonstrate that, similar to the parental bivalent anti-CD3 monoclonal antibody (mAB), anti-CD3 CSANs selectively bind to CD3+ leukemia cells and undergo rapid internalization through a caveolin-independent pathway that requires cholesterol, actin polymn., and protein tyrosine kinase activation.  While treatment with the monoclonal antibody leads to T-cell activation and nearly complete loss (i.e., 90%) of the surface displayed T-cell receptor (TCR), only 25-30% of the TCR down regulate and no significant T-cell proliferation is obsd. after treatment of peripheral blood mononuclear cells (PBMCs) with anti-CD3 CSANs.  Consistent with the proliferation findings, 15-25% less CD25 (IL-2 receptor) was found on the surface of PBMCs treated with either the polyvalent or bivalent anti-CD3 CSANs, resp., than on PBMCs treated with the parental mAB.  Comparative expts. with F(ab')2 derived from the mAB confirm that the activation of the T-cells by the mAB is dependent on the Fc domain, and thus interactions of the PBMC T-cells with accessory cells, such as macrophages.  Taken together, these results demonstrate that anti-CD3 CSANs with valencies ranging from 2 to 8 could be employed for radionuclide, drug, or potentially oligonucleotide delivery to T-cells without, as has been obsd. for other antibody conjugated nanoparticles, the deleterious effects of activation obsd. for mAB.  Further the CSAN construct may be adapted for the prepn. of other multivalent scFvs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ATWinihbCrVg90H21EOLACvtfcHk0lhWzpG7OL07Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWrtbzO&md5=f48d7dae3bf8c7b40ffadadafba1de1e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fja107153a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja107153a%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DSo%26aufirst%3DC.%2BR.%26aulast%3DFegan%26aufirst%3DA.%26aulast%3DCody%26aufirst%3DV.%26aulast%3DSarikaya%26aufirst%3DM.%26aulast%3DVallera%26aufirst%3DD.%2BA.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DChemically%2520Self-Assembled%2520Antibody%2520Nanorings%2520%2528CSANs%2529%253A%2520Design%2520and%2520Characterization%2520of%2520an%2520Anti-CD3%2520IgM%2520Biomimetic%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D17247%26epage%3D17257%26doi%3D10.1021%2Fja107153a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Csizmar, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersburg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozumalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackel, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">251</span>â <span class="NLM_lpage">261</span>, <span class="refDoi">Â DOI: 10.1021/jacs.8b09198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b09198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSgsL7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=251-261&author=C.+M.+Csizmarauthor=J.+R.+Petersburgauthor=T.+J.+Perryauthor=L.+Rozumalskiauthor=B.+J.+Hackelauthor=C.+R.+Wagner&title=Multivalent+Ligand+Binding+to+Cell+Membrane+Antigens%3A+Defining+the+Interplay+of+Affinity%2C+Valency%2C+and+Expression+Density&doi=10.1021%2Fjacs.8b09198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density</span></div><div class="casAuthors">Csizmar, Clifford M.; Petersburg, Jacob R.; Perry, Thomas J.; Rozumalski, Lakmal; Hackel, Benjamin J.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-261</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nature uses multi-valency to govern many biol. processes.  The development of macromol. and cellular therapies has largely been dependent on engineering similar polyvalent interactions to enable effective targeting.  Such therapeutics typically utilize high-affinity binding domains that have the propensity to recognize both antigen-overexpressing tumors and normal-expressing tissues, leading to "on-target, off-tumor" toxicities.  One strategy to improve these agents' selectivity is to reduce the binding affinity, such that biol. relevant interactions between the therapeutic and target cell will only exist under conditions of high avidity.  Preclin. studies have validated this principle of avidity optimization in the context of chimeric antigen receptor (CAR) T cells; however, a rigorous anal. of this approach in the context of sol. multi-valent targeting scaffolds has yet to be undertaken.  Using a modular protein nanoring capable of displaying â¤8 fibronectin domains with engineered specificity for a model antigen, epithelial cell adhesion mol. (EpCAM), this study demonstrates that binding affinity and ligand valency can be optimized to afford discrimination between EpCAMHigh (2.8-3.8 Ã 106 antigens/cell) and EpCAMLow (5.2 Ã 104 to 2.2 Ã 105 antigens/cell) tissues both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs_HpPRNfnD7Vg90H21EOLACvtfcHk0lhb9WdrNy_3Lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSgsL7N&md5=e568fa64b58f3264445fb73c53f3689a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b09198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b09198%26sid%3Dliteratum%253Aachs%26aulast%3DCsizmar%26aufirst%3DC.%2BM.%26aulast%3DPetersburg%26aufirst%3DJ.%2BR.%26aulast%3DPerry%26aufirst%3DT.%2BJ.%26aulast%3DRozumalski%26aufirst%3DL.%26aulast%3DHackel%26aufirst%3DB.%2BJ.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DMultivalent%2520Ligand%2520Binding%2520to%2520Cell%2520Membrane%2520Antigens%253A%2520Defining%2520the%2520Interplay%2520of%2520Affinity%252C%2520Valency%252C%2520and%2520Expression%2520Density%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D251%26epage%3D261%26doi%3D10.1021%2Fjacs.8b09198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petersburg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csizmar, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fife, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Eradication of Established Tumors by Chemically Self-Assembled Nanoring (CSAN) Labelled T Cells</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">6563</span>â <span class="NLM_lpage">6576</span>, <span class="refDoi">Â DOI: 10.1021/acsnano.8b01308</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.8b01308" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVWntL%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=6563-6576&author=J.+Petersburgauthor=J.+Shenauthor=C.+M.+Csizmarauthor=K.+A.+Murphyauthor=J.+Spanierauthor=K.+Gabrielseauthor=T.+S.+Griffithauthor=B.+Fifeauthor=C.+R.+Wagner&title=Eradication+of+Established+Tumors+by+Chemically+Self-Assembled+Nanoring+%28CSAN%29+Labelled+T+Cells&doi=10.1021%2Facsnano.8b01308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells</span></div><div class="casAuthors">Petersburg, Jacob R.; Shen, Jingjing; Csizmar, Clifford M.; Murphy, Katherine A.; Spanier, Justin; Gabrielse, Kari; Griffith, Thomas S.; Fife, Brian; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">6563-6576</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our lab. has developed chem. self-assembled nanorings (CSANs) as prosthetic antigen receptors (PARs) for the non-genetic modification of T-cell surfaces.  PARs have been successfully employed in vitro to activate T cells for the selective killing of leukemia cells.  However, PAR efficacy has yet to be evaluated in vivo or against solid tumors.  Therefore, we developed bispecific PARs that selectively target the human CD3 receptor and human Epithelial Cell Adhesion Mol. (EpCAM), which is overexpressed on multiple carcinomas and cancer stem cells.  The Î±EpCAM/Î±CD3 PARs were found to stably bind T cells for >4 days, and treating EpCAM+ MCF-7 breast cancer cells with Î±EpCAM/Î±CD3 PAR-functionalized T cells resulted in the induction of IL-2, IFN-Î³ and MCF-7 cytotoxicity.  Furthermore, an orthotopic breast cancer model validated the ability of Î±EpCAM/Î±CD3 PAR therapy to direct T cell lytic activity towards EpCAM+ breast cancer cells in vivo leading to tumor eradication.  In vivo biodistribution studies demonstrated that PAR-T cells were formed in vivo and persist for over 48 h.  In addn., PARs were shown to rapidly and specifically accumulate in tumor tissue.  Following PAR treatment, the prodn. of IL-2, IFN-Î³, IL-6 and TNF-Î± could be significantly reduced by an infusion of clin.-relevant concns. of the FDA-approved antibiotic, trimethoprim, signaling pharmacol. PAR deactivation.  Importantly, CSANs did not induce naive T cell activation and thus exhibit a limited potential to induce naive T cell anergy.  In addn., murine immunogenicity studies demonstrated that CSANs do not induce a significant antibody response, nor do they activate splenic cells.  Collectively, our results demonstrate that bispecific CSANs are able to non-genetically generate reversibly modified T cells that are capable of eradicating targeted solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplfpTkekefBbVg90H21EOLACvtfcHk0lhb9WdrNy_3Lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVWntL%252FK&md5=b95edef95aeccd9c2f75141905aee7ff</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsnano.8b01308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.8b01308%26sid%3Dliteratum%253Aachs%26aulast%3DPetersburg%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DCsizmar%26aufirst%3DC.%2BM.%26aulast%3DMurphy%26aufirst%3DK.%2BA.%26aulast%3DSpanier%26aufirst%3DJ.%26aulast%3DGabrielse%26aufirst%3DK.%26aulast%3DGriffith%26aufirst%3DT.%2BS.%26aulast%3DFife%26aufirst%3DB.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DEradication%2520of%2520Established%2520Tumors%2520by%2520Chemically%2520Self-Assembled%2520Nanoring%2520%2528CSAN%2529%2520Labelled%2520T%2520Cells%26jtitle%3DACS%2520Nano%26date%3D2018%26volume%3D12%26spage%3D6563%26epage%3D6576%26doi%3D10.1021%2Facsnano.8b01308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Reversible Re-Programing of Cell-Cell Interactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5112</span>â <span class="NLM_lpage">5116</span>, <span class="refDoi">Â DOI: 10.1002/anie.201310645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1002%2Fanie.201310645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFyhsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=5112-5116&author=K.+Gabrielseauthor=A.+Gangarauthor=N.+Kumarauthor=J.+C.+Leeauthor=A.+Feganauthor=J.+J.+Shenauthor=Q.+Liauthor=D.+Valleraauthor=C.+R.+Wagner&title=Reversible+Re-Programing+of+Cell-Cell+Interactions&doi=10.1002%2Fanie.201310645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible Re-programing of Cell-Cell Interactions</span></div><div class="casAuthors">Gabrielse, Kari; Gangar, Amit; Kumar, Nigam; Lee, Jae Chul; Fegan, Adrian; Shen, Jing Jing; Li, Qing; Vallera, Daniel; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5112-5116</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ability to engineer and re-program the surfaces of cells would provide an enabling synthetic biol. method for the design of cell- and tissue-based therapies.  A new cell surface-engineering strategy is described that uses lipid-chem. self-assembled nanorings (lipid-CSANs) that can be used for the stable and reversible modification of any cell surface with a mol. reporter or targeting ligand.  In the presence of a non-toxic FDA-approved drug, the nanorings were quickly disassembled and the cell-cell interactions reversed.  Similar to T-cells genetically engineered to express chimeric antigen receptors (CARS), when activated peripheral blood mononuclear cells (PBMCs) were functionalized with the anti-EpCAM-lipid-CSANs, they were shown to selectively kill antigen-pos. cancer cells.  Taken together, these results demonstrate that lipid-CSANs have the potential to be a rapid, stable, and general method for the reversible engineering of cell surfaces and cell-cell interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3XK8P4-__17Vg90H21EOLACvtfcHk0liiLP9Dw9MFnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFyhsrs%253D&md5=4f25f5ef5ec39078fb19289ad475421a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.201310645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201310645%26sid%3Dliteratum%253Aachs%26aulast%3DGabrielse%26aufirst%3DK.%26aulast%3DGangar%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DFegan%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DJ.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DVallera%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DReversible%2520Re-Programing%2520of%2520Cell-Cell%2520Interactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D5112%26epage%3D5116%26doi%3D10.1002%2Fanie.201310645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LipovÅ¡ek, D.</span></span> <span> </span><span class="NLM_article-title">Adnectins: Engineered Target-Binding Protein Therapeutics</span>. <i>Protein Eng., Des. Sel.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">9</span>, <span class="refDoi">Â DOI: 10.1093/protein/gzq097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1093%2Fprotein%2Fgzq097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=21068165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FjtlyqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=3-9&author=D.+Lipov%C5%A1ek&title=Adnectins%3A+Engineered+Target-Binding+Protein+Therapeutics&doi=10.1093%2Fprotein%2Fgzq097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Adnectins: engineered target-binding protein therapeutics</span></div><div class="casAuthors">Lipovsek D</div><div class="citationInfo"><span class="NLM_cas:title">Protein engineering, design & selection : PEDS</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">3-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AdnectinsÂ® are a new family of therapeutic proteins based on the 10th fibronectin type III domain, and designed to bind with high affinity and specificity to therapeutically relevant targets.  Adnectins share with antibody variable domains a beta-sheet sandwich fold with diversified loops, but differ from antibodies in primary sequence and have a simpler, single-domain structure without disulfide bonds.  As a consequence, Adnectins bind targets with affinity and specificity as high as those of antibodies, but are easier to manipulate genetically and compatible with bacterial expression systems.  Adnectins that bind macromolecular targets with nanomolar and picomolar affinity have been selected using in vitro evolution methods, including mRNA display, phage display and yeast display.  CT-322, a PEGylated, anti-angiogenic Adnectin that binds vascular endothelial growth factor (VEGF) receptor 2 and blocks its interaction with VEGF A, C and D, is being evaluated in Phase II clinical trials for efficacy in several oncology indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJCiDBpjep9QxyojvcjibhfW6udTcc2eYo9ByCxkEVQ7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FjtlyqsQ%253D%253D&md5=52669f5feb2b96fa457c701f813f21c2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2Fgzq097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252Fgzq097%26sid%3Dliteratum%253Aachs%26aulast%3DLipov%25C5%25A1ek%26aufirst%3DD.%26atitle%3DAdnectins%253A%2520Engineered%2520Target-Binding%2520Protein%2520Therapeutics%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D2011%26volume%3D24%26spage%3D3%26epage%3D9%26doi%3D10.1093%2Fprotein%2Fgzq097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersburg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangar, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumarapperuma, S. C.</span></span> <span> </span><span class="NLM_article-title">In Vivo Evaluation of Site-Specifically PEGylated Chemically Self-Assembled Protein Nanostructures</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2193</span>â <span class="NLM_lpage">2203</span>, <span class="refDoi">Â DOI: 10.1021/acs.molpharmaceut.6b00110</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00110" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlWqtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=2193-2203&author=R.+Shahauthor=J.+Petersburgauthor=A.+C.+Gangarauthor=A.+Feganauthor=C.+R.+Wagnerauthor=S.+C.+Kumarapperuma&title=In+Vivo+Evaluation+of+Site-Specifically+PEGylated+Chemically+Self-Assembled+Protein+Nanostructures&doi=10.1021%2Facs.molpharmaceut.6b00110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Evaluation of Site-Specifically PEGylated Chemically Self-Assembled Protein Nanostructures</span></div><div class="casAuthors">Shah, Rachit; Petersburg, Jacob; Gangar, Amit C.; Fegan, Adrian; Wagner, Carston R.; Kumarapperuma, Sidath C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2193-2203</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. self-assembled nanorings (CSANs) are made of dihydrofolate reductase (DHFR) fusion proteins and have been successfully used in vitro for cellular cargo delivery and cell surface engineering applications.  However, CSANs have yet to be evaluated for their in vivo stability, circulation, and tissue distribution.  In an effort to evaluate CSANs in vivo, we engineered a site-specifically PEGylated epidermal growth factor receptor (EGFR) targeting DHFR mols., characterized their self-assembly into CSANs with bivalent methotrexates (bis-MTX), visualized their in vivo tissue localization by microPET/CT imaging, and detd. their ex vivo organ biodistribution by tissue-based gamma counting.  A dimeric DHFR (DHFR2) mol. fused with a C-terminal EGFR targeting peptide (LARLLT) was engineered to incorporate a site-specific ketone functionality using unnatural amino acid mutagenesis.  Aminooxy-PEG, of differing chain lengths, was successfully conjugated to the protein using oxime chem.  These proteins were self-assembled into CSANs with bis-MTX DHFR dimerizers and characterized by size exclusion chromatog. and dynamic light scattering.  In vitro binding studies were performed with fluorescent CSANs assembled using bis-MTX-FITC, while in vivo microPET/CT imaging was performed with radiolabeled CSANs assembled using bis-MTX-DOTA[64Cu].  PEGylation reduced the uptake of anti-EGFR CSANs by mouse macrophages (RAW 264.7) up to 40% without altering the CSAN's binding affinity toward U-87 MG glioblastoma cells in vitro.  A significant time dependent tumor accumulation of 64Cu labeled anti-EGFR-CSANs was obsd. by microPET/CT imaging and biodistribution studies in mice bearing U-87 MG xenografts.  PEGylated CSANs demonstrated a reduced uptake by the liver, kidneys, and spleen resulting in high contrast tumor imaging within an hour of i.v. injection (9.6% ID/g), and continued to increase up to 24 h (11.7% ID/g) while the background signal diminished.  CSANs displayed an in vivo profile between those of rapidly clearing small mols. and slow clearing antibodies.  Thus, CSANs offer a modular, programmable, and stable protein based platform that can be used for in vivo drug delivery and imaging applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIrnDsag7iX7Vg90H21EOLACvtfcHk0liiLP9Dw9MFnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlWqtrY%253D&md5=f1476344340b5c10592561a7bdf92a3a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00110%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DR.%26aulast%3DPetersburg%26aufirst%3DJ.%26aulast%3DGangar%26aufirst%3DA.%2BC.%26aulast%3DFegan%26aufirst%3DA.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26aulast%3DKumarapperuma%26aufirst%3DS.%2BC.%26atitle%3DIn%2520Vivo%2520Evaluation%2520of%2520Site-Specifically%2520PEGylated%2520Chemically%2520Self-Assembled%2520Protein%2520Nanostructures%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D2193%26epage%3D2203%26doi%3D10.1021%2Facs.molpharmaceut.6b00110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerrab, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamdad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penault-Llorca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubel, C.</span></span> <span> </span><span class="NLM_article-title">Anti-EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors as Combination Therapy for Triple-Negative Breast Cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">73618</span>â <span class="NLM_lpage">73637</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.12037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.18632%2Foncotarget.12037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=27655662" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=73618-73637&author=A.+E.+Guerrabauthor=M.+Bamdadauthor=F.+Kwiatkowskiauthor=Y.-J.+Bignonauthor=F.+Penault-Llorcaauthor=C.+Aubel&title=Anti-EGFR+Monoclonal+Antibodies+and+EGFR+Tyrosine+Kinase+Inhibitors+as+Combination+Therapy+for+Triple-Negative+Breast+Cancer&doi=10.18632%2Foncotarget.12037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12037%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrab%26aufirst%3DA.%2BE.%26aulast%3DBamdad%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DF.%26aulast%3DBignon%26aufirst%3DY.-J.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DAubel%26aufirst%3DC.%26atitle%3DAnti-EGFR%2520Monoclonal%2520Antibodies%2520and%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%2520as%2520Combination%2520Therapy%2520for%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D73618%26epage%3D73637%26doi%3D10.18632%2Foncotarget.12037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, P.</span></span> <span> </span><span class="NLM_article-title">Distribution and Function of EGFR in Human Tissue and the Effect of EGFR Tyrosine Kinase Inhibition</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3639</span>â <span class="NLM_lpage">3650</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=14666659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFWn" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=3639-3650&author=S.+Yanoauthor=K.+Kondoauthor=M.+Yamaguchiauthor=G.+Richmondauthor=M.+Hutchisonauthor=A.+Wakelingauthor=S.+Averbuchauthor=P.+Wadsworth&title=Distribution+and+Function+of+EGFR+in+Human+Tissue+and+the+Effect+of+EGFR+Tyrosine+Kinase+Inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition</span></div><div class="casAuthors">Yano, Seiichi; Kondo, Kaoru; Yamaguchi, Motonori; Richmond, Graham; Hutchison, Michael; Wakeling, Alan; Averbuch, Steven; Wadsworth, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5A</span>),
    <span class="NLM_cas:pages">3639-3650</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  From immunohistochem. and ligand-binding studies, it is known that the epidermal growth factor receptor (EGFR), a member of the erbB family of receptors, is expressed in tissues of epithelial, mesenchymal and neuronal origin and plays a major role in normal cellular processes such as proliferation, differentiation and development.  EGFR is highly expressed in a no. of solid tumors and its expression correlates with tumor progression, resistance to chemotherapy and a poor prognosis; it is consequently an attractive target for the rational design of novel anticancer agents.  Knowledge of the role of EGFR in normal tissues will help the understanding of the adverse events assocd. with such agents.  Studies in knockout mice and preclin. toxicol. studies have shown that the major effects of inhibiting the EGFR are skin and, gastrointestinal toxicities.  Clin. studies with inhibitors of EGFR, such as gefitinib, cetuximab and erlotinib, have shown a favorable adverse-event profile, primarily consisting of skin and gastrointestinal toxicities, as predicted from the mechanism-based effects obsd. in preclin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Lrciisy4g7Vg90H21EOLACvtfcHk0lhVlMoF8IAsGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFWn&md5=70a289e6c8c5492e9c3537d77880af8d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYano%26aufirst%3DS.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DHutchison%26aufirst%3DM.%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DAverbuch%26aufirst%3DS.%26aulast%3DWadsworth%26aufirst%3DP.%26atitle%3DDistribution%2520and%2520Function%2520of%2520EGFR%2520in%2520Human%2520Tissue%2520and%2520the%2520Effect%2520of%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibition%26jtitle%3DAnticancer%2520Res.%26date%3D2003%26volume%3D23%26spage%3D3639%26epage%3D3650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, H.-J.</span></span> <span> </span><span class="NLM_article-title">Anti-EGFR Mechanism of Action: Antitumor Effect and Underlying Cause of Adverse Events</span>. <i>Oncology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5</span>â <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=16736978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BD28zhs1agtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=5-13&author=H.-J.+Lenz&title=Anti-EGFR+Mechanism+of+Action%3A+Antitumor+Effect+and+Underlying+Cause+of+Adverse+Events"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events</span></div><div class="casAuthors">Lenz Heinz-Josef</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5 Suppl 2</span>),
    <span class="NLM_cas:pages">5-13</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">Overexpression of the epidermal growth factor receptor (EGFR) is correlated with poor prognosis in many human cancers.  Two main classes of anticancer agents affect the EGFR: those targeting the extracellular ligand-binding domain and those that block the intracellular tyrosine kinase (TK) domain.  Cetuximab (Erbitux) is a mouse/human chimeric monoclonal antibody that targets the ligand-binding domain of the EGFR, whereas erlotinib (Tarceva) and gefitinib (Iressa) are small-molecule TK inhibitors.  Common toxicities of agents targeting the EGFR differ from those associated with traditional chemotherapy.  Given the common pathway through which these agents work, some adverse events are similar.  Many patients treated with these agents develop an acne-like rash on the face and upper body, most likely related to keratinocyte alterations and hair follicle proliferation and maturation.  Although clinical manifestation of this reaction closely resembles acne vulgaris, the histology is more similar to infectious folliculitis.  Other adverse events appear to be related to a drug class or individual agent.  For example, interstitial lung disease is a rare but potentially fatal reaction that has been reported with gefitinib.  Hypomagnesemia reported in association with cetuximab may be related to EGFR blockade in the kidney.  Anaphylactic or anaphylactoid infusion reactions are also seen with cetuximab, as with other monoclonal antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKebKMi1UHmcjl5L8hwNX0fW6udTcc2eZ5QjHR75gCwLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zhs1agtA%253D%253D&md5=60e15f1bd8f6f670cc6cf928530c8719</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DH.-J.%26atitle%3DAnti-EGFR%2520Mechanism%2520of%2520Action%253A%2520Antitumor%2520Effect%2520and%2520Underlying%2520Cause%2520of%2520Adverse%2520Events%26jtitle%3DOncology%26date%3D2006%26volume%3D20%26spage%3D5%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matzka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">StÃ¶hr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colditz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KÃ¶ck-HÃ³di, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, H.</span></span> <span> </span><span class="NLM_article-title">Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy</span>. <i>Pflege</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">17</span>, <span class="refDoi">Â DOI: 10.1024/1012-5302/a000521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1024%2F1012-5302%2Fa000521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=27901405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhvVCmug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=9-17&author=M.+Matzkaauthor=D.+St%C3%B6hrauthor=A.+Colditzauthor=S.+K%C3%B6ck-H%C3%B3diauthor=M.+Kollerauthor=H.+Mayer&title=Skin+toxicities+and+unmet+supportive+care+needs+of+patients+with+cancer+undergoing+EGFR-inhibitor+therapy&doi=10.1024%2F1012-5302%2Fa000521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy</span></div><div class="casAuthors">Matzka Martin; Stohr Doreen; Colditz Alexandra; Kock-Hodi Sabine; Koller Martina; Mayer Hanna</div><div class="citationInfo"><span class="NLM_cas:title">Pflege</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-17</span>
        ISSN:<span class="NLM_cas:issn">1012-5302</span>.
    </div><div class="casAbstract">Background: Targeted therapies, such as the EGFR (epidermal growth factor receptor) inhibitor therapy, are being used to treat patients with various solid and metastatic tumours.  Skin toxicities are a common side effect of this therapy.  Aim: The aim of this study was to assess the effects of skin toxicities on quality of life of patients with cancer undergoing EGFR inhibitor therapy, as well as their unmet supportive care needs.  Method: Embedded design.  A standardised quantitative survey was administered and analysed.  In addition, memos and audiotaped material of insightful conversations with the patients after survey administration were included in the analyses.  Results: Among the three domains of the effects of skin toxicities on quality of life, physical symptoms (e. g. itching skin, rash) were most frequently reported to impair quality of life, while associated emotional and functional impairments were less frequently reported.  Patients don't consider the management of skin toxicities to be a priority during their treatment, skin toxicities are rather perceived in context of the total symptom burden.  Yet, we observed significant correlations between the assessed quality of life and unmet supportive care need domains, especially concerning physical and psychological needs.  Conclusions: Although no clinically significant impairment of quality of life of patients undergoing EGFR inhibitor therapy was found, skin changes should be addressed in supportive interventions embedded in routine symptom management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvNHKFbAPwvYYPsCkJIw00fW6udTcc2eZ5QjHR75gCwLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhvVCmug%253D%253D&md5=17f2d84649902fe5fbfb5318dc747e44</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1024%2F1012-5302%2Fa000521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1024%252F1012-5302%252Fa000521%26sid%3Dliteratum%253Aachs%26aulast%3DMatzka%26aufirst%3DM.%26aulast%3DSt%25C3%25B6hr%26aufirst%3DD.%26aulast%3DColditz%26aufirst%3DA.%26aulast%3DK%25C3%25B6ck-H%25C3%25B3di%26aufirst%3DS.%26aulast%3DKoller%26aufirst%3DM.%26aulast%3DMayer%26aufirst%3DH.%26atitle%3DSkin%2520toxicities%2520and%2520unmet%2520supportive%2520care%2520needs%2520of%2520patients%2520with%2520cancer%2520undergoing%2520EGFR-inhibitor%2520therapy%26jtitle%3DPflege%26date%3D2017%26volume%3D30%26spage%3D9%26epage%3D17%26doi%3D10.1024%2F1012-5302%2Fa000521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Rahman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouad, M.</span></span> <span> </span><span class="NLM_article-title">Correlation of Cetuximab-Induced Skin Rash and Outcomes of Solid Tumor Patients Treated with Cetuximab: A Systematic Review and Meta-Analysis</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">135</span>, <span class="refDoi">Â DOI: 10.1016/j.critrevonc.2014.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.critrevonc.2014.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25139841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FjtlCmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2015&pages=127-135&author=O.+Abdel-Rahmanauthor=M.+Fouad&title=Correlation+of+Cetuximab-Induced+Skin+Rash+and+Outcomes+of+Solid+Tumor+Patients+Treated+with+Cetuximab%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1016%2Fj.critrevonc.2014.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis</span></div><div class="casAuthors">Abdel-Rahman Omar; Fouad Mona</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We performed a systematic review and meta-analysis of the correlation between cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab.  PATIENTS AND METHODS:  Eligible studies included phase I, II and III trials of patients with solid tumors on cetuximab; describing events of skin rash and correlating skin rash with overall survival (OS), progression free survival (PFS) and/or overall response rate (ORR).  RESULTS:  Our search strategy yielded 409 potentially relevant citations on CETUXIMAB from Pubmed/Medline, CENTRAL Cochrane registry and ASCO meeting library.  After exclusion of ineligible studies, a total of 13 clinical trials were considered eligible for the meta-analysis, including 4 phase III trials, 8 phase II trials and one phase I trial.  The occurrence of cetuximab-induced rash in patients was highly associated with improvements in PFS (HR=0.74; 95% CI: 0.63-0.86, P<0.0002), OS (HR=0.60; 95% CI: 0.47-0.76, P<0.0001), and ORR (RR=1.51, 95% CI: 1.26-1.81, P<0.00001), as compared to patients without rash.  Exploratory subgroup analysis showed no effect of tumor types on the RR of ORR.  CONCLUSIONS:  Our meta-analysis has demonstrated that cetuximab-induced rash is associated with a significantly improved OS, PFS and ORR.  Cetuximab-induced skin rash may represent a prognostic factor in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTi1Ilwxe8M8FUIs6wFK5xJfW6udTcc2eam_XQH92eri7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FjtlCmsg%253D%253D&md5=bdfcf90b616d7296430c29b93b8df838</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2014.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2014.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DAbdel-Rahman%26aufirst%3DO.%26aulast%3DFouad%26aufirst%3DM.%26atitle%3DCorrelation%2520of%2520Cetuximab-Induced%2520Skin%2520Rash%2520and%2520Outcomes%2520of%2520Solid%2520Tumor%2520Patients%2520Treated%2520with%2520Cetuximab%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2015%26volume%3D93%26spage%3D127%26epage%3D135%26doi%3D10.1016%2Fj.critrevonc.2014.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flutter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif-Paghaleh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestle, F. O.</span></span> <span> </span><span class="NLM_article-title">Xenogeneic Graft-versus-Host-Disease in NOD-Scid IL-2RÎ³null Mice Display a T-Effector Memory Phenotype</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e44219</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0044219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1371%2Fjournal.pone.0044219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=22937164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yktLrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=N.+Aliauthor=B.+Flutterauthor=R.+S.+Rodriguezauthor=E.+Sharif-Paghalehauthor=L.+D.+Barberauthor=G.+Lombardiauthor=F.+O.+Nestle&title=Xenogeneic+Graft-versus-Host-Disease+in+NOD-Scid+IL-2R%CE%B3null+Mice+Display+a+T-Effector+Memory+Phenotype&doi=10.1371%2Fjournal.pone.0044219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2RÎ³null mice display a T-effector memory phenotype</span></div><div class="casAuthors">Ali, Niwa; Flutter, Barry; Sanchez Rodriguez, Robert; Sharif-Paghaleh, Ehsan; Barber, Linda D.; Lombardi, Giovanna; Nestle, Frank O.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e44219</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The occurrence of Graft-vs.-Host Disease (GvHD) is a prevalent and potentially lethal complication that develops following hematopoietic stem cell transplantation.  Humanized mouse models of xenogeneic-GvHD based upon immunodeficient strains injected with human peripheral blood mononuclear cells (PBMC; "Hu-PBMC mice") are important tools to study human immune function in vivo.  The recent introduction of targeted deletions at the interleukin-2 common gamma chain (IL-2RÎ³null), notably the NOD-scid IL-2RÎ³null (NSG) and BALB/c-Rag2null IL-2RÎ³null (BRG) mice, has led to improved human cell engraftment.  Despite their widespread use, a comprehensive characterization of engraftment and GvHD development in the Hu-PBMC NSG and BRG models has never been performed in parallel.  We compared engrafted human lymphocyte populations in the peripheral blood, spleens, lymph nodes and bone marrow of these mice.  Kinetics of engraftment differed between the two strains, in particular a significantly faster expansion of the human CD45+ compartment and higher engraftment levels of CD3+ T-cells were obsd. in NSG mice, which may explain the faster rate of GvHD development in this model.  The pathogenesis of human GvHD involves anti-host effector cell reactivity and cutaneous tissue infiltration.  Despite this, the presence of T-cell subsets and tissue homing markers has only recently been characterized in the peripheral blood of patients and has never been properly defined in Hu-PBMC models of GvHD.  Engrafted human cells in NSG mice shows a prevalence of tissue homing cells with a T-effector memory (TEM) phenotype and high levels of cutaneous lymphocyte antigen (CLA) expression.  Characterization of Hu-PBMC mice provides a strong preclin. platform for the application of novel immunotherapies targeting TEM-cell driven GvHD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_-rtPxhysvbVg90H21EOLACvtfcHk0lhkZkmRg7ZEoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yktLrP&md5=3a35880d28d57a1e964c22bc6427b30d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0044219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0044219%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DN.%26aulast%3DFlutter%26aufirst%3DB.%26aulast%3DRodriguez%26aufirst%3DR.%2BS.%26aulast%3DSharif-Paghaleh%26aufirst%3DE.%26aulast%3DBarber%26aufirst%3DL.%2BD.%26aulast%3DLombardi%26aufirst%3DG.%26aulast%3DNestle%26aufirst%3DF.%2BO.%26atitle%3DXenogeneic%2520Graft-versus-Host-Disease%2520in%2520NOD-Scid%2520IL-2R%25CE%25B3null%2520Mice%2520Display%2520a%2520T-Effector%2520Memory%2520Phenotype%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0044219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. X.</span></span> <span> </span><span class="NLM_article-title">Immune Checkpoint Inhibitors in Clinical Trials</span>. <i>Chin. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">434</span>â <span class="NLM_lpage">444</span>, <span class="refDoi">Â DOI: 10.5732/cjc.014.10122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.5732%2Fcjc.014.10122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25189716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFajtrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=434-444&author=E.+Sharonauthor=H.+Streicherauthor=P.+Goncalvesauthor=H.+X.+Chen&title=Immune+Checkpoint+Inhibitors+in+Clinical+Trials&doi=10.5732%2Fcjc.014.10122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Immune checkpoints in cancer clinical trials</span></div><div class="casAuthors">Sharon, Elad; Streicher, Howard; Goncalves, Priscila; Chen, Helen X.</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">434-444</span>CODEN:
                <span class="NLM_cas:coden">CJCHDJ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sun Yat-sen University Cancer Center</span>)
        </div><div class="casAbstract">A review.  Immunol.-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers.  We have learned over the last decade that powerful immunol. effector cells may be blocked by inhibitory regulatory pathways controlled by specific mols. often called "immune checkpoints".  These checkpoints serve to control or turn off the immune response when it is no longer needed to prevent tissue injury and autoimmunity.  Cancer cells have learned or evolved to use these mechanisms to evade immune control and elimination.  The development of a new therapeutic class of drugs that inhibit these inhibitory pathways has recently emerged as a potent strategy in oncol.  Three sets of agents have emerged in clin. trials exploiting this strategy.  These agents are antibody-based therapies targeting cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1).  These inhibitors of immune inhibition have demonstrated extensive activity as single agents and in combinations.  Clin. responses have been seen in melanoma, renal cell carcinoma, non-small cell lung cancer, and several other tumor types.  Despite the autoimmune or inflammatory immune-mediated adverse effects which have been seen, the responses and overall survival benefits exhibited thus far warrant further clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIaeAqleOVaLVg90H21EOLACvtfcHk0lhkZkmRg7ZEoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFajtrjO&md5=3ab93330ccb675f65cea034422fb8f69</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.5732%2Fcjc.014.10122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5732%252Fcjc.014.10122%26sid%3Dliteratum%253Aachs%26aulast%3DSharon%26aufirst%3DE.%26aulast%3DStreicher%26aufirst%3DH.%26aulast%3DGoncalves%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DH.%2BX.%26atitle%3DImmune%2520Checkpoint%2520Inhibitors%2520in%2520Clinical%2520Trials%26jtitle%3DChin.%2520J.%2520Cancer%26date%3D2014%26volume%3D33%26spage%3D434%26epage%3D444%26doi%3D10.5732%2Fcjc.014.10122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.-C.</span></span> <span> </span><span class="NLM_article-title">Glycosylation and Stabilization of Programmed Death Ligand-1 Suppresses T-Cell Activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">12632</span> <span class="refDoi">Â DOI: 10.1038/ncomms12632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1038%2Fncomms12632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=27572267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=C.-W.+Liauthor=S.-O.+Limauthor=W.+Xiaauthor=H.-H.+Leeauthor=L.-C.+Chanauthor=C.-W.+Kuoauthor=K.-H.+Khooauthor=S.-S.+Changauthor=J.-H.+Chaauthor=T.+Kimauthor=J.+L.+Hsuauthor=Y.+Wuauthor=J.-M.+Hsuauthor=H.+Yamaguchiauthor=Q.+Dingauthor=Y.+Wangauthor=J.+Yaoauthor=C.-C.+Leeauthor=H.-J.+Wuauthor=A.+A.+Sahinauthor=J.+P.+Allisonauthor=D.+Yuauthor=G.+N.+Hortobagyiauthor=M.-C.+Hung&title=Glycosylation+and+Stabilization+of+Programmed+Death+Ligand-1+Suppresses+T-Cell+Activity&doi=10.1038%2Fncomms12632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity</span></div><div class="casAuthors">Li, Chia-Wei; Lim, Seung-Oe; Xia, Weiya; Lee, Heng-Huan; Chan, Li-Chuan; Kuo, Chu-Wei; Khoo, Kay-Hooi; Chang, Shih-Shin; Cha, Jong-Ho; Kim, Taewan; Hsu, Jennifer L.; Wu, Yun; Hsu, Jung-Mao; Yamaguchi, Hirohito; Ding, Qingqing; Wang, Yan; Yao, Jun; Lee, Cheng-Chung; Wu, Hsing-Ju; Sahin, Aysegul A.; Allison, James P.; Yu, Dihua; Hortobagyi, Gabriel N.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12632</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) leads to tumor-assocd. immune escape.  Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination and N-glycosylation.  We show that glycogen synthase kinase 3Î² (GSK3Î²) interacts with PD-L1 and induces phosphorylation-dependent proteasome degrdn. of PD-L1 by Î²-TrCP.  In-depth anal. of PD-L1 N192, N200 and N219 glycosylation suggests that glycosylation antagonizes GSK3Î² binding.  In this regard, only non-glycosylated PD-L1 forms a complex with GSK3Î² and Î²-TrCP.  We also demonstrate that epidermal growth factor (EGF) stabilizes PD-L1 via GSK3Î² inactivation in basal-like breast cancer.  Inhibition of EGF signalling by gefitinib destabilizes PD-L1, enhances antitumor T-cell immunity and therapeutic efficacy of PD-1 blockade in syngeneic mouse models.  Together, our results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQnyTgbFXcD7Vg90H21EOLACvtfcHk0lhVP7NCiMbweA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsbnJ&md5=35cab8a1af28193769fe685c0e1f37b7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fncomms12632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12632%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.-W.%26aulast%3DLim%26aufirst%3DS.-O.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DChan%26aufirst%3DL.-C.%26aulast%3DKuo%26aufirst%3DC.-W.%26aulast%3DKhoo%26aufirst%3DK.-H.%26aulast%3DChang%26aufirst%3DS.-S.%26aulast%3DCha%26aufirst%3DJ.-H.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DHsu%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHsu%26aufirst%3DJ.-M.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.-C.%26aulast%3DWu%26aufirst%3DH.-J.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.-C.%26atitle%3DGlycosylation%2520and%2520Stabilization%2520of%2520Programmed%2520Death%2520Ligand-1%2520Suppresses%2520T-Cell%2520Activity%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26doi%3D10.1038%2Fncomms12632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.-P.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 Pathway in Non-Small-Cell Lung Cancer and Its Relation with EGFR Mutation</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">5</span> <span class="refDoi">Â DOI: 10.1186/s12967-014-0373-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1186%2Fs12967-014-0373-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25592115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Ggt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&author=M.+Jiauthor=Y.+Liuauthor=Q.+Liauthor=X.-D.+Liauthor=W.-Q.+Zhaoauthor=H.+Zhangauthor=X.+Zhangauthor=J.-T.+Jiangauthor=C.-P.+Wu&title=PD-1%2FPD-L1+Pathway+in+Non-Small-Cell+Lung+Cancer+and+Its+Relation+with+EGFR+Mutation&doi=10.1186%2Fs12967-014-0373-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation</span></div><div class="casAuthors">Ji, Mei; Liu, Yan; Li, Qing; Li, Xiao-Dong; Zhao, Wei-Qing; Zhang, Hanze; Zhang, Xiaofei; Jiang, Jing-Ting; Wu, Chang-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5/1-5/6, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Immunotherapy has become a crucial modality for non-small-cell lung cancer treatment.  Recently, two immune checkpoints, PD-1 and PD-L1, have emerged as important targets for immunotherapy.  Their antitumor efficacy has been confirmed by in vitro and in vivo studies.  But the correlation between PD-1/PD-L1 expression and EGFR expression was controversial and needs more evidences to support the combination of PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUGW50suey2rVg90H21EOLACvtfcHk0lhVP7NCiMbweA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Ggt70%253D&md5=e0005ebd642fb281d42bb3c8f1e67514</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1186%2Fs12967-014-0373-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-014-0373-0%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DX.-D.%26aulast%3DZhao%26aufirst%3DW.-Q.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DJ.-T.%26aulast%3DWu%26aufirst%3DC.-P.%26atitle%3DPD-1%252FPD-L1%2520Pathway%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%2520and%2520Its%2520Relation%2520with%2520EGFR%2520Mutation%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2015%26volume%3D13%26doi%3D10.1186%2Fs12967-014-0373-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellerman, D.</span></span> <span> </span><span class="NLM_article-title">Bispecific T-Cell Engagers: Towards Understanding Variables Influencing the in Vitro Potency and Tumor Selectivity and Their Modulation to Enhance Their Efficacy and Safety</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">102</span>â <span class="NLM_lpage">117</span>, <span class="refDoi">Â DOI: 10.1016/j.ymeth.2018.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.ymeth.2018.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=30395966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFyhur7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2019&pages=102-117&author=D.+Ellerman&title=Bispecific+T-Cell+Engagers%3A+Towards+Understanding+Variables+Influencing+the+in+Vitro+Potency+and+Tumor+Selectivity+and+Their+Modulation+to+Enhance+Their+Efficacy+and+Safety&doi=10.1016%2Fj.ymeth.2018.10.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety</span></div><div class="casAuthors">Ellerman, Diego</div><div class="citationInfo"><span class="NLM_cas:title">Methods (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102-117</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bispecific mols. redirecting the cytotoxicity of T-cells are a growing class of therapeutics with numerous mols. being tested in clin. trials.  However, it has been a long way since the proof of concept studies in the mid 1980's.  In the process we have learnt about the impact of different variables related to the bispecific mol. and the target antigen on the potency of this type of drugs.  This work reviews the insights gained and how that knowledge has been used to design more potent bispecific T-cell engagers.  The more recent advancement of antibodies with this modality into safety studies in non-human primates and as well as in clin. studies has revealed potential toxicity liabilities for the mode of action.  Modifications in existing antibody formats and new exptl. mols. designed to mitigate these problems are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUduNHkE38YbVg90H21EOLACvtfcHk0lhVP7NCiMbweA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFyhur7L&md5=e1f22c3f36180152b8fb7a9b0b033dd8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2018.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2018.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DEllerman%26aufirst%3DD.%26atitle%3DBispecific%2520T-Cell%2520Engagers%253A%2520Towards%2520Understanding%2520Variables%2520Influencing%2520the%2520in%2520Vitro%2520Potency%2520and%2520Tumor%2520Selectivity%2520and%2520Their%2520Modulation%2520to%2520Enhance%2520Their%2520Efficacy%2520and%2520Safety%26jtitle%3DMethods%26date%3D2019%26volume%3D154%26spage%3D102%26epage%3D117%26doi%3D10.1016%2Fj.ymeth.2018.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schietinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranz, D. M.</span></span> <span> </span><span class="NLM_article-title">A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CARs) and Bispecific T-Cell Engagers (BiTEs)</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">863</span>â <span class="NLM_lpage">873</span>, <span class="refDoi">Â DOI: 10.4161/onci.20592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.4161%2Fonci.20592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=23162754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC2sris1Wruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=863-873&author=J.+D.+Stoneauthor=D.+H.+Aggenauthor=A.+Schietingerauthor=H.+Schreiberauthor=D.+M.+Kranz&title=A+Sensitivity+Scale+for+Targeting+T+Cells+with+Chimeric+Antigen+Receptors+%28CARs%29+and+Bispecific+T-Cell+Engagers+%28BiTEs%29&doi=10.4161%2Fonci.20592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)</span></div><div class="casAuthors">Stone Jennifer D; Aggen David H; Schietinger Andrea; Schreiber Hans; Kranz David M</div><div class="citationInfo"><span class="NLM_cas:title">Oncoimmunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">863-873</span>
        ISSN:<span class="NLM_cas:issn">2162-4011</span>.
    </div><div class="casAbstract">Although T cells can mediate potent antitumor responses, immune tolerance mechanisms often result in the deletion or inactivation of T cells that express T-cell receptors (TCRs) against potentially effective target epitopes.  Various approaches have been devised to circumvent this problem.  In one approach, the gene encoding an antibody against a cancer-associated antigen is linked, in the form of a single-chain variable fragment (scFv), to genes that encode transmembrane and signaling domains.  This chimeric antigen receptor (CAR) is then introduced into T cells for adoptive T-cell therapy.  In another approach, the anti-cancer scFv is fused to a scFv that binds to the CD3Îµ subunit of the TCR/CD3 complex.  This fusion protein serves as a soluble, injectable product that has recently been termed bispecific T-cell engager (BiTE).  Both strategies have now been tested in clinical trials with promising results, but the comparative efficacies are not known.  Here, we performed a direct comparison of the in vitro sensitivity of each strategy, using the same anti-cancer scFv fragments, directed against a tumor-specific glycopeptide epitope on the sialomucin-like transmembrane glycoprotein OTS8, which results form a cancer-specific mutation of Cosmc.  While both approaches showed specific responses to the epitope as revealed by T cell-mediated cytokine release and target cell lysis, CAR-targeted T cells were more sensitive than BiTE-targeted T cells to low numbers of antigens per cell.  The sensitivity scale described here provides a guide to the potential use of these two different approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGcnTbQFS8PCCEBeYuoi7AfW6udTcc2ebj_O_j_-76_Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sris1Wruw%253D%253D&md5=7109405fb1e0f95855399c5e1e9b77f1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.4161%2Fonci.20592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fonci.20592%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DJ.%2BD.%26aulast%3DAggen%26aufirst%3DD.%2BH.%26aulast%3DSchietinger%26aufirst%3DA.%26aulast%3DSchreiber%26aufirst%3DH.%26aulast%3DKranz%26aufirst%3DD.%2BM.%26atitle%3DA%2520Sensitivity%2520Scale%2520for%2520Targeting%2520T%2520Cells%2520with%2520Chimeric%2520Antigen%2520Receptors%2520%2528CARs%2529%2520and%2520Bispecific%2520T-Cell%2520Engagers%2520%2528BiTEs%2529%26jtitle%3DOncoimmunology%26date%3D2012%26volume%3D1%26spage%3D863%26epage%3D873%26doi%3D10.4161%2Fonci.20592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hapka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallera, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Self-Assembly of Antibodies by Chemical Induction</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">10179</span>â <span class="NLM_lpage">10182</span>, <span class="refDoi">Â DOI: 10.1002/anie.200803507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1002%2Fanie.200803507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFaksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=10179-10182&author=Q.+Liauthor=D.+Hapkaauthor=H.+Chenauthor=D.+A.+Valleraauthor=C.+R.+Wagner&title=Self-Assembly+of+Antibodies+by+Chemical+Induction&doi=10.1002%2Fanie.200803507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Self-assembly of antibodies by chemical induction</span></div><div class="casAuthors">Li, Qing; Hapka, David; Chen, Hua; Vallera, Daniel A.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">10179-10182</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Circular arrays of recombinant antibodies can be produced reversibly by chem. controlled protein macrocyclization.  In the presence of bismethotrexate (bis-MTX), dimeric dihydrofolate reductase fusion protein (DHFR) with an anti-CD3 single-chain variable region (scFv) self-assembled spontaneously into diabodies, which were disassembled into monomers with an excess of the antibiotic trimethoprim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1shGTnV5ZtLVg90H21EOLACvtfcHk0liDkBkBH4J-hg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFaksA%253D%253D&md5=7acf419b0b64aa10f85eb21559bbb9b5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fanie.200803507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200803507%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DHapka%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DVallera%26aufirst%3DD.%2BA.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DSelf-Assembly%2520of%2520Antibodies%2520by%2520Chemical%2520Induction%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D10179%26epage%3D10182%26doi%3D10.1002%2Fanie.200803507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stutvoet, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kol, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrmann, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwisscha
van Scheltinga, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, S.</span></span> <span> </span><span class="NLM_article-title">MAPK Pathway Activity Plays a Key Role in PD-L1 Expression of Lung Adenocarcinoma Cells</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>249</i></span>,  <span class="NLM_fpage">52</span>â <span class="NLM_lpage">64</span>, <span class="refDoi">Â DOI: 10.1002/path.5280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1002%2Fpath.5280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=30972766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2rsLjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=2019&pages=52-64&author=T.+S.+Stutvoetauthor=A.+Kolauthor=E.+G.+de+Vriesauthor=M.+de+Bruynauthor=R.+S.+Fehrmannauthor=A.+G.+Terwisscha%0Avan+Scheltingaauthor=S.+de+Jong&title=MAPK+Pathway+Activity+Plays+a+Key+Role+in+PD-L1+Expression+of+Lung+Adenocarcinoma+Cells&doi=10.1002%2Fpath.5280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells</span></div><div class="casAuthors">Stutvoet, Thijs S.; Kol, Arjan; de Vries, Elisabeth G. E.; de Bruyn, Marco; Fehrmann, Rudolf S. N.; Terwisscha van Scheltinga, Anton G. T.; de Jong, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">249</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-64</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) have improved the survival of patients with non-small cell lung cancer (NSCLC).  Still, many patients do not respond to these inhibitors.  PD-L1 (CD274) expression, one of the factors that influences the efficacy of immune checkpoint inhibitors, is dynamic.  Here, we studied the regulation of PD-L1 expression in NSCLC without targetable genetic alterations in EGFR, ALK, BRAF, ROS1, MET, ERBB2 and RET.  Anal. of RNA sequencing data from these NSCLCs revealed that inferred IFNÎ³, EGFR and MAPK signaling correlated with CD274 gene expression in lung adenocarcinoma.  In a representative lung adenocarcinoma cell line panel, stimulation with EGF or IFNÎ³ increased CD274 mRNA and PD-L1 protein and membrane levels, which were further enhanced by combining EGF and IFNÎ³.  Similarly, tumor cell PD-L1 membrane levels increased after coculture with activated peripheral blood mononuclear cells.  Inhibition of the MAPK pathway, using EGFR inhibitors cetuximab and erlotinib or the MEK 1 and 2 inhibitor selumetinib, prevented EGF- and IFNÎ³-induced CD274 mRNA and PD-L1 protein and membrane upregulation, but had no effect on IFNÎ³-induced MHC-I upregulation.  Interestingly, although IFNÎ³ increases transcriptional activity of CD274, MAPK signaling also increased stabilization of CD274 mRNA.  In conclusion, MAPK pathway activity plays a key role in EGF- and IFNÎ³-induced PD-L1 expression in lung adenocarcinoma without targetable genetic alterations and may present a target to improve the efficacy of immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJaRr21pc9kbVg90H21EOLACvtfcHk0liDkBkBH4J-hg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2rsLjK&md5=8bedf3ad0e7d302b4f27336931efa5c7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fpath.5280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.5280%26sid%3Dliteratum%253Aachs%26aulast%3DStutvoet%26aufirst%3DT.%2BS.%26aulast%3DKol%26aufirst%3DA.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3Dde%2BBruyn%26aufirst%3DM.%26aulast%3DFehrmann%26aufirst%3DR.%2BS.%26aulast%3DTerwisscha%2Bvan%2BScheltinga%26aufirst%3DA.%2BG.%26aulast%3Dde%2BJong%26aufirst%3DS.%26atitle%3DMAPK%2520Pathway%2520Activity%2520Plays%2520a%2520Key%2520Role%2520in%2520PD-L1%2520Expression%2520of%2520Lung%2520Adenocarcinoma%2520Cells%26jtitle%3DJ.%2520Pathol.%26date%3D2019%26volume%3D249%26spage%3D52%26epage%3D64%26doi%3D10.1002%2Fpath.5280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yiao  Wang</span>, <span class="hlFld-ContribAuthor ">Ozgun  Kilic</span>, <span class="hlFld-ContribAuthor ">Clifford M.  Csizmar</span>, <span class="hlFld-ContribAuthor ">Sudhat  Ashok</span>, <span class="hlFld-ContribAuthor ">James L.  Hougland</span>, <span class="hlFld-ContribAuthor ">Mark D.  Distefano</span>, <span class="hlFld-ContribAuthor ">Carston R.  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Engineering reversible cellâcell interactions using enzymatically lipidated chemically self-assembled nanorings. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 331-340. <a href="https://doi.org/10.1039/D0SC03194A" title="DOI URL">https://doi.org/10.1039/D0SC03194A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC03194A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC03194A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DEngineering%252Breversible%252Bcell%2525E2%252580%252593cell%252Binteractions%252Busing%252Benzymatically%252Blipidated%252Bchemically%252Bself-assembled%252Bnanorings%26aulast%3DWang%26aufirst%3DYiao%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1%26spage%3D331%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Bispecific CSAN formation and characterization. (A) The bispecific nature of CSANs was confirmed by binding to two cell types. Effector T cells (left) are only CD3 positive and cancer cells (right) are only EGFR positive. (B) The monomeric nature of E1-1DD and CD3-1DD and size distribution of E1-CD3 bispecific rings upon dimerizer addition were confirmed by size exclusion chromatography (SEC). (C) The mean diameter and polydispersity of the bispecific rings were determined by dynamic light scattering (DLS). (D) Ring formation was also confirmed by cryo-TEM imaging of the E1-CD3 and E4-CD3 bispecific nanorings (scale bar, 10 nm).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cytotoxicity of EGFR-targeting PAR-T cells. In a 96-well plate, 0.5 Ã 10<sup>4</sup> cells were seeded and incubated with the protein treatments for 24 h. The supernatants were analyzed for cytotoxicity using the lactate dehydrogenase (LDH) assay. (A) Cytotoxicity toward MCF-7 cells. (B) Cytotoxicity toward MDA-MB-231 cells. (C) Cytotoxicity toward A431 cells. *<i>P</i> < 0.05 with respect to nontreated controls, by one-way analysis of variance (ANOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cytokine release profile of EGFR-targeting PAR-T cells. In a 96-well plate, 0.5 Ã 10<sup>4</sup> cells were seeded and incubated with the protein treatments for 24 h. The supernatants were analyzed for cytotoxicity using the ELISA kit. (A) IL-2 released from MCF-7 cells after cytotoxicity study. (B) IL-2 released from MDA-MB-231 cells after cytotoxicity study. (C) IFN-Î³ released from MCF-7 cells after cytotoxicity study. (D) IFN-Î³ released from MDA-MB-231 cells after cytotoxicity study. *<i>P</i> < 0.05 with respect to nontreated controls, by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Valency modulation of bispecific CSANs. Cells (0.5 Ã 10<sup>4</sup>) were seeded in 96-well plates and incubated with 25nM of protein treatments for 24 h. The cell lysis was quantified by the lactate dehydrogenase (LDH) assay. (A) Schematic demonstrating that by varying the valency of the rings, we can shift binding of rings predominantly to either cancer cells or T cells. (B) LDH-based cytotoxicity results for MDA-MB-231 cells when valency was modulated from CD3-targeting high (left) to EGFR-targeting high (right). Other than the PBS control and 2:6 valency groups, at every valency examined, E1-CD3 rings were significantly more cytotoxic compared to 1DD-CD3 rings. (C) LDH-based cytotoxicity results for MCF-7 cells when the valency was modulated from CD3-targeting high (left) to EGFR-targeting high (right). There was no significant difference between E1-CD3 and 1DD-CD3 rings at any valency ratio. *<i>P</i> < 0.05 with respect to E1-CD3 rings and 1DD-CD3 ring controls, by a two-tailed Studentâs t test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vivo</i> efficacy study of FN3-PARs using an orthotopic NSG mouse model. NSG mice (6â8 weeks old) were implanted with 1.0 Ã 10<sup>6</sup> MDA-MB-231 and 20 Ã 10<sup>6</sup> PBMCs. Mice in each group (<i>n</i> = 5) received a total of six treatments of 1 mg/kg intravenously, given every other day. Tumor volume and body weight were monitored to track disease progression. (A) Schematic demonstrating the time of tumor and PBMC implantation and the treatment schedule. (B) Mean tumor volumes were measured every other day and recorded. Tumor volume measurements were done with a caliper. Arrows indicate the days of treatment. *<i>P</i> < 0.05 with respect to nontreated controls, by two-way ANOVA, followed by Dunnettâs test for multiple comparisons. (C) The average body weight within each group is recorded. Arrows indicate the days of treatment. There was no significant difference between the average weights within each group throughout the study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/medium/jm0c00489_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representative immunohistochemistry (IHC) images and quantification. (A) ki67, (B), CD3, (C) total EGFR, (D) phospho-EGFR, (E) programmed cell death ligand-1(PD-L1), and (F) programmed cell death-1 (PD-1). Brown staining indicates that the cell is positive for the markers listed. For each staining representative image for PBS, CD3 and E1-CD3 groups are shown. On the right side of the image panels, the expression of each marker is quantified, where blue indicates low expression, red indicates medium expression, and green indicates high expression for the marker within regions of each image.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00489&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62323" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62323" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leyfman, Y.</span></span> <span> </span><span class="NLM_article-title">Chimeric Antigen Receptors: Unleashing a New Age of Anti-Cancer Therapy</span>. <i>Cancer Cell Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>, <span class="NLM_elocation-id">182</span> <span class="refDoi">Â DOI: 10.1186/s12935-018-0685-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1186%2Fs12935-018-0685-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=30459530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2ksrbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&author=Y.+Leyfman&title=Chimeric+Antigen+Receptors%3A+Unleashing+a+New+Age+of+Anti-Cancer+Therapy&doi=10.1186%2Fs12935-018-0685-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptors: unleashing a new age of anti-cancer therapy</span></div><div class="casAuthors">Leyfman, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell International</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">182</span>CODEN:
                <span class="NLM_cas:coden">CCIACC</span>;
        ISSN:<span class="NLM_cas:issn">1475-2867</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Chimeric antigen receptors (CARs) represent a novel facet of modern day synthetic biol. that exemplifies personalized medicine at work through their ability to harness and redirect a patient's immune system to fight cancer.  By combining the target-specificity of antibodies to the effector capabilities of T cells, CARs have yielded high remission rates for many late staged and relapsed/refractory (r/r) hematol. malignancies, including acute lymphoblastic leukemias (ALL) and Non-Hodgkin's lymphomas.  Despite toxicities of cytokine release syndrome and neurotoxicity, recent studies have uncovered their underlying mechanisms and devised effective therapies to manage and possibly prevent them.  In 2017, CAR T cell therapy became a reality for the general public despite the high costs, when Novartis's Kymriah, became the first product to receive FDA approval for pediatric r/r B cell ALL with Gilead's Yescarta following several months later.  Although effective in hematol. malignancies, CAR response has been limited in solid tumors largely attributed to the heterogeneous and immunosuppressive tumor microenvironment along tumor defense mechanisms, such as antigenic escape.  Despite the current challenges of CAR T therapy, this technol. is still in its infancy and its promise will continue to grow as scientists continue to develop novel approaches to enhance its efficacy.  As its prevalence continues to increase, institutions and pharmaceuticals worldwide are investing in this technol. in hopes of driving therapeutic innovation, while providing greater access to their resp. populations through clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Y3AeKgo28LVg90H21EOLACvtfcHk0lhC45G0y2oVBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2ksrbP&md5=f3345b091d5a10940913bf6e13668f7e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1186%2Fs12935-018-0685-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12935-018-0685-x%26sid%3Dliteratum%253Aachs%26aulast%3DLeyfman%26aufirst%3DY.%26atitle%3DChimeric%2520Antigen%2520Receptors%253A%2520Unleashing%2520a%2520New%2520Age%2520of%2520Anti-Cancer%2520Therapy%26jtitle%3DCancer%2520Cell%2520Int.%26date%3D2018%26volume%3D18%26doi%3D10.1186%2Fs12935-018-0685-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dreier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenczewski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syring, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanakam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riethmuller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeuerle, P. A.</span></span> <span> </span><span class="NLM_article-title">Extremely Potent, Rapid and Costimulation-Independent Cytotoxic T-Cell Response against Lymphoma Cells Catalyzed by a Single-Chain Bispecific Antibody</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">690</span>â <span class="NLM_lpage">697</span>, <span class="refDoi">Â DOI: 10.1002/ijc.10557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1002%2Fijc.10557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=12209608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFKgsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=690-697&author=T.+Dreierauthor=G.+Lorenczewskiauthor=C.+Brandlauthor=P.+Hoffmannauthor=U.+Syringauthor=F.+Hanakamauthor=P.+Kuferauthor=G.+Riethmullerauthor=R.+Bargouauthor=P.+A.+Baeuerle&title=Extremely+Potent%2C+Rapid+and+Costimulation-Independent+Cytotoxic+T-Cell+Response+against+Lymphoma+Cells+Catalyzed+by+a+Single-Chain+Bispecific+Antibody&doi=10.1002%2Fijc.10557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody</span></div><div class="casAuthors">Dreier, Torsten; Lorenczewski, Grit; Brandl, Christian; Hoffmann, Patrick; Syring, Uwe; Hanakam, Frank; Kufer, Peter; Riethmuller, Gert; Bargou, Ralf; Baeuerle, Patrick A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">690-697</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A recent study reported on an anti-CD19/anti-CD3 single-chain bispecific antibody (bscCD19ÃCD3) exhibiting high activity against human B lymphoma cell lines.  In the present study, we have explored in detail the in vitro efficacy, T-cell donor variability, binding characteristics, specificity, kinetics and interleukin-2 (IL-2) dependence of bscCD19ÃCD3.  We found that a majority of human donor T cells tested (n = 86) gave half-maximal B-lymphoma cell lysis (ED50) within a range of 10-50 pg/mL bscCD19ÃCD3, corresponding to sub-picomolar concns. of the bispecific antibody.  Under identical exptl. conditions, the anti-CD20 monoclonal antibody rituximab had an at least 100,000-fold lower in vitro efficacy.  The extreme potency of bscCD19ÃCD3 was in sharp contrast to the relatively low affinity of the anti-CD3 and anti-CD19 single-chain Fv portions in KD ranges of 10-7 and 10-9 M, resp.  Cell lysis by bscCD19ÃCD3 was predominantly mediated by the population of CD8/CD45RO-pos. T cells.  Both immortalized CD4- and CD8-pos. human T-cell clones were highly active effector cells as well.  Cell lysis by bscCD19ÃCD3 was rapid and specific.  The resp. parental monoclonal antibodies inhibited cell lysis and CD19-neg. cells were not harmed by T cells in the presence of high amts. of bscCD19ÃCD3.  The potent T-cell stimulus IL-2 could not markedly augment the activity of bscCD19ÃCD3-stimulated T cells.  In conclusion, bscCD19ÃCD3 could redirect unstimulated cytotoxic T cells against CD19-pos. cells in an unexpectedly potent, rapid and specific fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSKchUnK877Vg90H21EOLACvtfcHk0ljiuXaw9qeArQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFKgsr0%253D&md5=24a4615794140f62610725a9641ed69b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fijc.10557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10557%26sid%3Dliteratum%253Aachs%26aulast%3DDreier%26aufirst%3DT.%26aulast%3DLorenczewski%26aufirst%3DG.%26aulast%3DBrandl%26aufirst%3DC.%26aulast%3DHoffmann%26aufirst%3DP.%26aulast%3DSyring%26aufirst%3DU.%26aulast%3DHanakam%26aufirst%3DF.%26aulast%3DKufer%26aufirst%3DP.%26aulast%3DRiethmuller%26aufirst%3DG.%26aulast%3DBargou%26aufirst%3DR.%26aulast%3DBaeuerle%26aufirst%3DP.%2BA.%26atitle%3DExtremely%2520Potent%252C%2520Rapid%2520and%2520Costimulation-Independent%2520Cytotoxic%2520T-Cell%2520Response%2520against%2520Lymphoma%2520Cells%2520Catalyzed%2520by%2520a%2520Single-Chain%2520Bispecific%2520Antibody%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D100%26spage%3D690%26epage%3D697%26doi%3D10.1002%2Fijc.10557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, D.</span></span> <span> </span><span class="NLM_article-title">The Development of Bispecific Antibodies and Their Applications in Tumor Immune Escape</span>. <i>Exp. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">12</span> <span class="refDoi">Â DOI: 10.1186/s40164-017-0072-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1186%2Fs40164-017-0072-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=28469973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVGntrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&author=X.+Zhangauthor=Y.+Yangauthor=D.+Fanauthor=D.+Xiong&title=The+Development+of+Bispecific+Antibodies+and+Their+Applications+in+Tumor+Immune+Escape&doi=10.1186%2Fs40164-017-0072-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The development of bispecific antibodies and their applications in tumor immune escape</span></div><div class="casAuthors">Zhang, Xiaolong; Yang, Yuanyuan; Fan, Dongmei; Xiong, Dongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology & Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12/1-12/6</span>CODEN:
                <span class="NLM_cas:coden">EHOXAU</span>;
        ISSN:<span class="NLM_cas:issn">2162-3619</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">During the past two decades, a great evolution of bispecific antibodies (BsAbs) for therapeutic applications has been made.  BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wide range of applications including redirecting T cells or NK cells to tumor cells, blocking two different signaling pathways, dual targeting of different disease mediators, and delivering payloads to targeted sites.  Aside from approved catumaxomab (anti-CD3 and anti-EpCAM) and blinatumomab (anti-CD3 and anti-CD19), many more BsAbs are now in various phases of clin. development.  Here, this review focus on the development of bispecific antibodies and their applications in tumor immune escape.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgF1LZW9dH3LVg90H21EOLACvtfcHk0ljiuXaw9qeArQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVGntrc%253D&md5=c5da87ad9e5f525866d314ae1cfef279</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fs40164-017-0072-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40164-017-0072-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DD.%26aulast%3DXiong%26aufirst%3DD.%26atitle%3DThe%2520Development%2520of%2520Bispecific%2520Antibodies%2520and%2520Their%2520Applications%2520in%2520Tumor%2520Immune%2520Escape%26jtitle%3DExp.%2520Hematol.%2520Oncol.%26date%3D2017%26volume%3D6%26doi%3D10.1186%2Fs40164-017-0072-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span> <span> </span><span class="NLM_article-title">Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">767</span> <span class="refDoi">Â DOI: 10.3389/fonc.2019.00767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.3389%2Ffonc.2019.00767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=31482064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BB3MrkvVyguw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=Y.+Caoauthor=W.+Luauthor=R.+Sunauthor=X.+Jinauthor=L.+Chengauthor=X.+Heauthor=L.+Wangauthor=T.+Yuanauthor=C.+Lyuauthor=M.+Zhao&title=Anti-CD19+Chimeric+Antigen+Receptor+T+Cells+in+Combination+With+Nivolumab+Are+Safe+and+Effective+Against+Relapsed%2FRefractory+B-Cell+Non-Hodgkin+Lymphoma&doi=10.3389%2Ffonc.2019.00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma</span></div><div class="casAuthors">Cao Yaqing; Sun Rui; Cheng Lin; Wang Luqiao; Lu Wenyi; Yuan Ting; Lyu Cuicui; Zhao Mingfeng; Jin Xin; He Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">767</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment for patients with refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL), and combination with PD1 inhibitors may further improve the efficacy of anti-CD19 CAR (CD19 CAR)-T cells in the treatment of lymphomas.  In a single-center study, we evaluated the safety and efficacy of a combination therapy with CD19 CAR-T cells and an anti-PD-1 antibody (nivolumab) in patients with relapsed/refractory B-NHL.  A total of 11 patients with refractory/relapsed B-NHL were recruited and subsequently received CD19 CAR-T cells and nivolumab.  The primary end points were safety and feasibility.  The infusions were safe, and no dose-limiting toxicities occurred.  Grade 1 or 2 cytokine release syndrome (CRS) was observed in 25% (3/11) and 50% (6/11) of the patients, respectively, and only one patient (1/11) experienced neurotoxicity.  The objective response rate (ORR) and complete response (CR) rate were 81.81% (9/11) and 45.45% (5/11), respectively.  The median follow-up time was 6 (1~15) months.  The median progression-free survival (PFS) time was 6 months (1~14 months), and 3 patients continued to have a response at the time of this writing.  Our study demonstrated that the combination of CD19 CAR-T cells and nivolumab was feasible and safe and mediated potent anti-lymphoma activity, which should be examined further in prospective clinical trials in refractory/relapsed B-NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbUklrjYont4xhnOQkIHOxfW6udTcc2eYmwzInuWeUuLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrkvVyguw%253D%253D&md5=6bc45fcdc1fa2f8b5d87f5351a80f2c3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00767%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DT.%26aulast%3DLyu%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DM.%26atitle%3DAnti-CD19%2520Chimeric%2520Antigen%2520Receptor%2520T%2520Cells%2520in%2520Combination%2520With%2520Nivolumab%2520Are%2520Safe%2520and%2520Effective%2520Against%2520Relapsed%252FRefractory%2520B-Cell%2520Non-Hodgkin%2520Lymphoma%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26doi%3D10.3389%2Ffonc.2019.00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brentjens, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davila, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borquez-Ojeda, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasielewska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rijo, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedvat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinherz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maslak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadelain, M.</span></span> <span> </span><span class="NLM_article-title">CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">177ra38</span> <span class="refDoi">Â DOI: 10.1126/scitranslmed.3005930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1126%2Fscitranslmed.3005930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=23515080" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&author=R.+J.+Brentjensauthor=M.+L.+Davilaauthor=I.+Riviereauthor=J.+Parkauthor=X.+Wangauthor=L.+G.+Cowellauthor=S.+Bartidoauthor=J.+Stefanskiauthor=C.+Taylorauthor=M.+Olszewskaauthor=O.+Borquez-Ojedaauthor=J.+Quauthor=T.+Wasielewskaauthor=Q.+Heauthor=Y.+Bernalauthor=I.+V.+Rijoauthor=C.+Hedvatauthor=R.+Kobosauthor=K.+Curranauthor=P.+Steinherzauthor=J.+Jurcicauthor=T.+Rosenblatauthor=P.+Maslakauthor=M.+Frattiniauthor=M.+Sadelain&title=CD19-Targeted+T+Cells+Rapidly+Induce+Molecular+Remissions+in+Adults+with+Chemotherapy-Refractory+Acute+Lymphoblastic+Leukemia&doi=10.1126%2Fscitranslmed.3005930"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005930%26sid%3Dliteratum%253Aachs%26aulast%3DBrentjens%26aufirst%3DR.%2BJ.%26aulast%3DDavila%26aufirst%3DM.%2BL.%26aulast%3DRiviere%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCowell%26aufirst%3DL.%2BG.%26aulast%3DBartido%26aufirst%3DS.%26aulast%3DStefanski%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DOlszewska%26aufirst%3DM.%26aulast%3DBorquez-Ojeda%26aufirst%3DO.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DWasielewska%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DBernal%26aufirst%3DY.%26aulast%3DRijo%26aufirst%3DI.%2BV.%26aulast%3DHedvat%26aufirst%3DC.%26aulast%3DKobos%26aufirst%3DR.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DSteinherz%26aufirst%3DP.%26aulast%3DJurcic%26aufirst%3DJ.%26aulast%3DRosenblat%26aufirst%3DT.%26aulast%3DMaslak%26aufirst%3DP.%26aulast%3DFrattini%26aufirst%3DM.%26aulast%3DSadelain%26aufirst%3DM.%26atitle%3DCD19-Targeted%2520T%2520Cells%2520Rapidly%2520Induce%2520Molecular%2520Remissions%2520in%2520Adults%2520with%2520Chemotherapy-Refractory%2520Acute%2520Lymphoblastic%2520Leukemia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26doi%3D10.1126%2Fscitranslmed.3005930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kochenderfer, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerville, R. P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler-Stevenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranick, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, D.-A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toomey, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span> <span> </span><span class="NLM_article-title">Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">540</span>â <span class="NLM_lpage">549</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2014.56.2025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1200%2FJCO.2014.56.2025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25154820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktlCntr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=540-549&author=J.+N.+Kochenderferauthor=M.+E.+Dudleyauthor=S.+H.+Kassimauthor=R.+P.+T.+Somervilleauthor=R.+O.+Carpenterauthor=M.+Stetler-Stevensonauthor=J.+C.+Yangauthor=G.+Q.+Phanauthor=M.+S.+Hughesauthor=R.+M.+Sherryauthor=M.+Raffeldauthor=S.+Feldmanauthor=L.+Luauthor=Y.+F.+Liauthor=L.+T.+Ngoauthor=A.+Goyauthor=T.+Feldmanauthor=D.+E.+Spanerauthor=M.+L.+Wangauthor=C.+C.+Chenauthor=S.+M.+Kranickauthor=A.+Nathauthor=D.-A.+N.+Nathanauthor=K.+E.+Mortonauthor=M.+A.+Toomeyauthor=S.+A.+Rosenberg&title=Chemotherapy-Refractory+Diffuse+Large+B-Cell+Lymphoma+and+Indolent+B-Cell+Malignancies+Can+Be+Effectively+Treated+with+Autologous+T+Cells+Expressing+an+Anti-CD19+Chimeric+Antigen+Receptor&doi=10.1200%2FJCO.2014.56.2025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD 19 chimeric antigen receptor</span></div><div class="casAuthors">Kochenderfer, James N.; Dudley, Mark E.; Kassim, Sadik H.; Somerville, Robert P. T.; Carpenter, Robert O.; Stetler-Stevenson, Maryalice; Yang, James C.; Phan, Giao Q.; Hughes, Marybeth S.; Sherry, Richard M.; Raffeld, Mark; Feldman, Steven; Lu, Lily; Li, Yong F.; Ngo, Lien T.; Goy, Andre; Feldman, Tatyana; Spaner, David E.; Wang, Michael L.; Chen, Clara C.; Kranick, Sarah M.; Nath, Avindra; Nathan, Debbie-Ann N.; Morton, Kathleen E.; Toomey, Maly Ann; Rosenberg, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">540-549</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR).  We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19+ B-cell malignancies.  Patients and Methods: We treated 15 patients with advanced B-cell malignancies.  Nine patients had diffuse large B-cell lymphoma (DLBCL), two had indolent lymphomas, and four had chronic lymphocytic leukemia.  Patients received a conditioning chemotherapy regimen of cyclophosphamide and fludarabine followed by a single infusion of anti-CD19 CAR T cells.  Results: Of 15 patients, eight achieved complete remissions (CRs), four achieved partial remissions, one had stable lymphoma, and two were not evaluable for response.  CRs were obtained by four of seven evaluable patients with chemotherapy-refractory DLBCL; three of these four CRs are ongoing, with durations ranging from 9 to 22 mo.  Acute toxicities including fever, hypotension, delirium, and other neurol. toxicities occurred in some patients after infusion of anti-CD19 CAR T cells; these toxicities resolved within 3 wk after cell infusion.  One patient died suddenly as a result of an unknown cause 16 days after cell infusion.  CAR T cells were detected in the blood of patients at peak levels, ranging from nine to 777 CAR-pos. T cells/Î¼L.  Conclusion This is the first report to our knowledge of successful treatment of DLBCL with anti-CD19 CAR T cells.  These results demonstrate the feasibility and effectiveness of treating chemotherapy-refractory B-cell malignancies with anti-CD19 CAR T cells.  The numerous remissions obtained provide strong support for further development of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIqip2risUlbVg90H21EOLACvtfcHk0lgrrdcPfoYiBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktlCntr4%253D&md5=494054bba74644cd28a1a5977f4d52b0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.56.2025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.56.2025%26sid%3Dliteratum%253Aachs%26aulast%3DKochenderfer%26aufirst%3DJ.%2BN.%26aulast%3DDudley%26aufirst%3DM.%2BE.%26aulast%3DKassim%26aufirst%3DS.%2BH.%26aulast%3DSomerville%26aufirst%3DR.%2BP.%2BT.%26aulast%3DCarpenter%26aufirst%3DR.%2BO.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPhan%26aufirst%3DG.%2BQ.%26aulast%3DHughes%26aufirst%3DM.%2BS.%26aulast%3DSherry%26aufirst%3DR.%2BM.%26aulast%3DRaffeld%26aufirst%3DM.%26aulast%3DFeldman%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%2BF.%26aulast%3DNgo%26aufirst%3DL.%2BT.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DFeldman%26aufirst%3DT.%26aulast%3DSpaner%26aufirst%3DD.%2BE.%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DChen%26aufirst%3DC.%2BC.%26aulast%3DKranick%26aufirst%3DS.%2BM.%26aulast%3DNath%26aufirst%3DA.%26aulast%3DNathan%26aufirst%3DD.-A.%2BN.%26aulast%3DMorton%26aufirst%3DK.%2BE.%26aulast%3DToomey%26aufirst%3DM.%2BA.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DChemotherapy-Refractory%2520Diffuse%2520Large%2520B-Cell%2520Lymphoma%2520and%2520Indolent%2520B-Cell%2520Malignancies%2520Can%2520Be%2520Effectively%2520Treated%2520with%2520Autologous%2520T%2520Cells%2520Expressing%2520an%2520Anti-CD19%2520Chimeric%2520Antigen%2520Receptor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D540%26epage%3D549%26doi%3D10.1200%2FJCO.2014.56.2025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maude, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aplenc, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahnke, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melenhorst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheingold, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teachey, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span> <span> </span><span class="NLM_article-title">Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1507</span>â <span class="NLM_lpage">1517</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1407222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1056%2FNEJMoa1407222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25317870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSls73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1507-1517&author=S.+L.+Maudeauthor=N.+Freyauthor=P.+A.+Shawauthor=R.+Aplencauthor=D.+M.+Barrettauthor=N.+J.+Buninauthor=A.+Chewauthor=V.+E.+Gonzalezauthor=Z.+Zhengauthor=S.+F.+Laceyauthor=Y.+D.+Mahnkeauthor=J.+J.+Melenhorstauthor=S.+R.+Rheingoldauthor=A.+Shenauthor=D.+T.+Teacheyauthor=B.+L.+Levineauthor=C.+H.+Juneauthor=D.+L.+Porterauthor=S.+A.+Grupp&title=Chimeric+Antigen+Receptor+T+Cells+for+Sustained+Remissions+in+Leukemia&doi=10.1056%2FNEJMoa1407222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptor T cells for sustained remissions in leukemia</span></div><div class="casAuthors">Maude, Shannon L.; Frey, Noelle; Shaw, Pamela A.; Aplenc, Richard; Barrett, David M.; Bunin, Nancy J.; Chew, Anne; Gonzalez, Vanessa E.; Zheng, Zhaohui; Lacey, Simon F.; Mahnke, Yolanda D.; Melenhorst, Jan J.; Rheingold, Susan R.; Shen, Angela; Teachey, David T.; Levine, Bruce L.; June, Carl H.; Porter, David L.; Grupp, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1507-1517, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies.  Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.  Methods: We infused autologous T cells transduced with a CD19-directed chimeric antigen receptor (CTL019) lentiviral vector in patients with relapsed or refractory ALL at doses of 0.76 Ã 106 to 20.6 Ã 106 CTL019 cells per kg of body wt.  Patients were monitored for a response, toxic effects, and the expansion and persistence of circulating CTL019 T cells.  Results: A total of 30 children and adults received CTL019.  Complete remission was achieved in 27 patients (90%), including 2 patients with blinatumomab-refractory disease and 15 who had undergone stem-cell transplantation.  CTL019 cells proliferated in vivo and were detectable in the blood, bone marrow, and cerebrospinal fluid of patients who had a response.  Sustained remission was achieved with a 6-mo event-free survival rate of 67% (95% confidence interval [CI], 51 to 88) and an overall survival rate of 78% (95% CI, 65 to 95).  At 6 mo, the probability that a patient would have persistence of CTL019 was 68% (95% CI, 50 to 92) and the probability that a patient would have relapse-free B-cell aplasia was 73% (95% CI, 57 to 94).  All the patients had the cytokine-release syndrome.  Severe cytokine-release syndrome, which developed in 27% of the patients, was assocd. with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.  Conclusions: Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL.  CTL019 was assocd. with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 mo were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMldO024V5VrVg90H21EOLACvtfcHk0lgrrdcPfoYiBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSls73K&md5=7f13aaa25ae118901d3bec614b07cc3a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1407222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1407222%26sid%3Dliteratum%253Aachs%26aulast%3DMaude%26aufirst%3DS.%2BL.%26aulast%3DFrey%26aufirst%3DN.%26aulast%3DShaw%26aufirst%3DP.%2BA.%26aulast%3DAplenc%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DD.%2BM.%26aulast%3DBunin%26aufirst%3DN.%2BJ.%26aulast%3DChew%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DV.%2BE.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DLacey%26aufirst%3DS.%2BF.%26aulast%3DMahnke%26aufirst%3DY.%2BD.%26aulast%3DMelenhorst%26aufirst%3DJ.%2BJ.%26aulast%3DRheingold%26aufirst%3DS.%2BR.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DTeachey%26aufirst%3DD.%2BT.%26aulast%3DLevine%26aufirst%3DB.%2BL.%26aulast%3DJune%26aufirst%3DC.%2BH.%26aulast%3DPorter%26aufirst%3DD.%2BL.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26atitle%3DChimeric%2520Antigen%2520Receptor%2520T%2520Cells%2520for%2520Sustained%2520Remissions%2520in%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1507%26epage%3D1517%26doi%3D10.1056%2FNEJMoa1407222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochenderfer, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler-Stevenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbrook, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orentas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroncek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschernia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayne, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackall, C. L.</span></span> <span> </span><span class="NLM_article-title">T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">517</span>â <span class="NLM_lpage">528</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(14)61403-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2FS0140-6736%2814%2961403-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25319501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGjtLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=517-528&author=D.+W.+Leeauthor=J.+N.+Kochenderferauthor=M.+Stetler-Stevensonauthor=Y.+K.+Cuiauthor=C.+Delbrookauthor=S.+A.+Feldmanauthor=T.+J.+Fryauthor=R.+Orentasauthor=M.+Sabatinoauthor=N.+N.+Shahauthor=S.+M.+Steinbergauthor=D.+Stroncekauthor=N.+Tscherniaauthor=C.+Yuanauthor=H.+Zhangauthor=L.+Zhangauthor=S.+A.+Rosenbergauthor=A.+S.+Wayneauthor=C.+L.+Mackall&title=T+Cells+Expressing+CD19+Chimeric+Antigen+Receptors+for+Acute+Lymphoblastic+Leukaemia+in+Children+and+Young+Adults%3A+A+Phase+1+Dose-Escalation+Trial&doi=10.1016%2FS0140-6736%2814%2961403-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial</span></div><div class="casAuthors">Lee, Daniel W.; Kochenderfer, James N.; Stetler-Stevenson, Maryalice; Cui, Yongzhi K.; Delbrook, Cindy; Feldman, Steven A.; Fry, Terry J.; Orentas, Rimas; Sabatino, Marianna; Shah, Nirali N.; Steinberg, Seth M.; Stroncek, Dave; Tschernia, Nick; Yuan, Constance; Zhang, Hua; Zhang, Ling; Rosenberg, Steven A.; Wayne, Alan S.; Mackall, Crystal L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">9967</span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported.  We aimed to define feasibility, toxicity, max. tolerated dose, response rate, and biol. correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells.  This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukemia or non-Hodgkin lymphoma.  Autologous T cells were engineered via an 11-day manufg. process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains.  All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells.  Using a std. 3 + 3 design to establish the max. tolerated dose, patients received either 1 Ã 106 CAR-transduced T cells per kg (dose 1), 3 Ã 106 CAR-transduced T cells per kg (dose 2), or the entire CAR T-cell product if sufficient nos. of cells to meet the assigned dose were not generated.  After the dose-escalation phase, an expansion cohort was treated at the max. tolerated dose.  The trial is registered with ClinicalTrials.gov, no. NCT01593696.  Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concn. could not be generated for two patients (90% feasible).  All patients enrolled were assessed for response.  The max. tolerated dose was defined as 1 Ã 106 CD19-CAR T cells per kg.  All toxicities were fully reversible, with the most severe being grade 4 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 3Â·0-36Â·3).  The most common non-haematol. grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients).  CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukemia.  All toxicities were reversible and prolonged B-cell aplasia did not occur.  National Institutes of Health Intramural funds and St Baldrick's Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoItCLZAV3HoLVg90H21EOLACvtfcHk0lj6Y0waxRi2sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGjtLbM&md5=6d2ae3cb6d1672a1f0b3c0fedef2c337</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961403-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961403-3%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DKochenderfer%26aufirst%3DJ.%2BN.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DY.%2BK.%26aulast%3DDelbrook%26aufirst%3DC.%26aulast%3DFeldman%26aufirst%3DS.%2BA.%26aulast%3DFry%26aufirst%3DT.%2BJ.%26aulast%3DOrentas%26aufirst%3DR.%26aulast%3DSabatino%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DN.%2BN.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DStroncek%26aufirst%3DD.%26aulast%3DTschernia%26aufirst%3DN.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26aulast%3DWayne%26aufirst%3DA.%2BS.%26aulast%3DMackall%26aufirst%3DC.%2BL.%26atitle%3DT%2520Cells%2520Expressing%2520CD19%2520Chimeric%2520Antigen%2520Receptors%2520for%2520Acute%2520Lymphoblastic%2520Leukaemia%2520in%2520Children%2520and%2520Young%2520Adults%253A%2520A%2520Phase%25201%2520Dose-Escalation%2520Trial%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D517%26epage%3D528%26doi%3D10.1016%2FS0140-6736%2814%2961403-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albelda, S. M.</span></span> <span> </span><span class="NLM_article-title">CAR T Cell Therapy for Solid Tumors</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">139</span>â <span class="NLM_lpage">152</span>, <span class="refDoi">Â DOI: 10.1146/annurev-med-062315-120245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1146%2Fannurev-med-062315-120245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=27860544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvV2hsrbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2017&pages=139-152&author=K.+Newickauthor=S.+O%E2%80%99Brienauthor=E.+Moonauthor=S.+M.+Albelda&title=CAR+T+Cell+Therapy+for+Solid+Tumors&doi=10.1146%2Fannurev-med-062315-120245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">CAR T Cell Therapy for Solid Tumors</span></div><div class="casAuthors">Newick, Kheng; O'Brien, Shaun; Moon, Edmund; Albelda, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">139-152</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The field of cancer immunotherapy has been re-energized by the application of chimeric antigen receptor (CAR) T cell therapy in cancers.  These CAR T cells are engineered to express synthetic receptors that redirect polyclonal T cells to surface antigens for subsequent tumor elimination.  Many CARs are designed with elements that augment T cell persistence and activity.  To date, CAR T cells have demonstrated tremendous success in eradicating hematol. malignancies (e.g., CD19 CARs in leukemias).  However, this success has yet to be extrapolated to solid tumors, and the reasons for this are being actively investigated.  We characterize some of the challenges that CAR T cells have to surmount in the solid tumor microenvironment and new approaches that are being considered to overcome these hurdles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN74osDaZwLbVg90H21EOLACvtfcHk0lj6Y0waxRi2sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvV2hsrbO&md5=9c9442940e68a19f9430e4366c1a3cd0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-062315-120245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-062315-120245%26sid%3Dliteratum%253Aachs%26aulast%3DNewick%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DMoon%26aufirst%3DE.%26aulast%3DAlbelda%26aufirst%3DS.%2BM.%26atitle%3DCAR%2520T%2520Cell%2520Therapy%2520for%2520Solid%2520Tumors%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2017%26volume%3D68%26spage%3D139%26epage%3D152%26doi%3D10.1146%2Fannurev-med-062315-120245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinay, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2466</span>â <span class="NLM_lpage">2476</span>, <span class="refDoi">Â DOI: 10.1016/j.ymthe.2017.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.ymthe.2017.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=28784559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOjurbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2466-2476&author=X.+Hanauthor=G.+E.+Cinayauthor=Y.+Zhaoauthor=Y.+Guoauthor=X.+Zhangauthor=P.+Wang&title=Adnectin-Based+Design+of+Chimeric+Antigen+Receptor+for+T+Cell+Engineering&doi=10.1016%2Fj.ymthe.2017.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering</span></div><div class="casAuthors">Han, Xiaolu; Cinay, Gunce E.; Zhao, Yifan; Guo, Yunfei; Zhang, Xiaoyang; Wang, Pin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2466-2476</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although chimeric antigen receptor (CAR)-engineered T cell therapy has achieved encouraging clin. trial results for treating hematol. cancers, further optimization can likely expand this therapeutic success to more patients and other cancer types.  Most CAR constructs used in clin. trials incorporate single chain variable fragment (scFv) as the extracellular antigen recognition domain.  The immunogenicity of nonhuman scFv could cause host rejection against CAR T cells and compromise their persistence and efficacy.  The limited availability of scFvs and slow discovery of new monoclonal antibodies also limit the development of novel CAR constructs.  Adnectin, a class of affinity mols. derived from the tenth type III domain of human fibronectin, can be an alternative to scFv as an antigen-binding moiety in the design of CAR mols.  We constructed adnectin-based CARs targeting epithelial growth factor receptor (EGFR) and found that compared to scFv-based CAR, T cells engineered with adnectin-based CARs exhibited equiv. cell-killing activity against target H292 lung cancer cells in vitro and had comparable antitumor efficacy in xenograft tumor-bearing mice in vivo.  In addn., with optimal affinity tuning, adnectin-based CAR showed higher selectivity on target cells with high EGFR expression than on those with low expression.  This new design of adnectin CARs can potentially facilitate the development of T cell immunotherapy for cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJmB-M3xf8prVg90H21EOLACvtfcHk0lg5ouQYvu97BQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOjurbM&md5=33deaae40e0551a759107d8bd104edb7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2017.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2017.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DCinay%26aufirst%3DG.%2BE.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DAdnectin-Based%2520Design%2520of%2520Chimeric%2520Antigen%2520Receptor%2520for%2520T%2520Cell%2520Engineering%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D2466%26epage%3D2476%26doi%3D10.1016%2Fj.ymthe.2017.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirabayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span> <span> </span><span class="NLM_article-title">Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">773</span>â <span class="NLM_lpage">783</span>, <span class="refDoi">Â DOI: 10.1158/2326-6066.CIR-18-0636</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1158%2F2326-6066.CIR-18-0636" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=30842091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyjur3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=773-783&author=S.+Ahnauthor=J.+Liauthor=C.+Sunauthor=K.+Gaoauthor=K.+Hirabayashiauthor=H.+Liauthor=B.+Savoldoauthor=R.+Liuauthor=G.+Dotti&title=Cancer+Immunotherapy+with+T+Cells+Carrying+Bispecific+Receptors+That+Mimic+Antibodies&doi=10.1158%2F2326-6066.CIR-18-0636"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy with T cells carrying bispecific receptors that mimic antibodies</span></div><div class="casAuthors">Ahn, Sarah; Li, Jingjing; Sun, Chuang; Gao, Keliang; Hirabayashi, Koichi; Li, Hongxia; Savoldo, Barbara; Liu, Rihe; Dotti, Gianpietro</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">773-783</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumors are inherently heterogeneous in antigen expression, and escape from immune surveillance due to antigen loss remains one of the limitations of targeted immunotherapy.  Despite the clin. use of adoptive therapy with chimeric antigen receptor (CAR)-redirected T cells in lymphoblastic leukemia, treatment failure due to epitope loss occurs.  Targeting multiple tumor-assocd. antigens (TAAs) may thus improve the outcome of CAR-T cell therapies.  CARs developed to simultaneously target multiple targets are limited by the large size of each single-chain variable fragment and compromised protein folding when several single chains are linearly assembled.  Here, we describe single-domain antibody mimics that function within CAR parameters but form a very compact structure.  We show that antibody mimics targeting EGFR and HER2 of the ErbB receptor tyrosine kinase family can be assembled into receptor mols., which we call antibody mimic receptors (amR).  These amR can redirect T cells to recognize two different epitopes of the same antigen or two different TAAs in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_2xgL-jMMGbVg90H21EOLACvtfcHk0lg5ouQYvu97BQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyjur3P&md5=34466ee0f4919448e1401d1c9561f49c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-18-0636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-18-0636%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DK.%26aulast%3DHirabayashi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DDotti%26aufirst%3DG.%26atitle%3DCancer%2520Immunotherapy%2520with%2520T%2520Cells%2520Carrying%2520Bispecific%2520Receptors%2520That%2520Mimic%2520Antibodies%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2019%26volume%3D7%26spage%3D773%26epage%3D783%26doi%3D10.1158%2F2326-6066.CIR-18-0636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells</span>. <i>Hum. Gene Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">726</span>â <span class="NLM_lpage">736</span>, <span class="refDoi">Â DOI: 10.1089/hum.2017.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1089%2Fhum.2017.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=28796529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVSlsrzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=726-736&author=E.+Sieglerauthor=S.+Liauthor=Y.+J.+Kimauthor=P.+Wang&title=Designed+Ankyrin+Repeat+Proteins+as+Her2+Targeting+Domains+in+Chimeric+Antigen+Receptor-Engineered+T+Cells&doi=10.1089%2Fhum.2017.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells</span></div><div class="casAuthors">Siegler, Elizabeth; Li, Si; Kim, Yu Jeong; Wang, Pin</div><div class="citationInfo"><span class="NLM_cas:title">Human Gene Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">726-736</span>CODEN:
                <span class="NLM_cas:coden">HGTHE3</span>;
        ISSN:<span class="NLM_cas:issn">1043-0342</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR) engineering is a branch of cancer immunotherapy that equips immune cells to target tumor antigens expressed on the cell surface using antibody-derived single-chain variable fragments (scFvs).  However, other antibody mimetics, such as designed ankyrin repeat proteins (DARPins), can also serve as antigen-binding domains in CARs.  This study shows that CAR-engineered T (CAR-T) cells utilizing Her2-targeting DARPins G3 and 929 can target human epidermal growth factor receptor 2 (Her2)-overexpressing cancer cells as effectively as CAR-T cells with the scFv 4D5 in vitro, and G3 CAR-T cells can slow or eliminate tumor growth in vivo as effectively as 4D5 CAR-T cells.  Some DARPins may offer an attractive alternative to scFv usage in CARs, as they are smaller, thermodynamically stable, poorly immunogenic, and can be generated with different binding properties from DARPin libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqledSUXJ6NQrVg90H21EOLACvtfcHk0lg5ouQYvu97BQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVSlsrzP&md5=9bbfb1bb6852f16bb3c0732dbc598754</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1089%2Fhum.2017.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fhum.2017.021%26sid%3Dliteratum%253Aachs%26aulast%3DSiegler%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DDesigned%2520Ankyrin%2520Repeat%2520Proteins%2520as%2520Her2%2520Targeting%2520Domains%2520in%2520Chimeric%2520Antigen%2520Receptor-Engineered%2520T%2520Cells%26jtitle%3DHum.%2520Gene%2520Ther.%26date%3D2017%26volume%3D28%26spage%3D726%26epage%3D736%26doi%3D10.1089%2Fhum.2017.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulemzin, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorchakov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikaev, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsova, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkova, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matvienko, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaritskey, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taranin, A. V.</span></span> <span> </span><span class="NLM_article-title">VEGFR2-Specific FnCAR Effectively Redirects the Cytotoxic Activity of T Cells and YT NK Cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">9021</span>â <span class="NLM_lpage">9029</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.24078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.18632%2Foncotarget.24078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=29507671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC1MrnvFyrtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=9021-9029&author=S.+V.+Kulemzinauthor=A.+A.+Gorchakovauthor=A.+N.+Chikaevauthor=V.+V.+Kuznetsovaauthor=O.+Y.+Volkovaauthor=D.+A.+Matvienkoauthor=A.+V.+Petukhovauthor=A.+Y.+Zaritskeyauthor=A.+V.+Taranin&title=VEGFR2-Specific+FnCAR+Effectively+Redirects+the+Cytotoxic+Activity+of+T+Cells+and+YT+NK+Cells&doi=10.18632%2Foncotarget.24078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells</span></div><div class="casAuthors">Kulemzin Sergey V; Gorchakov Andrey A; Chikaev Anton N; Kuznetsova Valeriya V; Volkova Olga Y; Matvienko Daria A; Taranin Alexandr V; Gorchakov Andrey A; Matvienko Daria A; Taranin Alexandr V; Petukhov Alexey V; Zaritskey Andrey Y</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">9021-9029</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">T and NK cells armed with chimeric antigen receptors (CAR) are promising tools for the specific elimination of cancer cells.  In most CAR designs implemented to date, the recognition of target cells is mediated by single-chain variable fragments (scFvs) derived from murine monoclonal antibodies.  This format, however, has a number of limitations, including its relatively large size and potential immunogenicity in humans.  In this study, we explored the feasibility of using human fibronectin type III domains (Fn3) as the antigen recognition domain in CARs.  Human Fn3 domains have lower predicted immunogenicity compared to mouse-derived sequences, and a reduced molecular weight compared to scFvs.  We created a functional CAR using a VEGFR2-specific Fn3 module replacing the conventional scFv.  The resulting FnCAR specifically potentiates the cytotoxic activity of human T cells and YT NK cells in the presence of VEGFR2-positive targets.  These findings demonstrate that Fn3 domains can be used in CARs for antigen recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVdg7un3fKXuLt9HypzAgQfW6udTcc2eaqVL9XLgNrl7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrnvFyrtw%253D%253D&md5=4b2b56bfe75e197ff24f243c8f9dfeb3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.24078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.24078%26sid%3Dliteratum%253Aachs%26aulast%3DKulemzin%26aufirst%3DS.%2BV.%26aulast%3DGorchakov%26aufirst%3DA.%2BA.%26aulast%3DChikaev%26aufirst%3DA.%2BN.%26aulast%3DKuznetsova%26aufirst%3DV.%2BV.%26aulast%3DVolkova%26aufirst%3DO.%2BY.%26aulast%3DMatvienko%26aufirst%3DD.%2BA.%26aulast%3DPetukhov%26aufirst%3DA.%2BV.%26aulast%3DZaritskey%26aufirst%3DA.%2BY.%26aulast%3DTaranin%26aufirst%3DA.%2BV.%26atitle%3DVEGFR2-Specific%2520FnCAR%2520Effectively%2520Redirects%2520the%2520Cytotoxic%2520Activity%2520of%2520T%2520Cells%2520and%2520YT%2520NK%2520Cells%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D9021%26epage%3D9029%26doi%3D10.18632%2Foncotarget.24078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">KÃ¶nning, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolmar, H.</span></span> <span> </span><span class="NLM_article-title">Beyond Antibody Engineering: Directed Evolution of Alternative Binding Scaffolds and Enzymes Using Yeast Surface Display</span>. <i>Microb. Cell Fact.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>, <span class="NLM_elocation-id">32</span> <span class="refDoi">Â DOI: 10.1186/s12934-018-0881-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1186%2Fs12934-018-0881-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=29482656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC1MrlsFeisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&author=D.+K%C3%B6nningauthor=H.+Kolmar&title=Beyond+Antibody+Engineering%3A+Directed+Evolution+of+Alternative+Binding+Scaffolds+and+Enzymes+Using+Yeast+Surface+Display&doi=10.1186%2Fs12934-018-0881-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond antibody engineering: directed evolution of alternative binding scaffolds and enzymes using yeast surface display</span></div><div class="casAuthors">Konning Doreen; Konning Doreen; Kolmar Harald</div><div class="citationInfo"><span class="NLM_cas:title">Microbial cell factories</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pioneered exactly 20 years ago, yeast surface display (YSD) continues to take a major role in protein engineering among the high-throughput display methodologies that have been developed to date.  The classical yeast display technology relies on tethering an engineered protein to the cell wall by genetic fusion to one subunit of a dimeric yeast-mating agglutination receptor complex.  This method enables an efficient genotype-phenotype linkage while exploiting the benefits of a eukaryotic expression machinery.  Over the past two decades, a plethora of protein engineering efforts encompassing conventional antibody Fab and scFv fragments have been reported.  In this review, we will focus on the versatility of YSD beyond conventional antibody engineering and, instead, place the focus on alternative scaffold proteins and enzymes which have successfully been tailored for purpose with regard to improving binding, activity or specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHGxSU2OPDkpggzHGM8X5CfW6udTcc2eaqVL9XLgNrl7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrlsFeisg%253D%253D&md5=9d04ab71c72dfa37f831d4cb098e0f4d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1186%2Fs12934-018-0881-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12934-018-0881-3%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6nning%26aufirst%3DD.%26aulast%3DKolmar%26aufirst%3DH.%26atitle%3DBeyond%2520Antibody%2520Engineering%253A%2520Directed%2520Evolution%2520of%2520Alternative%2520Binding%2520Scaffolds%2520and%2520Enzymes%2520Using%2520Yeast%2520Surface%2520Display%26jtitle%3DMicrob.%2520Cell%2520Fact.%26date%3D2018%26volume%3D17%26doi%3D10.1186%2Fs12934-018-0881-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerra, A.</span></span> <span> </span><span class="NLM_article-title">Engineering of Binding Functions into Proteins</span>. <i>Curr. Opin. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">230</span>â <span class="NLM_lpage">241</span>, <span class="refDoi">Â DOI: 10.1016/j.copbio.2019.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.copbio.2019.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=31207556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2iur7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=230-241&author=M.+Gebauerauthor=A.+Skerra&title=Engineering+of+Binding+Functions+into+Proteins&doi=10.1016%2Fj.copbio.2019.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering of binding functions into proteins</span></div><div class="casAuthors">Gebauer, Michaela; Skerra, Arne</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Biotechnology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">230-241</span>CODEN:
                <span class="NLM_cas:coden">CUOBE3</span>;
        ISSN:<span class="NLM_cas:issn">0958-1669</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Initially emerging as a highly innovative concept in the late 1990s, the concept of creating novel binding reagents based on stable protein scaffolds from outside the Ig (Ig) superfamily has become a well-developed area of research and discovery today.  Numerous scaffolds based on extracellular, membrane-bound or intracellular proteins (or their domains) have been recruited, yielding versatile research reagents and even biol. drug candidates to serve as a viable alternative to antibodies.  This minireview discusses both established and novel concepts in this field and summarizes the current state of clin. development of the more advanced protein scaffolds, in particular Affibody, Adnectin, Anticalin and DARPin drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZlymyT0zZYLVg90H21EOLACvtfcHk0lggifoe81mR4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2iur7O&md5=a9a0022281cee8e1336aca51dfc37b28</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.copbio.2019.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.copbio.2019.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DGebauer%26aufirst%3DM.%26aulast%3DSkerra%26aufirst%3DA.%26atitle%3DEngineering%2520of%2520Binding%2520Functions%2520into%2520Proteins%26jtitle%3DCurr.%2520Opin.%2520Biotechnol.%26date%3D2019%26volume%3D60%26spage%3D230%26epage%3D241%26doi%3D10.1016%2Fj.copbio.2019.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edqvist, P.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GrÃ¤slund, T.</span></span> <span> </span><span class="NLM_article-title">Affibody-Derived Drug Conjugates: Potent Cytotoxic Molecules for Treatment of HER2 over-Expressing Tumors</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">84</span>â <span class="NLM_lpage">95</span>, <span class="refDoi">Â DOI: 10.1016/j.jconrel.2018.08.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.jconrel.2018.08.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=30172673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1yltbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2018&pages=84-95&author=M.+Altaiauthor=H.+Liuauthor=H.+Dingauthor=B.+Mitranauthor=P.-H.+Edqvistauthor=V.+Tolmachevauthor=A.+Orlovaauthor=T.+Gr%C3%A4slund&title=Affibody-Derived+Drug+Conjugates%3A+Potent+Cytotoxic+Molecules+for+Treatment+of+HER2+over-Expressing+Tumors&doi=10.1016%2Fj.jconrel.2018.08.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors</span></div><div class="casAuthors">Altai, Mohamed; Liu, Hao; Ding, Haozhong; Mitran, Bogdan; Edqvist, Per-Henrik; Tolmachev, Vladimir; Orlova, Anna; Graeslund, Torbjoern</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-95</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Patients with HER2-pos. tumors often suffer resistance to therapy, warranting development of novel treatment modalities.  Affibody mols. are small affinity proteins which can be engineered to bind to desired targets.  They have in recent years been found to allow precise targeting of cancer specific mol. signatures such as the HER2 receptor.  In this study, we have investigated the potential of an affibody mol. targeting HER2, ZHER2:2891, conjugated with the cytotoxic maytansine derivate MC-DM1, for targeted cancer therapy.  ZHER2:2891 was expressed as a monomer (ZHER2:2891), dimer ((ZHER2:2891)2) and dimer with an albumin binding domain (ABD) for half-life extension ((ZHER2:2891)2-ABD).  All proteins had a unique C-terminal cysteine that could be used for efficient and site-specific conjugation with MC-DM1.  The resulting affibody drug conjugates were potent cytotoxic mols. for human cells over-expressing HER2, with sub-nanomolar IC50-values similar to trastuzumab emtansine, and did not affect cells with low HER2 expression.  A biodistribution study of a radiolabeled version of (ZHER2:2891)2-ABD-MC-DM1, showed that it was taken up by the tumor.  The major site of off-target uptake was the kidneys and to some extent the liver.  (ZHER2:2891)2-ABD-MC-DM1 was found to have a half-life in circulation of 14 h.  The compd. was tolerated well by mice at 8.5 mg/kg and was shown to extend survival of mice bearing HER2 over-expressing tumors.  The findings in this study show that affibody mols. are a promising class of engineered affinity proteins to specifically deliver small mol. drugs to cancer cells and that such conjugates are potential candidates for clin. evaluation on HER2-overexpressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEU1sTv0hKsLVg90H21EOLACvtfcHk0lhULZ73v0tHQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1yltbjL&md5=bc237905f974dad24fa52a9eed301867</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2018.08.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2018.08.040%26sid%3Dliteratum%253Aachs%26aulast%3DAltai%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DMitran%26aufirst%3DB.%26aulast%3DEdqvist%26aufirst%3DP.-H.%26aulast%3DTolmachev%26aufirst%3DV.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DGr%25C3%25A4slund%26aufirst%3DT.%26atitle%3DAffibody-Derived%2520Drug%2520Conjugates%253A%2520Potent%2520Cytotoxic%2520Molecules%2520for%2520Treatment%2520of%2520HER2%2520over-Expressing%2520Tumors%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2018%26volume%3D288%26spage%3D84%26epage%3D95%26doi%3D10.1016%2Fj.jconrel.2018.08.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zorba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoemberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, D.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of a Human Protein Kinase with Monobodies</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">13937</span>â <span class="NLM_lpage">13942</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1906024116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1073%2Fpnas.1906024116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=31239342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlChu7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=13937-13942&author=A.+Zorbaauthor=V.+Nguyenauthor=A.+Koideauthor=M.+Hoembergerauthor=Y.+Zhengauthor=S.+Kutterauthor=C.+Kimauthor=S.+Koideauthor=D.+Kern&title=Allosteric+Modulation+of+a+Human+Protein+Kinase+with+Monobodies&doi=10.1073%2Fpnas.1906024116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of a human protein kinase with monobodies</span></div><div class="casAuthors">Zorba, Adelajda; Nguyen, Vy; Koide, Akiko; Hoemberger, Marc; Zheng, Yuejiao; Kutter, Steffen; Kim, Chansik; Koide, Shohei; Kern, Dorothee</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">13937-13942</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Despite being the subject of intense effort and scrutiny, kinases have proven to be consistently challenging targets in inhibitor drug design.  A key obstacle has been promiscuity and consequent adverse effects of drugs targeting the ATP binding site.  Here we introduce an approach to controlling kinase activity by using monobodies that bind to the highly specific regulatory allosteric pocket of the oncoprotein Aurora A (AurA) kinase, thereby offering the potential for more specific kinase modulators.  Strikingly, we identify a series of highly specific monobodies acting either as strong kinase inhibitors or activators via differential recognition of structural motifs in the allosteric pocket.  X-ray crystal structures comparing AurA bound to activating vs inhibiting monobodies reveal the atomistic mechanism underlying allosteric modulation.  The results reveal 3 major advantages of targeting allosteric vs. orthosteric sites: extreme selectivity, ability to inhibit as well as activate, and avoidance of competing with ATP that is present at high concns. in the cells.  We envision that exploiting allosteric networks for inhibition or activation will provide a general, powerful pathway toward rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotf-JJNIChYrVg90H21EOLACvtfcHk0lhULZ73v0tHQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlChu7jF&md5=79aae9cbc4c3785ff611525b45753ad7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1906024116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1906024116%26sid%3Dliteratum%253Aachs%26aulast%3DZorba%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DV.%26aulast%3DKoide%26aufirst%3DA.%26aulast%3DHoemberger%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DKutter%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DKoide%26aufirst%3DS.%26aulast%3DKern%26aufirst%3DD.%26atitle%3DAllosteric%2520Modulation%2520of%2520a%2520Human%2520Protein%2520Kinase%2520with%2520Monobodies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D13937%26epage%3D13942%26doi%3D10.1073%2Fpnas.1906024116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Binz, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶ttler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigrist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekawardhani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolado, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saliba, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpp, M. T.</span></span> <span> </span><span class="NLM_article-title">Design and Characterization of MP0250, a Tri-Specific Anti-HGF/Anti-VEGF DARPin Drug Candidate</span>. <i>MAbs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1262</span>â <span class="NLM_lpage">1269</span>, <span class="refDoi">Â DOI: 10.1080/19420862.2017.1305529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1080%2F19420862.2017.1305529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=29035637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslCmtb7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1262-1269&author=H.+K.+Binzauthor=T.+R.+Bakkerauthor=D.+J.+Phillipsauthor=A.+Corneliusauthor=C.+Zittauthor=T.+G%C3%B6ttlerauthor=G.+Sigristauthor=U.+Fiedlerauthor=S.+Ekawardhaniauthor=I.+Doladoauthor=J.+A.+Salibaauthor=G.+Treschauthor=K.+Probaauthor=M.+T.+Stumpp&title=Design+and+Characterization+of+MP0250%2C+a+Tri-Specific+Anti-HGF%2FAnti-VEGF+DARPin+Drug+Candidate&doi=10.1080%2F19420862.2017.1305529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin drug candidate</span></div><div class="casAuthors">Binz, H. Kaspar; Bakker, Talitha R.; Phillips, Douglas J.; Cornelius, Andreas; Zitt, Christof; Gottler, Thomas; Sigrist, Gabriel; Fiedler, Ulrike; Ekawardhani, Savira; Dolado, Ignacio; Saliba, Johan Abram; Tresch, Gaby; Proba, Karl; Stumpp, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1262-1269</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">MP0250 is a multi-domain drug candidate currently being tested in clin. trials for the treatment of cancer.  It comprises one anti-vascular endothelial growth factor-A (VEGF-A), one anti-hepatocyte growth factor (HGF), and two anti-human serum albumin (HSA) DARPin domains within a single polypeptide chain.  While there is first clin. validation of a single-domain DARPin drug candidate, little is known about DARPin drug candidates comprising multiple domains.  Here, we show that MP0250 can be expressed at 15 g/L in sol. form in E. coli high cell-d. fermn., it is stable in sol./frozen formulation for 2 years as assessed by reverse phase HPLC, it has picomolar potency in inhibiting VEGF-A and HGF in ELISA and cellular assays, and its domains are simultaneously active as shown by surface plasmon resonance.  The inclusion of HSA-binding DARPin domains leads to a favorable pharmacokinetic profile in mouse and cynomolgus monkey, with terminal half-lives of â¼ 30 h in mouse and â¼ 5 days in cynomolgus monkey.  MP0250 is thus a highly potent drug candidate that could be particularly useful in oncol.  Beyond MP0250, the properties of MP0250 indicate that multi-domain DARPin proteins can be valuable next-generation drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6KlL9EtBwKrVg90H21EOLACvtfcHk0lir6T7H2lB2MQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslCmtb7J&md5=62acbc24b39b26234aad5d2fb83c58e9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1080%2F19420862.2017.1305529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2017.1305529%26sid%3Dliteratum%253Aachs%26aulast%3DBinz%26aufirst%3DH.%2BK.%26aulast%3DBakker%26aufirst%3DT.%2BR.%26aulast%3DPhillips%26aufirst%3DD.%2BJ.%26aulast%3DCornelius%26aufirst%3DA.%26aulast%3DZitt%26aufirst%3DC.%26aulast%3DG%25C3%25B6ttler%26aufirst%3DT.%26aulast%3DSigrist%26aufirst%3DG.%26aulast%3DFiedler%26aufirst%3DU.%26aulast%3DEkawardhani%26aufirst%3DS.%26aulast%3DDolado%26aufirst%3DI.%26aulast%3DSaliba%26aufirst%3DJ.%2BA.%26aulast%3DTresch%26aufirst%3DG.%26aulast%3DProba%26aufirst%3DK.%26aulast%3DStumpp%26aufirst%3DM.%2BT.%26atitle%3DDesign%2520and%2520Characterization%2520of%2520MP0250%252C%2520a%2520Tri-Specific%2520Anti-HGF%252FAnti-VEGF%2520DARPin%2520Drug%2520Candidate%26jtitle%3DMAbs%26date%3D2017%26volume%3D9%26spage%3D1262%26epage%3D1269%26doi%3D10.1080%2F19420862.2017.1305529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, R. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinka-Doms, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudkin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, K. T.</span></span> <span> </span><span class="NLM_article-title">Engineering a Targeted Delivery Platform Using Centyrins</span>. <i>Protein Eng., Des. Sel.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">563</span>â <span class="NLM_lpage">572</span>, <span class="refDoi">Â DOI: 10.1093/protein/gzw054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1093%2Fprotein%2Fgzw054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=27737926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlWltro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=563-572&author=S.+D.+Goldbergauthor=R.+M.+F.+Cardosoauthor=T.+Linauthor=T.+Spinka-Domsauthor=D.+Kleinauthor=S.+A.+Jacobsauthor=V.+Dudkinauthor=G.+Gillilandauthor=K.+T.+O%E2%80%99Neil&title=Engineering+a+Targeted+Delivery+Platform+Using+Centyrins&doi=10.1093%2Fprotein%2Fgzw054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering a targeted delivery platform using Centyrins</span></div><div class="casAuthors">Goldberg, Shalom D.; Cardoso, Rosa M. F.; Lin, Tricia; Spinka-Doms, Tracy; Klein, Donna; Jacobs, Steven A.; Dudkin, Vadim; Gilliland, Gary; O'Neil, Karyn T.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Engineering, Design & Selection</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">563-572</span>CODEN:
                <span class="NLM_cas:coden">PEDSBR</span>;
        ISSN:<span class="NLM_cas:issn">1741-0126</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Targeted delivery of therapeutic payloads to specific tissues and cell types is an important component of modern pharmaceutical development.  Antibodies or other scaffold proteins can provide the cellular address for delivering a covalently linked therapeutic via specific binding to cell-surface receptors.  Optimization of the conjugation site on the targeting protein, linker chem. and intracellular trafficking pathways can all influence the efficiency of delivery and potency of the drug candidate.  In this study, we describe a comprehensive engineering expt. for an EGFR binding Centyrin, a highly stable fibronectin type III (FN3) domain, wherein all possible single-cysteine replacements were evaluated for expression, purifn., conjugation efficiency, retention of target binding, biophys. properties and delivery of a cytotoxic small mol. payload.  Overall, 26 of the 94 positions were identified as ideal for cysteine modification, conjugation and drug delivery.  Conjugation-tolerant positions were mapped onto a crystal structure of the Centyrin, providing a structural context for interpretation of the mutagenesis expt. and providing a foundation for a Centyrin-targeted delivery platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_9DH_s_sUabVg90H21EOLACvtfcHk0lir6T7H2lB2MQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlWltro%253D&md5=552b7c2e553c457c3a804110d7662e72</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2Fgzw054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252Fgzw054%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DS.%2BD.%26aulast%3DCardoso%26aufirst%3DR.%2BM.%2BF.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DSpinka-Doms%26aufirst%3DT.%26aulast%3DKlein%26aufirst%3DD.%26aulast%3DJacobs%26aufirst%3DS.%2BA.%26aulast%3DDudkin%26aufirst%3DV.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DK.%2BT.%26atitle%3DEngineering%2520a%2520Targeted%2520Delivery%2520Platform%2520Using%2520Centyrins%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D2016%26volume%3D29%26spage%3D563%26epage%3D572%26doi%3D10.1093%2Fprotein%2Fgzw054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sokolova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grishina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospelov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guryev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deyev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balalaeva, I.</span></span> <span> </span><span class="NLM_article-title">Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">219</span> <span class="refDoi">Â DOI: 10.3390/pharmaceutics11050219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.3390%2Fpharmaceutics11050219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslamtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=E.+Sokolovaauthor=O.+Kutovaauthor=A.+Grishinaauthor=A.+Pospelovauthor=E.+Guryevauthor=A.+Schulgaauthor=S.+Deyevauthor=I.+Balalaeva&title=Penetration+Efficiency+of+Antitumor+Agents+in+Ovarian+Cancer+Spheroids%3A+The+Case+of+Recombinant+Targeted+Toxin+DARPin-LoPE+and+the+Chemotherapy+Drug%2C+Doxorubicin&doi=10.3390%2Fpharmaceutics11050219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Penetration efficiency of antitumor agents in ovarian cancer spheroids: the case of recombinant targeted toxin DARPin-LoPE and the chemotherapy drug, doxorubicin</span></div><div class="casAuthors">Sokolova, Evgeniya; Kutova, Olga; Grishina, Alena; Pospelov, Anton; Guryev, Evgeniy; Schulga, Alexey; Deyev, Sergey; Balalaeva, Irina</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">219</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The efficiency of delivering a therapeutic agent into a tumor is among the crucial factors detg. the prospects for its clin. use.  This problem is particularly acute in the case of targeted antitumor agents since many of them are high-mol.-wt. compds.  In this work, the penetration of therapeutic agents of two distinct mol. wts. into the spheroids of ovarian adenocarcinoma overexpressing human epidermal growth factor receptor 2 (HER2) was studied.  It was shown that the low-mol.-wt. chemotherapy drug, doxorubicin (â¼0.5 kDa), effectively penetrates through almost the entire depth of a 300 to 400 Î¼m spheroid, while the penetration depth of the HER2-specific recombinant targeted toxin, DARPin-LoPE (â¼42 kDa), is only a few surface layers of cells and does not exceed 70 Î¼m.  The low penetration of the targeted toxin into spheroid was shown along with a significant decrease in its efficiency against the three-dimensional tumor spheroid as compared with the two-dimensional monolayer culture.  The approaches to increasing the accumulation of agents in the tumor are presented and prospects of their use in order to improve the effectiveness of therapy are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXiF4CaJRhLVg90H21EOLACvtfcHk0lir6T7H2lB2MQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslamtb0%253D&md5=34101115c383bc1f47335fc2c9e541b7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics11050219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics11050219%26sid%3Dliteratum%253Aachs%26aulast%3DSokolova%26aufirst%3DE.%26aulast%3DKutova%26aufirst%3DO.%26aulast%3DGrishina%26aufirst%3DA.%26aulast%3DPospelov%26aufirst%3DA.%26aulast%3DGuryev%26aufirst%3DE.%26aulast%3DSchulga%26aufirst%3DA.%26aulast%3DDeyev%26aufirst%3DS.%26aulast%3DBalalaeva%26aufirst%3DI.%26atitle%3DPenetration%2520Efficiency%2520of%2520Antitumor%2520Agents%2520in%2520Ovarian%2520Cancer%2520Spheroids%253A%2520The%2520Case%2520of%2520Recombinant%2520Targeted%2520Toxin%2520DARPin-LoPE%2520and%2520the%2520Chemotherapy%2520Drug%252C%2520Doxorubicin%26jtitle%3DPharmaceutics%26date%3D2019%26volume%3D11%26doi%3D10.3390%2Fpharmaceutics11050219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirie, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittrup, K. D.</span></span> <span> </span><span class="NLM_article-title">Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1774</span>â <span class="NLM_lpage">1782</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-12-1023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1158%2F1535-7163.MCT-12-1023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=23832121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1774-1782&author=C.+M.+Pirieauthor=D.+V.+Liuauthor=K.+D.+Wittrup&title=Targeted+Cytolysins+Synergistically+Potentiate+Cytoplasmic+Delivery+of+Gelonin+Immunotoxin&doi=10.1158%2F1535-7163.MCT-12-1023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin</span></div><div class="casAuthors">Pirie, Christopher M.; Liu, David V.; Wittrup, K. Dane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1774-1782</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted endocytic uptake is a first step toward tissue-specific cytoplasmic macromol. delivery; however, inefficient escape from the endolysosomal compartment makes this generally impractical at present.  We report here a targeted cytolysin approach that dramatically potentiates endosomal release of an independently targeted potent gelonin immunotoxin.  Fibronectin domains engineered for affinity to EGF receptor or carcinoembryonic antigen were fused to the plant toxin gelonin or bacterial pore-forming cytolysins.  These fusion proteins display synergistic activity in both antigen-specific cytotoxicity in vitro, enhancing potency by several orders of magnitude, and in tumor growth inhibition in vivo.  In addn., the no. of internalized gelonin mols. required to induce apoptosis is reduced from approx. 5Ã106 to less than 103.  Targeted potentiation shows promise for enhancing cytoplasmic delivery of other macromol. payloads such as DNA, siRNA, and miRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3N0OkETIhArVg90H21EOLACvtfcHk0li-js_GjDvGOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7F&md5=be44f50fac1e3baebcdec9ee4196e10a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1023%26sid%3Dliteratum%253Aachs%26aulast%3DPirie%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DD.%2BV.%26aulast%3DWittrup%26aufirst%3DK.%2BD.%26atitle%3DTargeted%2520Cytolysins%2520Synergistically%2520Potentiate%2520Cytoplasmic%2520Delivery%2520of%2520Gelonin%2520Immunotoxin%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1774%26epage%3D1782%26doi%3D10.1158%2F1535-7163.MCT-12-1023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koide, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, S.</span></span> <span> </span><span class="NLM_article-title">The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">1141</span>â <span class="NLM_lpage">1151</span>, <span class="refDoi">Â DOI: 10.1006/jmbi.1998.2238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1006%2Fjmbi.1998.2238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=9837732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADyaK1MXivFCgtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1998&pages=1141-1151&author=A.+Koideauthor=C.+W.+Baileyauthor=X.+Huangauthor=S.+Koide&title=The+Fibronectin+Type+III+Domain+as+a+Scaffold+for+Novel+Binding+Proteins&doi=10.1006%2Fjmbi.1998.2238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The fibronectin type III domain as a scaffold for novel binding proteins</span></div><div class="casAuthors">Koide, Akiko; Bailey, Charles W.; Huang, Xiaolin; Koide, Shohei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1141-1151</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The fibronectin type III domain (FN3) is a small autonomous folding unit which occurs in many animal proteins involving in ligand binding.  The Î²-sandwich structure of FN3 closely resembles that of Ig domains.  We have prepd. a phage display library of FN3 in which residues in two surface loops were randomized.  We have selected mutant FN3s which bind to a test ligand, ubiquitin, with significant affinities, while the wild-type FN3 shows no measurable affinity.  A dominant clone was expressed as a sol. protein and its properties were investigated in detail.  Heteronuclear NMR characterization revealed that the selected mutant protein retains the global fold of FN3.  It also has a modest conformational stability despite mutations at 12 out of 94 residues.  These results clearly show the potential of FN3 as a scaffold for engineering novel binding proteins.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCs6_Saq9nbrVg90H21EOLACvtfcHk0li-js_GjDvGOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFCgtA%253D%253D&md5=f99791d8351f59411b29eec0c675e420</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1998.2238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1998.2238%26sid%3Dliteratum%253Aachs%26aulast%3DKoide%26aufirst%3DA.%26aulast%3DBailey%26aufirst%3DC.%2BW.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DKoide%26aufirst%3DS.%26atitle%3DThe%2520Fibronectin%2520Type%2520III%2520Domain%2520as%2520a%2520Scaffold%2520for%2520Novel%2520Binding%2520Proteins%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1998%26volume%3D284%26spage%3D1141%26epage%3D1151%26doi%3D10.1006%2Fjmbi.1998.2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futter, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eden, E. R.</span></span> <span> </span><span class="NLM_article-title">EGF Receptor Trafficking: Consequences for Signaling and Cancer</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">26</span>â <span class="NLM_lpage">34</span>, <span class="refDoi">Â DOI: 10.1016/j.tcb.2013.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.tcb.2013.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=24295852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2gt7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=26-34&author=A.+Tomasauthor=C.+E.+Futterauthor=E.+R.+Eden&title=EGF+Receptor+Trafficking%3A+Consequences+for+Signaling+and+Cancer&doi=10.1016%2Fj.tcb.2013.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor trafficking: consequences for signaling and cancer</span></div><div class="casAuthors">Tomas, Alejandra; Futter, Clare E.; Eden, Emily R.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-34</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The ligand-stimulated epidermal growth factor receptor (EGFR) has been extensively studied in the anal. of mol. mechanisms regulating endocytic traffic and the role of that traffic in signal transduction.  Although such studies have largely focused on mitogenic signaling and dysregulated traffic in tumorigenesis, there is growing interest in the potential role of EGFR traffic in cell survival and the consequent response to cancer therapy.  Here we review recent advances in our understanding of mol. mechanisms regulating ligand-stimulated EGFR activation, internalization, and post-endocytic sorting.  The role of EGFR overexpression/mutation and new modulators of EGFR traffic in cancer and the response to cancer therapeutics are also discussed.  Finally, we speculate on the relationship between EGFR traffic and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDLWxypVYs-bVg90H21EOLACvtfcHk0li-js_GjDvGOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2gt7zP&md5=850921a0c652f9401704f4152db482a5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2013.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2013.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DTomas%26aufirst%3DA.%26aulast%3DFutter%26aufirst%3DC.%2BE.%26aulast%3DEden%26aufirst%3DE.%2BR.%26atitle%3DEGF%2520Receptor%2520Trafficking%253A%2520Consequences%2520for%2520Signaling%2520and%2520Cancer%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2014%26volume%3D24%26spage%3D26%26epage%3D34%26doi%3D10.1016%2Fj.tcb.2013.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span> <span> </span><span class="NLM_article-title">Epidermal Growth Factor Receptor (EGFR): A Rising Star in the Era of Precision Medicine of Lung Cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">50209</span>â <span class="NLM_lpage">50220</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.16854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.18632%2Foncotarget.16854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=28430586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC1cvpvFaksw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=50209-50220&author=X.+Liuauthor=P.+Wangauthor=C.+Zhangauthor=Z.+Ma&title=Epidermal+Growth+Factor+Receptor+%28EGFR%29%3A+A+Rising+Star+in+the+Era+of+Precision+Medicine+of+Lung+Cancer&doi=10.18632%2Foncotarget.16854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer</span></div><div class="casAuthors">Liu Xiaomin; Wang Ping; Zhang Caiyan; Ma Zhongliang</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">50209-50220</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer is a leading cause of cancer mortality worldwide.  In tumors, the important role of noncoding RNA regulatory networks has been more and more reveal.  EGFR has been identified as an oncogenic driver of NSCLC, especially activating mutations EGFR and its inhibition with specific TKIs can generate dramatic tumor responses.  Studies have shown that EGFR plays significant roles in the progression of NSCLC.  Subset analysis of the small proportion of patients with EGFR-mutant lung cancer showed a disease-free survival benefit, but was underpowered to detect a survival advantage.  Herein, we highlight the progression of EGFR, noncoding RNA, and their roles in carcinogenesis.  We also focus on anti-lung cancer drug development and EGFR-related drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpqnqiBQBfJ6x48Rj5GnGofW6udTcc2ebPYjK-CIwBnbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvpvFaksw%253D%253D&md5=f42e000960487683e50bcd3ad83e3fa9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.16854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.16854%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DEpidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%253A%2520A%2520Rising%2520Star%2520in%2520the%2520Era%2520of%2520Precision%2520Medicine%2520of%2520Lung%2520Cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D50209%26epage%3D50220%26doi%3D10.18632%2Foncotarget.16854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emanuel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engle, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamniuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokemeijer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabrizio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das Gupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosselin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cataldo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryseck, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camphausen, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cload, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furfine, E. S.</span></span> <span> </span><span class="NLM_article-title">A Fibronectin Scaffold Approach to Bispecific Inhibitors of Epidermal Growth Factor Receptor and Insulin-like Growth Factor-I Receptor</span>. <i>MAbs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">38</span>â <span class="NLM_lpage">48</span>, <span class="refDoi">Â DOI: 10.4161/mabs.3.1.14168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.4161%2Fmabs.3.1.14168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=21099371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC3M7kt1arug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=38-48&author=S.+L.+Emanuelauthor=L.+J.+Engleauthor=G.+Chaoauthor=R.-R.+Zhuauthor=C.+Caoauthor=Z.+Linauthor=A.+Yamniukauthor=J.+Hosbachauthor=J.+Brownauthor=E.+Fitzpatrickauthor=J.+Gokemeijerauthor=P.+Morinauthor=B.+Morseauthor=I.+M.+Carvajalauthor=D.+Fabrizioauthor=M.+C.+Wrightauthor=R.+Das+Guptaauthor=M.+Gosselinauthor=D.+Cataldoauthor=R.+P.+Ryseckauthor=M.+L.+Doyleauthor=T.+W.+Wongauthor=R.+T.+Camphausenauthor=S.+T.+Cloadauthor=H.+N.+Marshauthor=M.+M.+Gottardisauthor=E.+S.+Furfine&title=A+Fibronectin+Scaffold+Approach+to+Bispecific+Inhibitors+of+Epidermal+Growth+Factor+Receptor+and+Insulin-like+Growth+Factor-I+Receptor&doi=10.4161%2Fmabs.3.1.14168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor</span></div><div class="casAuthors">Emanuel Stuart L; Engle Linda J; Chao Ginger; Zhu Rong-Rong; Cao Carolyn; Lin Zheng; Yamniuk Aaron P; Hosbach Jennifer; Brown Jennifer; Fitzpatrick Elizabeth; Gokemeijer Jochem; Morin Paul; Morse Brent A; Carvajal Irvith M; Fabrizio David; Wright Martin C; Das Gupta Ruchira; Gosselin Michael; Cataldo Daniel; Ryseck Rolf P; Doyle Michael L; Wong Tai W; Camphausen Raymond T; Cload Sharon T; Marsh H Nicholas; Gottardis Marco M; Furfine Eric S</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-48</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Engineered domains of human fibronectin (AdnectinsÂ®) were used to generate a bispecific Adnectin targeting epidermal growth factor receptor (EGFR) and insulin-like growth factor-I receptor (IGF-IR), two transmembrane receptors that mediate proliferative and survival cell signaling in cancer.  Single-domain Adnectins that specifically bind EGFR or IGF-IR were generated using mRNA display with a library containing as many as 10 ( 13) Adnectin variants. mRNA display was also used to optimize lead Adnectin affinities, resulting in clones that inhibited EGFR phosphorylation at 7 to 38 nM compared to 2.6 Î¼M for the parental clone.  Individual, optimized, Adnectins specific for blocking either EGFR or IGF-IR signaling were engineered into a single protein (EI-Tandem Adnectin).  The EI-Tandems inhibited phosphorylation of EGFR and IGF-IR, induced receptor degradation, and inhibited down-stream cell signaling and proliferation of human cancer cell lines (A431, H292, BxPC3 and RH41) with IC 50 values ranging from 0.1 to 113 nM.  Although Adnectins bound to EGFR at a site distinct from those of anti-EGFR antibodies cetuximab, panitumumab and nimotuzumab, like the antibodies, the anti-EGFR Adnectins blocked the binding of EGF to EGFR.  PEGylated EI-Tandem inhibited the growth of both EGFR and IGF-IR driven human tumor xenografts, induced degradation of EGFR, and reduced EGFR phosphorylation in tumors.  These results demonstrate efficient engineering of bispecific Adnectins with high potency and desired specificity.  The bispecificity may improve biological activity compared to monospecific biologics as tumor growth is driven by multiple growth factors.  Our results illustrate a technological advancement for constructing multi-specific biologics in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSFPXML4fLJC6Ufuk_1xoTfW6udTcc2ebPYjK-CIwBnbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7kt1arug%253D%253D&md5=22b23833330685a20588a745d2d9c706</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.4161%2Fmabs.3.1.14168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fmabs.3.1.14168%26sid%3Dliteratum%253Aachs%26aulast%3DEmanuel%26aufirst%3DS.%2BL.%26aulast%3DEngle%26aufirst%3DL.%2BJ.%26aulast%3DChao%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DR.-R.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DYamniuk%26aufirst%3DA.%26aulast%3DHosbach%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DFitzpatrick%26aufirst%3DE.%26aulast%3DGokemeijer%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DP.%26aulast%3DMorse%26aufirst%3DB.%26aulast%3DCarvajal%26aufirst%3DI.%2BM.%26aulast%3DFabrizio%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DM.%2BC.%26aulast%3DDas%2BGupta%26aufirst%3DR.%26aulast%3DGosselin%26aufirst%3DM.%26aulast%3DCataldo%26aufirst%3DD.%26aulast%3DRyseck%26aufirst%3DR.%2BP.%26aulast%3DDoyle%26aufirst%3DM.%2BL.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DCamphausen%26aufirst%3DR.%2BT.%26aulast%3DCload%26aufirst%3DS.%2BT.%26aulast%3DMarsh%26aufirst%3DH.%2BN.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DFurfine%26aufirst%3DE.%2BS.%26atitle%3DA%2520Fibronectin%2520Scaffold%2520Approach%2520to%2520Bispecific%2520Inhibitors%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520and%2520Insulin-like%2520Growth%2520Factor-I%2520Receptor%26jtitle%3DMAbs%26date%3D2011%26volume%3D3%26spage%3D38%26epage%3D48%26doi%3D10.4161%2Fmabs.3.1.14168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallera, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Prosthetic Antigen Receptors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">10108</span>â <span class="NLM_lpage">10111</span>, <span class="refDoi">Â DOI: 10.1021/jacs.5b06166</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b06166" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KmsrfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=10108-10111&author=J.+Shenauthor=D.+A.+Valleraauthor=C.+R.+Wagner&title=Prosthetic+Antigen+Receptors&doi=10.1021%2Fjacs.5b06166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Prosthetic antigen receptors</span></div><div class="casAuthors">Shen, Jingjing; Vallera, Daniel A.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">10108-10111</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chimeric antigen receptors (CARs) have shown great promise for the immunol. treatment of cancer.  Nevertheless, the need to genetically engineer a patient's T-cells has presented significant prodn. and safety challenges.  To address these issues, we have demonstrated that chem. self-assembled nanorings (CSANs) displaying single chain antibodies can bind to both the CD3 Îµ subunit of the T-cell-receptor/CD3 complex and the CD22 antigen on malignant B cells such as B-leukemias or lymphomas.  We demonstrate that the multivalent and bispecific format allows the antiCD3/antiCD22 CSANs to stably bind to T-cell surfaces for greater than 4 days, while being easily disassembled on the cell membrane by treatment with the nontoxic FDA approved drug, trimethoprim.  In the presence of CD22+ Raji cells, T-cells modified with antiCD3/antiCD22 CSANs were shown to selectively up-regulate the prodn. of interleukin-2 (IL-2) and interferon-Î³ (IFN-Î³) and to initiate cytotoxicity.  Taken together, our results demonstrate that antiCD3/antiCD22 bispecific CSANs offer a potential alternative to CARs, as prosthetic antigen receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLvNnipy3cRrVg90H21EOLACvtfcHk0lirNhE6wFzWyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KmsrfI&md5=8a336e42080592d53b3045acfaeb9fc5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b06166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b06166%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DVallera%26aufirst%3DD.%2BA.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DProsthetic%2520Antigen%2520Receptors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D10108%26epage%3D10111%26doi%3D10.1021%2Fjacs.5b06166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarikaya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallera, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">17247</span>â <span class="NLM_lpage">17257</span>, <span class="refDoi">Â DOI: 10.1021/ja107153a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja107153a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWrtbzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=17247-17257&author=Q.+Liauthor=C.+R.+Soauthor=A.+Feganauthor=V.+Codyauthor=M.+Sarikayaauthor=D.+A.+Valleraauthor=C.+R.+Wagner&title=Chemically+Self-Assembled+Antibody+Nanorings+%28CSANs%29%3A+Design+and+Characterization+of+an+Anti-CD3+IgM+Biomimetic&doi=10.1021%2Fja107153a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic</span></div><div class="casAuthors">Li, Qing; So, Christopher R.; Fegan, Adrian; Cody, Vivian; Sarikaya, Mehmet; Vallera, Daniel A.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">17247-17257</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A no. of clever recombinant methodologies have been developed that recapitulate the valencies of IgG's (bivalent) and IgA's (tetravalent).  Although higher synthetic valencies have been achieved by conjugation of either monoclonal antibodies or single-chain antibodies to nanoparticles and liposomes, a method for the prepn. of recombinant antibodies with valencies similar to IgM's (decavalent) but considerably less than what is generally found after antibody particle conjugation has yet to be devised.  Recently, we have developed a methodol. for the design of bivalent Chem. Self-Assembled Antibody Nanorings (CSANs).  We now report the crystal structure of the nanoring subunit composed of the E. coli DHFR dimer and a methotrexate dimerizer (MTX2-C9) contg. a visible nine methylene linker and a protocol for the prepn. of CSANs from this subunit with valencies similar to IgM's, ranging from 8-10 single chain antibodies (scFvs).  The multivalent CSANs were reversibly assembled from a fusion protein dihydrofolate reductase (DHFR)-DHFR-antiCD3 scFv contg. a single glycine linker between the two DHFR scaffolding proteins.  We also demonstrate that, similar to the parental bivalent anti-CD3 monoclonal antibody (mAB), anti-CD3 CSANs selectively bind to CD3+ leukemia cells and undergo rapid internalization through a caveolin-independent pathway that requires cholesterol, actin polymn., and protein tyrosine kinase activation.  While treatment with the monoclonal antibody leads to T-cell activation and nearly complete loss (i.e., 90%) of the surface displayed T-cell receptor (TCR), only 25-30% of the TCR down regulate and no significant T-cell proliferation is obsd. after treatment of peripheral blood mononuclear cells (PBMCs) with anti-CD3 CSANs.  Consistent with the proliferation findings, 15-25% less CD25 (IL-2 receptor) was found on the surface of PBMCs treated with either the polyvalent or bivalent anti-CD3 CSANs, resp., than on PBMCs treated with the parental mAB.  Comparative expts. with F(ab')2 derived from the mAB confirm that the activation of the T-cells by the mAB is dependent on the Fc domain, and thus interactions of the PBMC T-cells with accessory cells, such as macrophages.  Taken together, these results demonstrate that anti-CD3 CSANs with valencies ranging from 2 to 8 could be employed for radionuclide, drug, or potentially oligonucleotide delivery to T-cells without, as has been obsd. for other antibody conjugated nanoparticles, the deleterious effects of activation obsd. for mAB.  Further the CSAN construct may be adapted for the prepn. of other multivalent scFvs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ATWinihbCrVg90H21EOLACvtfcHk0lirNhE6wFzWyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWrtbzO&md5=f48d7dae3bf8c7b40ffadadafba1de1e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fja107153a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja107153a%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DSo%26aufirst%3DC.%2BR.%26aulast%3DFegan%26aufirst%3DA.%26aulast%3DCody%26aufirst%3DV.%26aulast%3DSarikaya%26aufirst%3DM.%26aulast%3DVallera%26aufirst%3DD.%2BA.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DChemically%2520Self-Assembled%2520Antibody%2520Nanorings%2520%2528CSANs%2529%253A%2520Design%2520and%2520Characterization%2520of%2520an%2520Anti-CD3%2520IgM%2520Biomimetic%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D17247%26epage%3D17257%26doi%3D10.1021%2Fja107153a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Csizmar, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersburg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozumalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackel, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">251</span>â <span class="NLM_lpage">261</span>, <span class="refDoi">Â DOI: 10.1021/jacs.8b09198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b09198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSgsL7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=251-261&author=C.+M.+Csizmarauthor=J.+R.+Petersburgauthor=T.+J.+Perryauthor=L.+Rozumalskiauthor=B.+J.+Hackelauthor=C.+R.+Wagner&title=Multivalent+Ligand+Binding+to+Cell+Membrane+Antigens%3A+Defining+the+Interplay+of+Affinity%2C+Valency%2C+and+Expression+Density&doi=10.1021%2Fjacs.8b09198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density</span></div><div class="casAuthors">Csizmar, Clifford M.; Petersburg, Jacob R.; Perry, Thomas J.; Rozumalski, Lakmal; Hackel, Benjamin J.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-261</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nature uses multi-valency to govern many biol. processes.  The development of macromol. and cellular therapies has largely been dependent on engineering similar polyvalent interactions to enable effective targeting.  Such therapeutics typically utilize high-affinity binding domains that have the propensity to recognize both antigen-overexpressing tumors and normal-expressing tissues, leading to "on-target, off-tumor" toxicities.  One strategy to improve these agents' selectivity is to reduce the binding affinity, such that biol. relevant interactions between the therapeutic and target cell will only exist under conditions of high avidity.  Preclin. studies have validated this principle of avidity optimization in the context of chimeric antigen receptor (CAR) T cells; however, a rigorous anal. of this approach in the context of sol. multi-valent targeting scaffolds has yet to be undertaken.  Using a modular protein nanoring capable of displaying â¤8 fibronectin domains with engineered specificity for a model antigen, epithelial cell adhesion mol. (EpCAM), this study demonstrates that binding affinity and ligand valency can be optimized to afford discrimination between EpCAMHigh (2.8-3.8 Ã 106 antigens/cell) and EpCAMLow (5.2 Ã 104 to 2.2 Ã 105 antigens/cell) tissues both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs_HpPRNfnD7Vg90H21EOLACvtfcHk0lhl6ifYD2MqVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSgsL7N&md5=e568fa64b58f3264445fb73c53f3689a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b09198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b09198%26sid%3Dliteratum%253Aachs%26aulast%3DCsizmar%26aufirst%3DC.%2BM.%26aulast%3DPetersburg%26aufirst%3DJ.%2BR.%26aulast%3DPerry%26aufirst%3DT.%2BJ.%26aulast%3DRozumalski%26aufirst%3DL.%26aulast%3DHackel%26aufirst%3DB.%2BJ.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DMultivalent%2520Ligand%2520Binding%2520to%2520Cell%2520Membrane%2520Antigens%253A%2520Defining%2520the%2520Interplay%2520of%2520Affinity%252C%2520Valency%252C%2520and%2520Expression%2520Density%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D251%26epage%3D261%26doi%3D10.1021%2Fjacs.8b09198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petersburg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csizmar, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fife, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Eradication of Established Tumors by Chemically Self-Assembled Nanoring (CSAN) Labelled T Cells</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">6563</span>â <span class="NLM_lpage">6576</span>, <span class="refDoi">Â DOI: 10.1021/acsnano.8b01308</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.8b01308" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVWntL%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=6563-6576&author=J.+Petersburgauthor=J.+Shenauthor=C.+M.+Csizmarauthor=K.+A.+Murphyauthor=J.+Spanierauthor=K.+Gabrielseauthor=T.+S.+Griffithauthor=B.+Fifeauthor=C.+R.+Wagner&title=Eradication+of+Established+Tumors+by+Chemically+Self-Assembled+Nanoring+%28CSAN%29+Labelled+T+Cells&doi=10.1021%2Facsnano.8b01308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells</span></div><div class="casAuthors">Petersburg, Jacob R.; Shen, Jingjing; Csizmar, Clifford M.; Murphy, Katherine A.; Spanier, Justin; Gabrielse, Kari; Griffith, Thomas S.; Fife, Brian; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">6563-6576</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our lab. has developed chem. self-assembled nanorings (CSANs) as prosthetic antigen receptors (PARs) for the non-genetic modification of T-cell surfaces.  PARs have been successfully employed in vitro to activate T cells for the selective killing of leukemia cells.  However, PAR efficacy has yet to be evaluated in vivo or against solid tumors.  Therefore, we developed bispecific PARs that selectively target the human CD3 receptor and human Epithelial Cell Adhesion Mol. (EpCAM), which is overexpressed on multiple carcinomas and cancer stem cells.  The Î±EpCAM/Î±CD3 PARs were found to stably bind T cells for >4 days, and treating EpCAM+ MCF-7 breast cancer cells with Î±EpCAM/Î±CD3 PAR-functionalized T cells resulted in the induction of IL-2, IFN-Î³ and MCF-7 cytotoxicity.  Furthermore, an orthotopic breast cancer model validated the ability of Î±EpCAM/Î±CD3 PAR therapy to direct T cell lytic activity towards EpCAM+ breast cancer cells in vivo leading to tumor eradication.  In vivo biodistribution studies demonstrated that PAR-T cells were formed in vivo and persist for over 48 h.  In addn., PARs were shown to rapidly and specifically accumulate in tumor tissue.  Following PAR treatment, the prodn. of IL-2, IFN-Î³, IL-6 and TNF-Î± could be significantly reduced by an infusion of clin.-relevant concns. of the FDA-approved antibiotic, trimethoprim, signaling pharmacol. PAR deactivation.  Importantly, CSANs did not induce naive T cell activation and thus exhibit a limited potential to induce naive T cell anergy.  In addn., murine immunogenicity studies demonstrated that CSANs do not induce a significant antibody response, nor do they activate splenic cells.  Collectively, our results demonstrate that bispecific CSANs are able to non-genetically generate reversibly modified T cells that are capable of eradicating targeted solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplfpTkekefBbVg90H21EOLACvtfcHk0lhl6ifYD2MqVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVWntL%252FK&md5=b95edef95aeccd9c2f75141905aee7ff</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsnano.8b01308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.8b01308%26sid%3Dliteratum%253Aachs%26aulast%3DPetersburg%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DCsizmar%26aufirst%3DC.%2BM.%26aulast%3DMurphy%26aufirst%3DK.%2BA.%26aulast%3DSpanier%26aufirst%3DJ.%26aulast%3DGabrielse%26aufirst%3DK.%26aulast%3DGriffith%26aufirst%3DT.%2BS.%26aulast%3DFife%26aufirst%3DB.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DEradication%2520of%2520Established%2520Tumors%2520by%2520Chemically%2520Self-Assembled%2520Nanoring%2520%2528CSAN%2529%2520Labelled%2520T%2520Cells%26jtitle%3DACS%2520Nano%26date%3D2018%26volume%3D12%26spage%3D6563%26epage%3D6576%26doi%3D10.1021%2Facsnano.8b01308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Reversible Re-Programing of Cell-Cell Interactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5112</span>â <span class="NLM_lpage">5116</span>, <span class="refDoi">Â DOI: 10.1002/anie.201310645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1002%2Fanie.201310645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFyhsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=5112-5116&author=K.+Gabrielseauthor=A.+Gangarauthor=N.+Kumarauthor=J.+C.+Leeauthor=A.+Feganauthor=J.+J.+Shenauthor=Q.+Liauthor=D.+Valleraauthor=C.+R.+Wagner&title=Reversible+Re-Programing+of+Cell-Cell+Interactions&doi=10.1002%2Fanie.201310645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible Re-programing of Cell-Cell Interactions</span></div><div class="casAuthors">Gabrielse, Kari; Gangar, Amit; Kumar, Nigam; Lee, Jae Chul; Fegan, Adrian; Shen, Jing Jing; Li, Qing; Vallera, Daniel; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5112-5116</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ability to engineer and re-program the surfaces of cells would provide an enabling synthetic biol. method for the design of cell- and tissue-based therapies.  A new cell surface-engineering strategy is described that uses lipid-chem. self-assembled nanorings (lipid-CSANs) that can be used for the stable and reversible modification of any cell surface with a mol. reporter or targeting ligand.  In the presence of a non-toxic FDA-approved drug, the nanorings were quickly disassembled and the cell-cell interactions reversed.  Similar to T-cells genetically engineered to express chimeric antigen receptors (CARS), when activated peripheral blood mononuclear cells (PBMCs) were functionalized with the anti-EpCAM-lipid-CSANs, they were shown to selectively kill antigen-pos. cancer cells.  Taken together, these results demonstrate that lipid-CSANs have the potential to be a rapid, stable, and general method for the reversible engineering of cell surfaces and cell-cell interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3XK8P4-__17Vg90H21EOLACvtfcHk0lgqQvr4r_xusA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFyhsrs%253D&md5=4f25f5ef5ec39078fb19289ad475421a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.201310645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201310645%26sid%3Dliteratum%253Aachs%26aulast%3DGabrielse%26aufirst%3DK.%26aulast%3DGangar%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DFegan%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DJ.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DVallera%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DReversible%2520Re-Programing%2520of%2520Cell-Cell%2520Interactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D5112%26epage%3D5116%26doi%3D10.1002%2Fanie.201310645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LipovÅ¡ek, D.</span></span> <span> </span><span class="NLM_article-title">Adnectins: Engineered Target-Binding Protein Therapeutics</span>. <i>Protein Eng., Des. Sel.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">9</span>, <span class="refDoi">Â DOI: 10.1093/protein/gzq097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1093%2Fprotein%2Fgzq097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=21068165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FjtlyqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=3-9&author=D.+Lipov%C5%A1ek&title=Adnectins%3A+Engineered+Target-Binding+Protein+Therapeutics&doi=10.1093%2Fprotein%2Fgzq097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Adnectins: engineered target-binding protein therapeutics</span></div><div class="casAuthors">Lipovsek D</div><div class="citationInfo"><span class="NLM_cas:title">Protein engineering, design & selection : PEDS</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">3-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AdnectinsÂ® are a new family of therapeutic proteins based on the 10th fibronectin type III domain, and designed to bind with high affinity and specificity to therapeutically relevant targets.  Adnectins share with antibody variable domains a beta-sheet sandwich fold with diversified loops, but differ from antibodies in primary sequence and have a simpler, single-domain structure without disulfide bonds.  As a consequence, Adnectins bind targets with affinity and specificity as high as those of antibodies, but are easier to manipulate genetically and compatible with bacterial expression systems.  Adnectins that bind macromolecular targets with nanomolar and picomolar affinity have been selected using in vitro evolution methods, including mRNA display, phage display and yeast display.  CT-322, a PEGylated, anti-angiogenic Adnectin that binds vascular endothelial growth factor (VEGF) receptor 2 and blocks its interaction with VEGF A, C and D, is being evaluated in Phase II clinical trials for efficacy in several oncology indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJCiDBpjep9QxyojvcjibhfW6udTcc2eYI6akNArMpw7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FjtlyqsQ%253D%253D&md5=52669f5feb2b96fa457c701f813f21c2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2Fgzq097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252Fgzq097%26sid%3Dliteratum%253Aachs%26aulast%3DLipov%25C5%25A1ek%26aufirst%3DD.%26atitle%3DAdnectins%253A%2520Engineered%2520Target-Binding%2520Protein%2520Therapeutics%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D2011%26volume%3D24%26spage%3D3%26epage%3D9%26doi%3D10.1093%2Fprotein%2Fgzq097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersburg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangar, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumarapperuma, S. C.</span></span> <span> </span><span class="NLM_article-title">In Vivo Evaluation of Site-Specifically PEGylated Chemically Self-Assembled Protein Nanostructures</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2193</span>â <span class="NLM_lpage">2203</span>, <span class="refDoi">Â DOI: 10.1021/acs.molpharmaceut.6b00110</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00110" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlWqtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=2193-2203&author=R.+Shahauthor=J.+Petersburgauthor=A.+C.+Gangarauthor=A.+Feganauthor=C.+R.+Wagnerauthor=S.+C.+Kumarapperuma&title=In+Vivo+Evaluation+of+Site-Specifically+PEGylated+Chemically+Self-Assembled+Protein+Nanostructures&doi=10.1021%2Facs.molpharmaceut.6b00110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Evaluation of Site-Specifically PEGylated Chemically Self-Assembled Protein Nanostructures</span></div><div class="casAuthors">Shah, Rachit; Petersburg, Jacob; Gangar, Amit C.; Fegan, Adrian; Wagner, Carston R.; Kumarapperuma, Sidath C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2193-2203</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. self-assembled nanorings (CSANs) are made of dihydrofolate reductase (DHFR) fusion proteins and have been successfully used in vitro for cellular cargo delivery and cell surface engineering applications.  However, CSANs have yet to be evaluated for their in vivo stability, circulation, and tissue distribution.  In an effort to evaluate CSANs in vivo, we engineered a site-specifically PEGylated epidermal growth factor receptor (EGFR) targeting DHFR mols., characterized their self-assembly into CSANs with bivalent methotrexates (bis-MTX), visualized their in vivo tissue localization by microPET/CT imaging, and detd. their ex vivo organ biodistribution by tissue-based gamma counting.  A dimeric DHFR (DHFR2) mol. fused with a C-terminal EGFR targeting peptide (LARLLT) was engineered to incorporate a site-specific ketone functionality using unnatural amino acid mutagenesis.  Aminooxy-PEG, of differing chain lengths, was successfully conjugated to the protein using oxime chem.  These proteins were self-assembled into CSANs with bis-MTX DHFR dimerizers and characterized by size exclusion chromatog. and dynamic light scattering.  In vitro binding studies were performed with fluorescent CSANs assembled using bis-MTX-FITC, while in vivo microPET/CT imaging was performed with radiolabeled CSANs assembled using bis-MTX-DOTA[64Cu].  PEGylation reduced the uptake of anti-EGFR CSANs by mouse macrophages (RAW 264.7) up to 40% without altering the CSAN's binding affinity toward U-87 MG glioblastoma cells in vitro.  A significant time dependent tumor accumulation of 64Cu labeled anti-EGFR-CSANs was obsd. by microPET/CT imaging and biodistribution studies in mice bearing U-87 MG xenografts.  PEGylated CSANs demonstrated a reduced uptake by the liver, kidneys, and spleen resulting in high contrast tumor imaging within an hour of i.v. injection (9.6% ID/g), and continued to increase up to 24 h (11.7% ID/g) while the background signal diminished.  CSANs displayed an in vivo profile between those of rapidly clearing small mols. and slow clearing antibodies.  Thus, CSANs offer a modular, programmable, and stable protein based platform that can be used for in vivo drug delivery and imaging applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIrnDsag7iX7Vg90H21EOLACvtfcHk0lgqQvr4r_xusA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlWqtrY%253D&md5=f1476344340b5c10592561a7bdf92a3a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00110%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DR.%26aulast%3DPetersburg%26aufirst%3DJ.%26aulast%3DGangar%26aufirst%3DA.%2BC.%26aulast%3DFegan%26aufirst%3DA.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26aulast%3DKumarapperuma%26aufirst%3DS.%2BC.%26atitle%3DIn%2520Vivo%2520Evaluation%2520of%2520Site-Specifically%2520PEGylated%2520Chemically%2520Self-Assembled%2520Protein%2520Nanostructures%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D2193%26epage%3D2203%26doi%3D10.1021%2Facs.molpharmaceut.6b00110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerrab, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamdad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penault-Llorca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubel, C.</span></span> <span> </span><span class="NLM_article-title">Anti-EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors as Combination Therapy for Triple-Negative Breast Cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">73618</span>â <span class="NLM_lpage">73637</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.12037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.18632%2Foncotarget.12037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=27655662" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=73618-73637&author=A.+E.+Guerrabauthor=M.+Bamdadauthor=F.+Kwiatkowskiauthor=Y.-J.+Bignonauthor=F.+Penault-Llorcaauthor=C.+Aubel&title=Anti-EGFR+Monoclonal+Antibodies+and+EGFR+Tyrosine+Kinase+Inhibitors+as+Combination+Therapy+for+Triple-Negative+Breast+Cancer&doi=10.18632%2Foncotarget.12037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12037%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrab%26aufirst%3DA.%2BE.%26aulast%3DBamdad%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DF.%26aulast%3DBignon%26aufirst%3DY.-J.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DAubel%26aufirst%3DC.%26atitle%3DAnti-EGFR%2520Monoclonal%2520Antibodies%2520and%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%2520as%2520Combination%2520Therapy%2520for%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D73618%26epage%3D73637%26doi%3D10.18632%2Foncotarget.12037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, P.</span></span> <span> </span><span class="NLM_article-title">Distribution and Function of EGFR in Human Tissue and the Effect of EGFR Tyrosine Kinase Inhibition</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3639</span>â <span class="NLM_lpage">3650</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=14666659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFWn" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=3639-3650&author=S.+Yanoauthor=K.+Kondoauthor=M.+Yamaguchiauthor=G.+Richmondauthor=M.+Hutchisonauthor=A.+Wakelingauthor=S.+Averbuchauthor=P.+Wadsworth&title=Distribution+and+Function+of+EGFR+in+Human+Tissue+and+the+Effect+of+EGFR+Tyrosine+Kinase+Inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition</span></div><div class="casAuthors">Yano, Seiichi; Kondo, Kaoru; Yamaguchi, Motonori; Richmond, Graham; Hutchison, Michael; Wakeling, Alan; Averbuch, Steven; Wadsworth, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5A</span>),
    <span class="NLM_cas:pages">3639-3650</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  From immunohistochem. and ligand-binding studies, it is known that the epidermal growth factor receptor (EGFR), a member of the erbB family of receptors, is expressed in tissues of epithelial, mesenchymal and neuronal origin and plays a major role in normal cellular processes such as proliferation, differentiation and development.  EGFR is highly expressed in a no. of solid tumors and its expression correlates with tumor progression, resistance to chemotherapy and a poor prognosis; it is consequently an attractive target for the rational design of novel anticancer agents.  Knowledge of the role of EGFR in normal tissues will help the understanding of the adverse events assocd. with such agents.  Studies in knockout mice and preclin. toxicol. studies have shown that the major effects of inhibiting the EGFR are skin and, gastrointestinal toxicities.  Clin. studies with inhibitors of EGFR, such as gefitinib, cetuximab and erlotinib, have shown a favorable adverse-event profile, primarily consisting of skin and gastrointestinal toxicities, as predicted from the mechanism-based effects obsd. in preclin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Lrciisy4g7Vg90H21EOLACvtfcHk0ljRqAzBox03Og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFWn&md5=70a289e6c8c5492e9c3537d77880af8d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYano%26aufirst%3DS.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DHutchison%26aufirst%3DM.%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DAverbuch%26aufirst%3DS.%26aulast%3DWadsworth%26aufirst%3DP.%26atitle%3DDistribution%2520and%2520Function%2520of%2520EGFR%2520in%2520Human%2520Tissue%2520and%2520the%2520Effect%2520of%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibition%26jtitle%3DAnticancer%2520Res.%26date%3D2003%26volume%3D23%26spage%3D3639%26epage%3D3650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, H.-J.</span></span> <span> </span><span class="NLM_article-title">Anti-EGFR Mechanism of Action: Antitumor Effect and Underlying Cause of Adverse Events</span>. <i>Oncology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5</span>â <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=16736978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BD28zhs1agtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=5-13&author=H.-J.+Lenz&title=Anti-EGFR+Mechanism+of+Action%3A+Antitumor+Effect+and+Underlying+Cause+of+Adverse+Events"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events</span></div><div class="casAuthors">Lenz Heinz-Josef</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5 Suppl 2</span>),
    <span class="NLM_cas:pages">5-13</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">Overexpression of the epidermal growth factor receptor (EGFR) is correlated with poor prognosis in many human cancers.  Two main classes of anticancer agents affect the EGFR: those targeting the extracellular ligand-binding domain and those that block the intracellular tyrosine kinase (TK) domain.  Cetuximab (Erbitux) is a mouse/human chimeric monoclonal antibody that targets the ligand-binding domain of the EGFR, whereas erlotinib (Tarceva) and gefitinib (Iressa) are small-molecule TK inhibitors.  Common toxicities of agents targeting the EGFR differ from those associated with traditional chemotherapy.  Given the common pathway through which these agents work, some adverse events are similar.  Many patients treated with these agents develop an acne-like rash on the face and upper body, most likely related to keratinocyte alterations and hair follicle proliferation and maturation.  Although clinical manifestation of this reaction closely resembles acne vulgaris, the histology is more similar to infectious folliculitis.  Other adverse events appear to be related to a drug class or individual agent.  For example, interstitial lung disease is a rare but potentially fatal reaction that has been reported with gefitinib.  Hypomagnesemia reported in association with cetuximab may be related to EGFR blockade in the kidney.  Anaphylactic or anaphylactoid infusion reactions are also seen with cetuximab, as with other monoclonal antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKebKMi1UHmcjl5L8hwNX0fW6udTcc2eZK3JkXBEUnAbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zhs1agtA%253D%253D&md5=60e15f1bd8f6f670cc6cf928530c8719</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DH.-J.%26atitle%3DAnti-EGFR%2520Mechanism%2520of%2520Action%253A%2520Antitumor%2520Effect%2520and%2520Underlying%2520Cause%2520of%2520Adverse%2520Events%26jtitle%3DOncology%26date%3D2006%26volume%3D20%26spage%3D5%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matzka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">StÃ¶hr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colditz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KÃ¶ck-HÃ³di, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, H.</span></span> <span> </span><span class="NLM_article-title">Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy</span>. <i>Pflege</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">17</span>, <span class="refDoi">Â DOI: 10.1024/1012-5302/a000521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1024%2F1012-5302%2Fa000521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=27901405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhvVCmug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=9-17&author=M.+Matzkaauthor=D.+St%C3%B6hrauthor=A.+Colditzauthor=S.+K%C3%B6ck-H%C3%B3diauthor=M.+Kollerauthor=H.+Mayer&title=Skin+toxicities+and+unmet+supportive+care+needs+of+patients+with+cancer+undergoing+EGFR-inhibitor+therapy&doi=10.1024%2F1012-5302%2Fa000521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy</span></div><div class="casAuthors">Matzka Martin; Stohr Doreen; Colditz Alexandra; Kock-Hodi Sabine; Koller Martina; Mayer Hanna</div><div class="citationInfo"><span class="NLM_cas:title">Pflege</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-17</span>
        ISSN:<span class="NLM_cas:issn">1012-5302</span>.
    </div><div class="casAbstract">Background: Targeted therapies, such as the EGFR (epidermal growth factor receptor) inhibitor therapy, are being used to treat patients with various solid and metastatic tumours.  Skin toxicities are a common side effect of this therapy.  Aim: The aim of this study was to assess the effects of skin toxicities on quality of life of patients with cancer undergoing EGFR inhibitor therapy, as well as their unmet supportive care needs.  Method: Embedded design.  A standardised quantitative survey was administered and analysed.  In addition, memos and audiotaped material of insightful conversations with the patients after survey administration were included in the analyses.  Results: Among the three domains of the effects of skin toxicities on quality of life, physical symptoms (e. g. itching skin, rash) were most frequently reported to impair quality of life, while associated emotional and functional impairments were less frequently reported.  Patients don't consider the management of skin toxicities to be a priority during their treatment, skin toxicities are rather perceived in context of the total symptom burden.  Yet, we observed significant correlations between the assessed quality of life and unmet supportive care need domains, especially concerning physical and psychological needs.  Conclusions: Although no clinically significant impairment of quality of life of patients undergoing EGFR inhibitor therapy was found, skin changes should be addressed in supportive interventions embedded in routine symptom management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvNHKFbAPwvYYPsCkJIw00fW6udTcc2ebPJhkoqk0zzLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhvVCmug%253D%253D&md5=17f2d84649902fe5fbfb5318dc747e44</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1024%2F1012-5302%2Fa000521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1024%252F1012-5302%252Fa000521%26sid%3Dliteratum%253Aachs%26aulast%3DMatzka%26aufirst%3DM.%26aulast%3DSt%25C3%25B6hr%26aufirst%3DD.%26aulast%3DColditz%26aufirst%3DA.%26aulast%3DK%25C3%25B6ck-H%25C3%25B3di%26aufirst%3DS.%26aulast%3DKoller%26aufirst%3DM.%26aulast%3DMayer%26aufirst%3DH.%26atitle%3DSkin%2520toxicities%2520and%2520unmet%2520supportive%2520care%2520needs%2520of%2520patients%2520with%2520cancer%2520undergoing%2520EGFR-inhibitor%2520therapy%26jtitle%3DPflege%26date%3D2017%26volume%3D30%26spage%3D9%26epage%3D17%26doi%3D10.1024%2F1012-5302%2Fa000521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Rahman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouad, M.</span></span> <span> </span><span class="NLM_article-title">Correlation of Cetuximab-Induced Skin Rash and Outcomes of Solid Tumor Patients Treated with Cetuximab: A Systematic Review and Meta-Analysis</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">135</span>, <span class="refDoi">Â DOI: 10.1016/j.critrevonc.2014.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.critrevonc.2014.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25139841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FjtlCmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2015&pages=127-135&author=O.+Abdel-Rahmanauthor=M.+Fouad&title=Correlation+of+Cetuximab-Induced+Skin+Rash+and+Outcomes+of+Solid+Tumor+Patients+Treated+with+Cetuximab%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1016%2Fj.critrevonc.2014.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis</span></div><div class="casAuthors">Abdel-Rahman Omar; Fouad Mona</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We performed a systematic review and meta-analysis of the correlation between cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab.  PATIENTS AND METHODS:  Eligible studies included phase I, II and III trials of patients with solid tumors on cetuximab; describing events of skin rash and correlating skin rash with overall survival (OS), progression free survival (PFS) and/or overall response rate (ORR).  RESULTS:  Our search strategy yielded 409 potentially relevant citations on CETUXIMAB from Pubmed/Medline, CENTRAL Cochrane registry and ASCO meeting library.  After exclusion of ineligible studies, a total of 13 clinical trials were considered eligible for the meta-analysis, including 4 phase III trials, 8 phase II trials and one phase I trial.  The occurrence of cetuximab-induced rash in patients was highly associated with improvements in PFS (HR=0.74; 95% CI: 0.63-0.86, P<0.0002), OS (HR=0.60; 95% CI: 0.47-0.76, P<0.0001), and ORR (RR=1.51, 95% CI: 1.26-1.81, P<0.00001), as compared to patients without rash.  Exploratory subgroup analysis showed no effect of tumor types on the RR of ORR.  CONCLUSIONS:  Our meta-analysis has demonstrated that cetuximab-induced rash is associated with a significantly improved OS, PFS and ORR.  Cetuximab-induced skin rash may represent a prognostic factor in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTi1Ilwxe8M8FUIs6wFK5xJfW6udTcc2ebPJhkoqk0zzLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FjtlCmsg%253D%253D&md5=bdfcf90b616d7296430c29b93b8df838</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2014.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2014.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DAbdel-Rahman%26aufirst%3DO.%26aulast%3DFouad%26aufirst%3DM.%26atitle%3DCorrelation%2520of%2520Cetuximab-Induced%2520Skin%2520Rash%2520and%2520Outcomes%2520of%2520Solid%2520Tumor%2520Patients%2520Treated%2520with%2520Cetuximab%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2015%26volume%3D93%26spage%3D127%26epage%3D135%26doi%3D10.1016%2Fj.critrevonc.2014.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flutter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif-Paghaleh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestle, F. O.</span></span> <span> </span><span class="NLM_article-title">Xenogeneic Graft-versus-Host-Disease in NOD-Scid IL-2RÎ³null Mice Display a T-Effector Memory Phenotype</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e44219</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0044219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1371%2Fjournal.pone.0044219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=22937164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yktLrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=N.+Aliauthor=B.+Flutterauthor=R.+S.+Rodriguezauthor=E.+Sharif-Paghalehauthor=L.+D.+Barberauthor=G.+Lombardiauthor=F.+O.+Nestle&title=Xenogeneic+Graft-versus-Host-Disease+in+NOD-Scid+IL-2R%CE%B3null+Mice+Display+a+T-Effector+Memory+Phenotype&doi=10.1371%2Fjournal.pone.0044219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2RÎ³null mice display a T-effector memory phenotype</span></div><div class="casAuthors">Ali, Niwa; Flutter, Barry; Sanchez Rodriguez, Robert; Sharif-Paghaleh, Ehsan; Barber, Linda D.; Lombardi, Giovanna; Nestle, Frank O.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e44219</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The occurrence of Graft-vs.-Host Disease (GvHD) is a prevalent and potentially lethal complication that develops following hematopoietic stem cell transplantation.  Humanized mouse models of xenogeneic-GvHD based upon immunodeficient strains injected with human peripheral blood mononuclear cells (PBMC; "Hu-PBMC mice") are important tools to study human immune function in vivo.  The recent introduction of targeted deletions at the interleukin-2 common gamma chain (IL-2RÎ³null), notably the NOD-scid IL-2RÎ³null (NSG) and BALB/c-Rag2null IL-2RÎ³null (BRG) mice, has led to improved human cell engraftment.  Despite their widespread use, a comprehensive characterization of engraftment and GvHD development in the Hu-PBMC NSG and BRG models has never been performed in parallel.  We compared engrafted human lymphocyte populations in the peripheral blood, spleens, lymph nodes and bone marrow of these mice.  Kinetics of engraftment differed between the two strains, in particular a significantly faster expansion of the human CD45+ compartment and higher engraftment levels of CD3+ T-cells were obsd. in NSG mice, which may explain the faster rate of GvHD development in this model.  The pathogenesis of human GvHD involves anti-host effector cell reactivity and cutaneous tissue infiltration.  Despite this, the presence of T-cell subsets and tissue homing markers has only recently been characterized in the peripheral blood of patients and has never been properly defined in Hu-PBMC models of GvHD.  Engrafted human cells in NSG mice shows a prevalence of tissue homing cells with a T-effector memory (TEM) phenotype and high levels of cutaneous lymphocyte antigen (CLA) expression.  Characterization of Hu-PBMC mice provides a strong preclin. platform for the application of novel immunotherapies targeting TEM-cell driven GvHD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_-rtPxhysvbVg90H21EOLACvtfcHk0lgoHTfIpXZApQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yktLrP&md5=3a35880d28d57a1e964c22bc6427b30d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0044219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0044219%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DN.%26aulast%3DFlutter%26aufirst%3DB.%26aulast%3DRodriguez%26aufirst%3DR.%2BS.%26aulast%3DSharif-Paghaleh%26aufirst%3DE.%26aulast%3DBarber%26aufirst%3DL.%2BD.%26aulast%3DLombardi%26aufirst%3DG.%26aulast%3DNestle%26aufirst%3DF.%2BO.%26atitle%3DXenogeneic%2520Graft-versus-Host-Disease%2520in%2520NOD-Scid%2520IL-2R%25CE%25B3null%2520Mice%2520Display%2520a%2520T-Effector%2520Memory%2520Phenotype%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0044219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. X.</span></span> <span> </span><span class="NLM_article-title">Immune Checkpoint Inhibitors in Clinical Trials</span>. <i>Chin. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">434</span>â <span class="NLM_lpage">444</span>, <span class="refDoi">Â DOI: 10.5732/cjc.014.10122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.5732%2Fcjc.014.10122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25189716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFajtrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=434-444&author=E.+Sharonauthor=H.+Streicherauthor=P.+Goncalvesauthor=H.+X.+Chen&title=Immune+Checkpoint+Inhibitors+in+Clinical+Trials&doi=10.5732%2Fcjc.014.10122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Immune checkpoints in cancer clinical trials</span></div><div class="casAuthors">Sharon, Elad; Streicher, Howard; Goncalves, Priscila; Chen, Helen X.</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">434-444</span>CODEN:
                <span class="NLM_cas:coden">CJCHDJ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sun Yat-sen University Cancer Center</span>)
        </div><div class="casAbstract">A review.  Immunol.-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers.  We have learned over the last decade that powerful immunol. effector cells may be blocked by inhibitory regulatory pathways controlled by specific mols. often called "immune checkpoints".  These checkpoints serve to control or turn off the immune response when it is no longer needed to prevent tissue injury and autoimmunity.  Cancer cells have learned or evolved to use these mechanisms to evade immune control and elimination.  The development of a new therapeutic class of drugs that inhibit these inhibitory pathways has recently emerged as a potent strategy in oncol.  Three sets of agents have emerged in clin. trials exploiting this strategy.  These agents are antibody-based therapies targeting cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1).  These inhibitors of immune inhibition have demonstrated extensive activity as single agents and in combinations.  Clin. responses have been seen in melanoma, renal cell carcinoma, non-small cell lung cancer, and several other tumor types.  Despite the autoimmune or inflammatory immune-mediated adverse effects which have been seen, the responses and overall survival benefits exhibited thus far warrant further clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIaeAqleOVaLVg90H21EOLACvtfcHk0lgoHTfIpXZApQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFajtrjO&md5=3ab93330ccb675f65cea034422fb8f69</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.5732%2Fcjc.014.10122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5732%252Fcjc.014.10122%26sid%3Dliteratum%253Aachs%26aulast%3DSharon%26aufirst%3DE.%26aulast%3DStreicher%26aufirst%3DH.%26aulast%3DGoncalves%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DH.%2BX.%26atitle%3DImmune%2520Checkpoint%2520Inhibitors%2520in%2520Clinical%2520Trials%26jtitle%3DChin.%2520J.%2520Cancer%26date%3D2014%26volume%3D33%26spage%3D434%26epage%3D444%26doi%3D10.5732%2Fcjc.014.10122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.-C.</span></span> <span> </span><span class="NLM_article-title">Glycosylation and Stabilization of Programmed Death Ligand-1 Suppresses T-Cell Activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">12632</span> <span class="refDoi">Â DOI: 10.1038/ncomms12632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1038%2Fncomms12632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=27572267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=C.-W.+Liauthor=S.-O.+Limauthor=W.+Xiaauthor=H.-H.+Leeauthor=L.-C.+Chanauthor=C.-W.+Kuoauthor=K.-H.+Khooauthor=S.-S.+Changauthor=J.-H.+Chaauthor=T.+Kimauthor=J.+L.+Hsuauthor=Y.+Wuauthor=J.-M.+Hsuauthor=H.+Yamaguchiauthor=Q.+Dingauthor=Y.+Wangauthor=J.+Yaoauthor=C.-C.+Leeauthor=H.-J.+Wuauthor=A.+A.+Sahinauthor=J.+P.+Allisonauthor=D.+Yuauthor=G.+N.+Hortobagyiauthor=M.-C.+Hung&title=Glycosylation+and+Stabilization+of+Programmed+Death+Ligand-1+Suppresses+T-Cell+Activity&doi=10.1038%2Fncomms12632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity</span></div><div class="casAuthors">Li, Chia-Wei; Lim, Seung-Oe; Xia, Weiya; Lee, Heng-Huan; Chan, Li-Chuan; Kuo, Chu-Wei; Khoo, Kay-Hooi; Chang, Shih-Shin; Cha, Jong-Ho; Kim, Taewan; Hsu, Jennifer L.; Wu, Yun; Hsu, Jung-Mao; Yamaguchi, Hirohito; Ding, Qingqing; Wang, Yan; Yao, Jun; Lee, Cheng-Chung; Wu, Hsing-Ju; Sahin, Aysegul A.; Allison, James P.; Yu, Dihua; Hortobagyi, Gabriel N.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12632</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) leads to tumor-assocd. immune escape.  Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination and N-glycosylation.  We show that glycogen synthase kinase 3Î² (GSK3Î²) interacts with PD-L1 and induces phosphorylation-dependent proteasome degrdn. of PD-L1 by Î²-TrCP.  In-depth anal. of PD-L1 N192, N200 and N219 glycosylation suggests that glycosylation antagonizes GSK3Î² binding.  In this regard, only non-glycosylated PD-L1 forms a complex with GSK3Î² and Î²-TrCP.  We also demonstrate that epidermal growth factor (EGF) stabilizes PD-L1 via GSK3Î² inactivation in basal-like breast cancer.  Inhibition of EGF signalling by gefitinib destabilizes PD-L1, enhances antitumor T-cell immunity and therapeutic efficacy of PD-1 blockade in syngeneic mouse models.  Together, our results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQnyTgbFXcD7Vg90H21EOLACvtfcHk0lgoHTfIpXZApQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsbnJ&md5=35cab8a1af28193769fe685c0e1f37b7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fncomms12632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12632%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.-W.%26aulast%3DLim%26aufirst%3DS.-O.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DChan%26aufirst%3DL.-C.%26aulast%3DKuo%26aufirst%3DC.-W.%26aulast%3DKhoo%26aufirst%3DK.-H.%26aulast%3DChang%26aufirst%3DS.-S.%26aulast%3DCha%26aufirst%3DJ.-H.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DHsu%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHsu%26aufirst%3DJ.-M.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.-C.%26aulast%3DWu%26aufirst%3DH.-J.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.-C.%26atitle%3DGlycosylation%2520and%2520Stabilization%2520of%2520Programmed%2520Death%2520Ligand-1%2520Suppresses%2520T-Cell%2520Activity%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26doi%3D10.1038%2Fncomms12632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.-P.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 Pathway in Non-Small-Cell Lung Cancer and Its Relation with EGFR Mutation</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">5</span> <span class="refDoi">Â DOI: 10.1186/s12967-014-0373-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1186%2Fs12967-014-0373-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=25592115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Ggt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&author=M.+Jiauthor=Y.+Liuauthor=Q.+Liauthor=X.-D.+Liauthor=W.-Q.+Zhaoauthor=H.+Zhangauthor=X.+Zhangauthor=J.-T.+Jiangauthor=C.-P.+Wu&title=PD-1%2FPD-L1+Pathway+in+Non-Small-Cell+Lung+Cancer+and+Its+Relation+with+EGFR+Mutation&doi=10.1186%2Fs12967-014-0373-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation</span></div><div class="casAuthors">Ji, Mei; Liu, Yan; Li, Qing; Li, Xiao-Dong; Zhao, Wei-Qing; Zhang, Hanze; Zhang, Xiaofei; Jiang, Jing-Ting; Wu, Chang-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5/1-5/6, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Immunotherapy has become a crucial modality for non-small-cell lung cancer treatment.  Recently, two immune checkpoints, PD-1 and PD-L1, have emerged as important targets for immunotherapy.  Their antitumor efficacy has been confirmed by in vitro and in vivo studies.  But the correlation between PD-1/PD-L1 expression and EGFR expression was controversial and needs more evidences to support the combination of PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUGW50suey2rVg90H21EOLACvtfcHk0lg2USfqk_U-lQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Ggt70%253D&md5=e0005ebd642fb281d42bb3c8f1e67514</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1186%2Fs12967-014-0373-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-014-0373-0%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DX.-D.%26aulast%3DZhao%26aufirst%3DW.-Q.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DJ.-T.%26aulast%3DWu%26aufirst%3DC.-P.%26atitle%3DPD-1%252FPD-L1%2520Pathway%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%2520and%2520Its%2520Relation%2520with%2520EGFR%2520Mutation%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2015%26volume%3D13%26doi%3D10.1186%2Fs12967-014-0373-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellerman, D.</span></span> <span> </span><span class="NLM_article-title">Bispecific T-Cell Engagers: Towards Understanding Variables Influencing the in Vitro Potency and Tumor Selectivity and Their Modulation to Enhance Their Efficacy and Safety</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">102</span>â <span class="NLM_lpage">117</span>, <span class="refDoi">Â DOI: 10.1016/j.ymeth.2018.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1016%2Fj.ymeth.2018.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=30395966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFyhur7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2019&pages=102-117&author=D.+Ellerman&title=Bispecific+T-Cell+Engagers%3A+Towards+Understanding+Variables+Influencing+the+in+Vitro+Potency+and+Tumor+Selectivity+and+Their+Modulation+to+Enhance+Their+Efficacy+and+Safety&doi=10.1016%2Fj.ymeth.2018.10.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety</span></div><div class="casAuthors">Ellerman, Diego</div><div class="citationInfo"><span class="NLM_cas:title">Methods (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102-117</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bispecific mols. redirecting the cytotoxicity of T-cells are a growing class of therapeutics with numerous mols. being tested in clin. trials.  However, it has been a long way since the proof of concept studies in the mid 1980's.  In the process we have learnt about the impact of different variables related to the bispecific mol. and the target antigen on the potency of this type of drugs.  This work reviews the insights gained and how that knowledge has been used to design more potent bispecific T-cell engagers.  The more recent advancement of antibodies with this modality into safety studies in non-human primates and as well as in clin. studies has revealed potential toxicity liabilities for the mode of action.  Modifications in existing antibody formats and new exptl. mols. designed to mitigate these problems are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUduNHkE38YbVg90H21EOLACvtfcHk0lg2USfqk_U-lQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFyhur7L&md5=e1f22c3f36180152b8fb7a9b0b033dd8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2018.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2018.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DEllerman%26aufirst%3DD.%26atitle%3DBispecific%2520T-Cell%2520Engagers%253A%2520Towards%2520Understanding%2520Variables%2520Influencing%2520the%2520in%2520Vitro%2520Potency%2520and%2520Tumor%2520Selectivity%2520and%2520Their%2520Modulation%2520to%2520Enhance%2520Their%2520Efficacy%2520and%2520Safety%26jtitle%3DMethods%26date%3D2019%26volume%3D154%26spage%3D102%26epage%3D117%26doi%3D10.1016%2Fj.ymeth.2018.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schietinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranz, D. M.</span></span> <span> </span><span class="NLM_article-title">A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CARs) and Bispecific T-Cell Engagers (BiTEs)</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">863</span>â <span class="NLM_lpage">873</span>, <span class="refDoi">Â DOI: 10.4161/onci.20592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.4161%2Fonci.20592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=23162754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A280%3ADC%252BC2sris1Wruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=863-873&author=J.+D.+Stoneauthor=D.+H.+Aggenauthor=A.+Schietingerauthor=H.+Schreiberauthor=D.+M.+Kranz&title=A+Sensitivity+Scale+for+Targeting+T+Cells+with+Chimeric+Antigen+Receptors+%28CARs%29+and+Bispecific+T-Cell+Engagers+%28BiTEs%29&doi=10.4161%2Fonci.20592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)</span></div><div class="casAuthors">Stone Jennifer D; Aggen David H; Schietinger Andrea; Schreiber Hans; Kranz David M</div><div class="citationInfo"><span class="NLM_cas:title">Oncoimmunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">863-873</span>
        ISSN:<span class="NLM_cas:issn">2162-4011</span>.
    </div><div class="casAbstract">Although T cells can mediate potent antitumor responses, immune tolerance mechanisms often result in the deletion or inactivation of T cells that express T-cell receptors (TCRs) against potentially effective target epitopes.  Various approaches have been devised to circumvent this problem.  In one approach, the gene encoding an antibody against a cancer-associated antigen is linked, in the form of a single-chain variable fragment (scFv), to genes that encode transmembrane and signaling domains.  This chimeric antigen receptor (CAR) is then introduced into T cells for adoptive T-cell therapy.  In another approach, the anti-cancer scFv is fused to a scFv that binds to the CD3Îµ subunit of the TCR/CD3 complex.  This fusion protein serves as a soluble, injectable product that has recently been termed bispecific T-cell engager (BiTE).  Both strategies have now been tested in clinical trials with promising results, but the comparative efficacies are not known.  Here, we performed a direct comparison of the in vitro sensitivity of each strategy, using the same anti-cancer scFv fragments, directed against a tumor-specific glycopeptide epitope on the sialomucin-like transmembrane glycoprotein OTS8, which results form a cancer-specific mutation of Cosmc.  While both approaches showed specific responses to the epitope as revealed by T cell-mediated cytokine release and target cell lysis, CAR-targeted T cells were more sensitive than BiTE-targeted T cells to low numbers of antigens per cell.  The sensitivity scale described here provides a guide to the potential use of these two different approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGcnTbQFS8PCCEBeYuoi7AfW6udTcc2ebRm5etTziiNbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sris1Wruw%253D%253D&md5=7109405fb1e0f95855399c5e1e9b77f1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.4161%2Fonci.20592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fonci.20592%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DJ.%2BD.%26aulast%3DAggen%26aufirst%3DD.%2BH.%26aulast%3DSchietinger%26aufirst%3DA.%26aulast%3DSchreiber%26aufirst%3DH.%26aulast%3DKranz%26aufirst%3DD.%2BM.%26atitle%3DA%2520Sensitivity%2520Scale%2520for%2520Targeting%2520T%2520Cells%2520with%2520Chimeric%2520Antigen%2520Receptors%2520%2528CARs%2529%2520and%2520Bispecific%2520T-Cell%2520Engagers%2520%2528BiTEs%2529%26jtitle%3DOncoimmunology%26date%3D2012%26volume%3D1%26spage%3D863%26epage%3D873%26doi%3D10.4161%2Fonci.20592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hapka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallera, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Self-Assembly of Antibodies by Chemical Induction</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">10179</span>â <span class="NLM_lpage">10182</span>, <span class="refDoi">Â DOI: 10.1002/anie.200803507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1002%2Fanie.200803507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFaksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=10179-10182&author=Q.+Liauthor=D.+Hapkaauthor=H.+Chenauthor=D.+A.+Valleraauthor=C.+R.+Wagner&title=Self-Assembly+of+Antibodies+by+Chemical+Induction&doi=10.1002%2Fanie.200803507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Self-assembly of antibodies by chemical induction</span></div><div class="casAuthors">Li, Qing; Hapka, David; Chen, Hua; Vallera, Daniel A.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">10179-10182</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Circular arrays of recombinant antibodies can be produced reversibly by chem. controlled protein macrocyclization.  In the presence of bismethotrexate (bis-MTX), dimeric dihydrofolate reductase fusion protein (DHFR) with an anti-CD3 single-chain variable region (scFv) self-assembled spontaneously into diabodies, which were disassembled into monomers with an excess of the antibiotic trimethoprim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1shGTnV5ZtLVg90H21EOLACvtfcHk0lgRxUnPj5S3NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFaksA%253D%253D&md5=7acf419b0b64aa10f85eb21559bbb9b5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fanie.200803507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200803507%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DHapka%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DVallera%26aufirst%3DD.%2BA.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DSelf-Assembly%2520of%2520Antibodies%2520by%2520Chemical%2520Induction%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D10179%26epage%3D10182%26doi%3D10.1002%2Fanie.200803507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stutvoet, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kol, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrmann, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwisscha
van Scheltinga, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, S.</span></span> <span> </span><span class="NLM_article-title">MAPK Pathway Activity Plays a Key Role in PD-L1 Expression of Lung Adenocarcinoma Cells</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>249</i></span>,  <span class="NLM_fpage">52</span>â <span class="NLM_lpage">64</span>, <span class="refDoi">Â DOI: 10.1002/path.5280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=10.1002%2Fpath.5280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=30972766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2rsLjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=2019&pages=52-64&author=T.+S.+Stutvoetauthor=A.+Kolauthor=E.+G.+de+Vriesauthor=M.+de+Bruynauthor=R.+S.+Fehrmannauthor=A.+G.+Terwisscha%0Avan+Scheltingaauthor=S.+de+Jong&title=MAPK+Pathway+Activity+Plays+a+Key+Role+in+PD-L1+Expression+of+Lung+Adenocarcinoma+Cells&doi=10.1002%2Fpath.5280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells</span></div><div class="casAuthors">Stutvoet, Thijs S.; Kol, Arjan; de Vries, Elisabeth G. E.; de Bruyn, Marco; Fehrmann, Rudolf S. N.; Terwisscha van Scheltinga, Anton G. T.; de Jong, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">249</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-64</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) have improved the survival of patients with non-small cell lung cancer (NSCLC).  Still, many patients do not respond to these inhibitors.  PD-L1 (CD274) expression, one of the factors that influences the efficacy of immune checkpoint inhibitors, is dynamic.  Here, we studied the regulation of PD-L1 expression in NSCLC without targetable genetic alterations in EGFR, ALK, BRAF, ROS1, MET, ERBB2 and RET.  Anal. of RNA sequencing data from these NSCLCs revealed that inferred IFNÎ³, EGFR and MAPK signaling correlated with CD274 gene expression in lung adenocarcinoma.  In a representative lung adenocarcinoma cell line panel, stimulation with EGF or IFNÎ³ increased CD274 mRNA and PD-L1 protein and membrane levels, which were further enhanced by combining EGF and IFNÎ³.  Similarly, tumor cell PD-L1 membrane levels increased after coculture with activated peripheral blood mononuclear cells.  Inhibition of the MAPK pathway, using EGFR inhibitors cetuximab and erlotinib or the MEK 1 and 2 inhibitor selumetinib, prevented EGF- and IFNÎ³-induced CD274 mRNA and PD-L1 protein and membrane upregulation, but had no effect on IFNÎ³-induced MHC-I upregulation.  Interestingly, although IFNÎ³ increases transcriptional activity of CD274, MAPK signaling also increased stabilization of CD274 mRNA.  In conclusion, MAPK pathway activity plays a key role in EGF- and IFNÎ³-induced PD-L1 expression in lung adenocarcinoma without targetable genetic alterations and may present a target to improve the efficacy of immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJaRr21pc9kbVg90H21EOLACvtfcHk0lgRxUnPj5S3NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2rsLjK&md5=8bedf3ad0e7d302b4f27336931efa5c7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fpath.5280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.5280%26sid%3Dliteratum%253Aachs%26aulast%3DStutvoet%26aufirst%3DT.%2BS.%26aulast%3DKol%26aufirst%3DA.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3Dde%2BBruyn%26aufirst%3DM.%26aulast%3DFehrmann%26aufirst%3DR.%2BS.%26aulast%3DTerwisscha%2Bvan%2BScheltinga%26aufirst%3DA.%2BG.%26aulast%3Dde%2BJong%26aufirst%3DS.%26atitle%3DMAPK%2520Pathway%2520Activity%2520Plays%2520a%2520Key%2520Role%2520in%2520PD-L1%2520Expression%2520of%2520Lung%2520Adenocarcinoma%2520Cells%26jtitle%3DJ.%2520Pathol.%26date%3D2019%26volume%3D249%26spage%3D52%26epage%3D64%26doi%3D10.1002%2Fpath.5280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i29"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00489">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_47527"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00489?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00489</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Characterization and binding of E1-1DD and E4-1DD; cross-reactivity with mouse EGFR; control groups from the bispecific CSANs PBMC-binding study; internalization of the E1-1DD monomer and rings; control groups from the bispecific CSANs PBMC-binding study; and western blot analysis and quantification of the tumor lysates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00489/suppl_file/jm0c00489_si_001.pdf">jm0c00489_si_001.pdf (1.56 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00489&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-18%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00489" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00489" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a5e1cbe1a3ce2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
